An investigation into the regulation of transcription of the splice factor kinase gene SRPK1 in prostate and leukaemia cancer cell lines by Belali, Tareg
  
 
  
 
 
 
 
 
An investigation into the regulation of transcription of the splice factor kinase 
gene SRPK1 in prostate and leukaemia cancer cell lines 
 
Tareg Belali 
 
 
 
 
A thesis submitted in partial fulfilment of the requirements of the University of the West of 
England, Bristol for the degree of Doctor of Philosophy 
 
 
Faculty of Health and Applied Sciences, University of the West of England, Frenchay 
Campus, Coldharbour Lane, Frenchay, Bristol, BS16 1QY 
 
September 2019 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This copy has been supplied on the understanding that it is copyright material and that no 
quotation from the thesis may be published without proper acknowledgement.
Author’s Declaration 
      
 
 
 
Page i 
 
  
I. Author’s Declaration 
 
 
This thesis is submitted in fulfilment of the requirements of a Ph.D., and except 
where duly acknowledged or referenced, it is entirely my work. It has not been submitted, 
either in whole or part, for any other award at the University of the West of England or 
elsewhere. 
  
 
 
Signed....... ...................    Date 01/07/2019 
 
  
Project Supervisors’ Declarations 
      
 
 
 
Page ii 
 
  
II. Project Supervisors’ Declarations 
 
I confirm that I have read this PhD thesis and that the work it describes was 
undertaken under my supervision. 
 
Prof. Michael R. Ladomery 
Associate Professor in Biomedical Science & Senior Fellow HEA 
Faculty of Health and Applied Sciences 
University of the West of England, Bristol 
T: +44-117-3283531 
www.ladomerylab.org 
Michael.Ladomery@uwe.ac.uk 
 
 
Signed                               Date 01/07/2019 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abstract 
      
 
 
 
Page iii 
 
  
III. Abstract 
 
The SRPK1 gene encodes a protein kinase that phosphorylates a class of splice factors 
called serine/arginine-rich proteins (SR proteins) modifying their ability to regulate 
alternative pre-mRNA splicing. Studies have linked high SRPK1 levels to tumour 
proliferation, growth and metastatic ability but little is known about how its expression 
is regulated. Different transcription factors including WT1 and ERG are thought to have 
some level of involvement in the regulation of SRPK1 transcription. The aim of this 
project was to study the transcriptional regulation of the splice factor kinase gene SRPK1. 
In this study, the regulation of SRPK1 expression was investigated in cancer cells and 
the results suggest that both the transcription factor WT1 and the co-repressor BASP1 
are present on the SRPK1 promoter region. SRPK1 transcription is activated by WT1, 
but not when the WT1 binding site is mutated. Consistent with these findings, the knock-
down of WT1 with siRNAs also resulted in decreased expression of endogenous SRPK1. 
The activity of the SRPK1 promoter in BASP1-expressing K562 cells or in PC3 cells 
transfected with a BASP1-expressing vector was repressed, consistent with BASP1 
turning WT1 into a transcriptional repressor rather an activator. The effect of SRPK1 
chemical inhibition via SPHINX and the overexpression of BASP1 on the alternative 
splicing of the vascular endothelial growth factor (VEGF) was also examined in this 
study; both SRPK1 inhibition and BASP1 expression promoted the expression of anti-
angiogenic VEGF. The transcription factor ERG, on the other hand, was also shown to 
bind to the SRPK1 promoter but it repressed its transcription. The overexpression of ERG 
isoforms reduced endogenous SRPK1 expression, whereas ERG knockdown increased 
SRPK1 expression. Finally, following manipulation of the expression of SRPK1, WT1, 
BASP1 and ERG in K562, PC3 and MG63 cell lines, changes in apoptosis, cell 
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proliferation and migration were observed, suggesting that this regulatory axis could 
present a valid cancer therapy target 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Acknowledgements 
      
 
 
 
Page v 
 
  
IV. Acknowledgements 
 
Firstly, I would like to thank my supervisor, Prof. Michael Ladomery, for his valuable 
support during the project and the production of this thesis. Despite an extremely busy 
eventful few years, he was able to provide a perfect balance of input, project guidance 
and support, while still allowing me the freedom to work and progress the project 
independently. This has been optimum for my development as a researcher and I am very 
grateful for everything he has done. 
I’m very much thankful to my other supervisors Dr Gabrielle Wheway and Dr Tim Craig 
for their sustained support and valuable guidance throughout my research programme. 
I also want to thank my research team members Dr Sean Porazinski and Dr Samantha 
Jumbe for teaching me most of the experimental procedures used in this project and 
providing valuable advice, throughout the majority of the project, particularly when 
navigating any experimental difficulties that arose. My thanks are also extended to 
Chigeru Wodi who, in the absence of Sam, helped me towards the end of the project, 
particularly with SPHINX treatments. 
I would like to thank my family, primarily my parents and my loving wife and kids for 
their unconditional love, support and believe in my ability to accomplish my full 
potential. Without their constant support, I would have been distressed and lost track of 
my goals, they reminded me constantly of my responsibilities and guided my compass 
toward my target.        
 
Table of Contents 
      
 
 
 
Page vi 
 
  
V. Table of Contents 
Contents 
I. Author’s Declaration .......................................................................................... i 
II. Project Supervisors’ Declarations ...................................................................... ii 
III. Abstract........................................................................................................... iii 
IV. Acknowledgements .......................................................................................... v 
V. Table of Contents ............................................................................................ vi 
VI. List of Figures ................................................................................................... x 
VII. List of Tables .............................................................................................. xiii 
VIII. Abbreviations ............................................................................................ xiv 
1 Chapter One: Introduction ................................................................................ 2 
1.1 Alternative splicing and disease ....................................................................................... 2 
1.1.1 Discovery of pre-mRNA splicing ................................................................................. 2 
1.1.2 Pre-mRNA splicing catalysed by the spliceosome ....................................................... 3 
1.1.3 Alternative splicing events: types and extent ............................................................... 4 
1.1.4 Regulation of alternative splicing and splice factor kinases ....................................... 5 
1.1.5 Atypical alternative splicing in cancer ........................................................................ 7 
1.2 Splice factor kinase-1 (SRPK1) ....................................................................................... 9 
1.2.1 SRPK kinases: structure and function ......................................................................... 9 
1.2.2 Regulation of SRPK1 activity .................................................................................... 10 
1.2.3 Molecular interactions of SRPK1 .............................................................................. 13 
1.2.4 SRPK1 expression in malignancies ........................................................................... 15 
1.2.5 SRPK1 as a therapeutic target .................................................................................. 16 
1.3 The Wilms tumour suppressor (WT1) ........................................................................... 17 
1.3.1 WT1; background ...................................................................................................... 17 
1.3.2 WT1 in cancer ............................................................................................................ 18 
1.3.3 WT1 structure and function ....................................................................................... 18 
1.3.4 The BASP1-WT1 interaction ...................................................................................... 20 
1.3.5 Regulation of SRPK1 transcription by Wilms’ tumour gene-1 (WT1) ....................... 21 
1.4 Brain abundant membrane attached signal protein 1 (BASP1) ...................................... 23 
1.4.1 BASP1; background................................................................................................... 23 
1.4.2 BASP1 in cancer ........................................................................................................ 23 
1.4.3 BASP1 structure ........................................................................................................ 25 
1.4.4 BASP1 functions ........................................................................................................ 26 
1.5 ERG (ETS-related gene) ................................................................................................ 28 
1.5.1 ERG (ETS-related gene) ............................................................................................ 28 
1.5.2 ERG in cancer ........................................................................................................... 28 
1.5.3 ERG structure and regulation ................................................................................... 29 
1.5.4 ERG function ............................................................................................................. 30 
1.6 Hypothesis and aims ...................................................................................................... 32 
1.6.1 Hypothesis ................................................................................................................. 32 
1.6.2 Aim and objectives of the project ............................................................................... 32 
 
Table of Contents 
      
 
 
 
Page vii 
 
  
2 Chapter Two: Material and Methods .............................................................. 33 
2.1 Tissue culture ................................................................................................................. 33 
2.1.1 K562 and B-K562 cells .............................................................................................. 33 
2.1.2 PC3, DU145 and MG63 cells .................................................................................... 33 
2.1.3 Cell line thawing and freezing ................................................................................... 34 
2.1.4 Plasmid transfections................................................................................................. 34 
2.1.5 Overexpression of WT1, ERG and BASP1 ................................................................. 35 
2.1.6 siRNA mediated knockdown of SRPK1, WT1 and ERG ............................................. 35 
2.1.7 Small molecule inhibitor (SPHINX) .......................................................................... 36 
2.1.8 Splice-switching oligonucleotides (Vivo-Morpholinos) ............................................. 37 
2.2 Plasmid constructs to study SRPK1 transcriptional regulation ...................................... 38 
2.2.1 Plasmid preparations................................................................................................. 38 
2.2.2 Growth of E.coli in Luria Broth ................................................................................ 39 
2.2.3 Plasmid miniprep ....................................................................................................... 39 
2.2.4 Plasmid Midiprep ...................................................................................................... 40 
2.2.5 Plasmid restriction digestion ..................................................................................... 40 
2.2.6 Bacterial transformation ........................................................................................... 41 
2.2.7 Plasmid DNA and cell strains storage ....................................................................... 41 
2.3 Dual luciferase reporter assay ........................................................................................ 42 
2.4 RNA extraction from cell lines ...................................................................................... 43 
2.5 cDNA synthesis.............................................................................................................. 44 
2.6 Assessment of RNA and cDNA yield ............................................................................ 44 
2.7 Polymerase chain reaction (PCR) .................................................................................. 44 
2.8 Agarose gel electrophoresis ........................................................................................... 46 
2.9 Chromatin immunoprecipitation assay .......................................................................... 46 
2.10 Gel extraction and purification of PCR products ........................................................... 47 
2.11 Protein extraction and quantification ............................................................................. 48 
2.12 Western Blotting ............................................................................................................ 49 
2.13 Cell biology assays......................................................................................................... 51 
2.13.1 MTT Assay; cell proliferation and viability ............................................................... 51 
2.13.2 Transwell cell migration and invasion assay ............................................................ 52 
2.13.3 Analysis of apoptosis signals; caspase-3/7 activity assay ......................................... 52 
2.14 Fluorescence microscopy ............................................................................................... 53 
2.15 Normalisation of western blots and PCR ....................................................................... 53 
3 Chapter Three: Effect of SRPK1 inhibition and knockdown on SRPK1 expression 
and cell biology ...................................................................................................... 54 
3.1 Background .................................................................................................................... 54 
3.2 Aims and objectives ....................................................................................................... 56 
3.3 Results ............................................................................................................................ 57 
3.3.1 Expression of the SRPK1a splice isoform.................................................................. 57 
3.3.2 Effect of siRNA mediated SRPK1 knockdown on SRPK1 expression ........................ 58 
3.3.3 Effect of the SRPK1 inhibitor SPHINX on SRPK1 protein levels and transcription . 60 
3.3.4 Effect of SPHINX treatment on VEGF-A alternative splicing ................................... 62 
3.3.5 Effect of SPHINX treatment on the alternative splicing of apoptotic genes BCL2L1 
and CASPASE-9...................................................................................................................... 64 
3.3.6 The Effect of SRPK1 chemical inhibition and siRNA knockdown on cellular viability 
and proliferation ..................................................................................................................... 69 
3.3.7 The effect of SRPK1 chemical inhibition and siRNA knockdown on cellular 
migration and invasion ........................................................................................................... 71 
3.4 Summary  ....................................................................................................................... 79 
Table of Contents 
      
 
 
 
Page viii 
 
  
4 Chapter Four: SR protein kinase 1 (SRPK1) regulation by WT1 ......................... 81 
4.1 Background .................................................................................................................... 81 
4.2 Aims and objective......................................................................................................... 83 
4.3 Results ............................................................................................................................ 84 
4.3.1 WT1 binds the SRPK1 promoter ................................................................................ 84 
4.3.2 WT1 activates SRPK1 transcription in PC3, DU145 and K562 ................................ 88 
4.3.3 Effect of WT1-siRNA knockdown on SRPK1 transcription and protein level ........... 90 
4.3.4 Effect of splice switching oligonucleotide-mediated WT1 knockdown on    SRPK1 
promoter activity ..................................................................................................................... 94 
4.3.5 WT1 overexpression and the effect of co-transfection of +/- KTS WT1 expressing 
plasmids on SRPK1 promoter activity .................................................................................... 96 
4.3.6 Effect of WT1 siRNA knockdown on the alternative splicing of apoptotic factors 
BCL2L1 and CASPASE-9 ....................................................................................................... 99 
4.3.7 The Effect siRNA WT1 knockdown and overexpression on cell proliferation and 
viability ................................................................................................................................. 106 
4.3.8 Effect of WT1 knockdown on cellular migration and invasion ................................ 108 
4.4 Summary  ..................................................................................................................... 112 
5 Chapter Five: Effect of the co-suppressor BASP1 on the transcriptional 
regulation of SRPK1 by WT1 ................................................................................. 114 
5.1 Background .................................................................................................................. 114 
5.2 Aims and objectives ..................................................................................................... 115 
5.3 Results .......................................................................................................................... 116 
5.3.1 BASP1 binds to the SRPK1 promoter (ChIP) .......................................................... 116 
5.3.2 Overexpression of the transcriptional co-repressor BASP1 prevents WT1 from 
activating SRPK1 transcription ............................................................................................ 118 
5.3.3 BASP1 expression limits the endogenous protein levels of WT1 and SRPK1 ......... 121 
5.3.4 Overexpression of WT1 co-suppressor BASP1 affects VEGF-A alternative splicing in 
PC3 cells ............................................................................................................................... 123 
5.3.5 Effect of BASP1 overexpression on cell proliferation and viability ........................ 125 
5.3.6 Effect of BASP1 overexpression on SRPK1 promoter activity in WT1 negative MG63 
cells 127 
5.4 Summary ...................................................................................................................... 128 
6 Chapter Six: Effect of the ERG transcription factor on SRPK1 transcription. .... 130 
6.1 Background .................................................................................................................. 130 
6.2 Aims and objectives ..................................................................................................... 131 
6.3 Results .......................................................................................................................... 132 
6.3.1 ERG binds the SRPK1 promoter .............................................................................. 132 
6.3.2 ERG suppresses SRPK1 transcription ..................................................................... 135 
6.3.3 Effect of ERG overexpression on SRPK1 protein levels .......................................... 139 
6.3.4 Effect of ERG -siRNA knockdown on SRPK1 transcription and protein levels ....... 142 
6.3.5 The effect of ERG Exon 4 skipping through splice switching   oligonucleotides on 
SRPK1 transcription and protein levels ............................................................................... 145 
6.3.6 The effect of ERG Exon 7b skipping through splice switching oligonucleotides on 
SRPK1 transcription and protein levels ............................................................................... 151 
6.3.7 Effect of ERG overexpression on the alternative splicing of apoptotic factors 
BCL2L1 and caspase 9 ......................................................................................................... 154 
6.3.8 The effect of ERG exon 4 skipping through splice switching oligonucleotides on the 
alternative splicing of apoptotic factors BCL2L1 and caspase 9 ......................................... 161 
6.3.9 Effect of ERG overexpression on cell proliferation and viability ............................ 166 
Table of Contents 
      
 
 
 
Page ix 
 
  
6.3.10 Effect of splice switching oligonucleotides and ERG knockdown on MG63 cells 
proliferation and viability ..................................................................................................... 168 
6.3.11 Effect of ERG inhibition on cell migration and invasion ......................................... 170 
6.3.12 Cancer Cell Line Encyclopaedia comparison ......................................................... 174 
6.4 Summary ...................................................................................................................... 176 
7 Chapter seven: General Discussion and future work ...................................... 180 
7.1 Discussion .................................................................................................................... 180 
7.1.1 Detection of the SRPK1a splice isoform and a potential autoregulatory loop ........ 180 
7.1.2 Effect of SRPK1 inhibition with SPHINX on alternative splicing of VEGF-A, 
BCL2L1 and caspase-9 ......................................................................................................... 181 
7.1.3 Effect of SRPK1 inhibition on cell proliferation ...................................................... 183 
7.1.4 Transcriptional regulation of SRPK1 by WT1 ......................................................... 184 
7.1.5 CASPASE-9 alternative splicing following WT1 siRNA knockdown ....................... 187 
7.1.6 Effect of siRNA mediated WT1 knockdown on cell growth ...................................... 188 
7.1.7 BASP1 as a tumour suppressor ............................................................................... 189 
7.1.8 The WT1/BASP1 repressive complex and the transcription of SRPK1 ................... 192 
7.1.9 Effect of BASP1 on VEGF-A splicing ...................................................................... 194 
7.1.10 ERG as a transcriptional regulator ......................................................................... 195 
7.1.11 ERG and apoptosis .................................................................................................. 197 
7.2 Significance of the research ......................................................................................... 199 
7.3 Future directions .......................................................................................................... 201 
7.3.1 Global RNA Sequencing and gene promoter scan ................................................... 201 
7.3.2 SRPK1 kinase activity .............................................................................................. 202 
7.3.3 Investigating other SRPK1 isoforms ........................................................................ 202 
7.3.4 SRPK1 intracellular localization ............................................................................. 202 
7.3.5 Inducible expression of ERG/WT1 and SRPK1 regulation...................................... 203 
7.3.6 SRPK1 expression and EMT Markers ..................................................................... 204 
8 References ................................................................................................... 205 
9 Appendices ................................................................................................... 227 
9.1 Plasmid preps ............................................................................................................... 227 
9.2 Restriction digests and plasmids validations ................................................................ 229 
9.3 Sequencing and NCBI Nucleotide Blast of Chip pull downs ...................................... 238 
9.4 TPM values of RNA-sequences ................................................................................... 249 
 
  
List of Figures 
      
 
 
 
Page x 
 
  
VI. List of Figures 
 
 
Figure 1. 1: Different types of alternative splicing (AS) events. ................................................ 5 
Figure 1. 2: possible mutations that can occur that affect splicing. .......................................... 7 
Figure 1. 3: Schematic presentation of SRPK1 domains. ........................................................ 11 
Figure 1. 4: Akt-mediated phosphorylation of SRPK1 at T326 and S587. .............................. 11 
Figure 1. 5: Summary of EGF signalling through the Akt-SRPK-SR axis to regulate 
alternative splicing in the nucleus. ............................................................................................ 13 
Figure 1. 6: structure of the WT1 protein. ................................................................................ 19 
Figure 1. 7: BASP1 acting as a transcriptional co-suppressor for WT1. ................................ 20 
Figure 1. 8: Structure of human BASP1 .................................................................................. 25 
Figure 1. 9: Human SRPK1 promoter sequence ...................................................................... 31 
Figure 3. 1 a: Schematic representation of human SRPK1a and SRPK1. .............................. 57 
Figure 3.1 b: PCR products electrophoresis. ............................................................................ 57 
Figure 3.2. Effect of SRPK1 knockdown on SRPK1 expression. ............................................. 59 
Figure 3.3. Effect of SPHINX on SRPK1 protein levels and transcription ............................. 61 
Figure 3. 4: Inhibition of SRPK1 by SPHINX results in a splicing switch from pro- to anti-
angiogenic VEGF isoforms in PC3 cells. .................................................................................. 63 
Figure 3. 5: Caspase-9 mRNA levels in SPHINX treated K562 cells. ..................................... 65 
Figure 3. 6: BCL2L1 Bcl mRNA levels in SPHINX treated K562 cells................................... 66 
Figure 3. 7: Caspase-9 mRNA levels in SPHINX treated PC3 cells. ....................................... 67 
Figure 3. 8: BCL2L1 mRNA levels in SPHINX treated PC3 cells. .......................................... 68 
Figure 3. 9: Cellular proliferation and viability in K562 and PC3 cells after SRPK1 
inhibition by siRNA and SPHINX treatment. ........................................................................... 70 
Figure 3. 10:  Transwell migration assay of PC3 cells. ............................................................ 73 
Figure 3. 11: Transwell cell invasion assay of PC3 cells. ........................................................ 74 
Figure 3. 12: Transwell migration assay of PC3 cells. ............................................................. 76 
Figure 3. 13: Transwell cell invasion assay of PC3 cells. ........................................................ 78 
Figure 4. 1: Sonicated DNA smear for PC3 and K562 cells in preparation for Chromatin 
Immunoprecipitation assay. ....................................................................................................... 85 
Figure 4. 2: WT1 binds the SRPK1 promoter. .......................................................................... 87 
Figure 4. 3: DLR assay of SRPK1 promoter activity in K562 (A), PC3 (B) and DU145(C) 
cells. ............................................................................................................................................ 89 
Figure 4.4: Effect of WT1 knockdown on SRPK1 levels in K562 and PC3 cells. ................... 93 
Figure 4. 5: Effect of splice switching oligonucleotides mediated WT1 knockdown on SRPK1 
expression. .................................................................................................................................. 95 
Figure 4. 6: Overexpression of WT1. ........................................................................................ 98 
Figure 4. 7: Overexpression of WT1 (-KTS) isoform significantly enhances SRPK1 
promoter’s activity. ..................................................................................................................... 99 
Figure 4. 8. Caspases 3 and 7 staining in K562 and PC3 cells where WT1 has been knocked 
down. ......................................................................................................................................... 101 
Figure 4. 9: Caspase-9 mRNA levels in K562 cells where WT1 has been knocked down..... 102 
Figure 4. 10: BCL2L1 mRNA levels in K562 cells where WT1 has been knocked down. .... 103 
Figure 4. 11: Caspase-9 mRNA levels in PC3 cells where WT1 has been knocked down. ... 104 
Figure 4. 12: BCL2L1 mRNA levels in PC3 cells where WT has been knocked down. ........ 105 
Figure 4. 13. Cellular proliferation and viability in K562 and PC3 cells after overexpression 
of WT1 isoform and WT1 knockdown. .................................................................................... 107 
Figure 4. 14: Transwell migration assay of PC3 cells following WT1 knockdown ............... 109 
Figure 4. 15: Transwell cell invasion assay of PC3 cells following WT1 knockdown. ......... 111 
Figure 5. 1: BASP1 binds the SRPK1 promoter. .................................................................... 117 
List of Figures 
      
 
 
 
Page xi 
 
  
Figure 5. 2: Overexpression of BASP1 in B-K562 (A). .......................................................... 119 
Figure 5.3: Effect of BASP1 on SRPK1 transcription ........................................................... 120 
Figure 5. 4 BASP1 expression limits the expression of endogenous WT1 and SRPK1 protein.
 ................................................................................................................................................... 122 
Figure 5.5. Overexpression of WT1 co-suppressor BASP1 Affects VEGF alternative Splicing 
in PC3 cells. .............................................................................................................................. 124 
Figure 5.6. Cellular proliferation and viability in K562 and PC3 cells after overexpression of 
BASP1. ...................................................................................................................................... 126 
Figure 5.7: Overexpression of BASP1 doesn’t repress SRPK1 transcription in MG63. ....... 127 
Figure 6. 1: Sonicated DNA smear for MG63 cells in preparation for Chromatin 
Immunoprecipitation (ChIP) assay. ........................................................................................ 133 
Figure 6. 2: ERG binds the SRPK1 promoter ......................................................................... 134 
Figure 6. 3: DLR assay of SRPK1 promoter activity in MG63 (A), PC3 (B) and K562 (C) 
cells. .......................................................................................................................................... 136 
Figure 6. 4 A&B: Transcriptional repression of SRPK1 promoter by different ERG isoforms 
in K562 and PC3 cells. ............................................................................................................. 137 
Figure 6.4.C: Transcriptional repression of SRPK1 promoter by full length ERG (+exon 7b) 
in MG63 cells............................................................................................................................ 138 
Figure 6. 5 A&B: Repression of SRPK1 protein levels by -7b and full-length ERG isoforms 
in K562 cells. ............................................................................................................................ 140 
Figure 6.5.C&D Repression of SRPK1 protein levels by +/- 7b ERG isoforms in PC3 cells.
 ................................................................................................................................................... 142 
Figure 6. 6: ERG knockdown in MG63 cells. ......................................................................... 144 
Figure 6. 7: DLR assay of SRPK1 promoter activity following siRNA mediated ERG 
knockdown in MG63 cells. ....................................................................................................... 145 
Figure 6. 8: ERG mRNA levels in E4 3′ SSO transfected MG63 cells. ................................. 148 
Figure 6. 9: DLR assay of SRPK1 promoter activity in E4 3′ SSO transfected MG63 cells. 149 
Figure 6. 10: Effect of exon 4 skipping on ERG and SRPK1 protein levels. ........................ 150 
Figure 6. 11: ERG mRNA levels in E7b 3′ SSO transfected MG63 cells. ............................. 152 
Figure 6. 12: DLR assay of SRPK1 promoter activity in E7b 3′ SSO transfected MG63 cells.
 ................................................................................................................................................... 153 
Figure 6. 13: Effect of exon7b skipping on ERG and SRPK1 protein levels. ....................... 154 
Figure 6. 14: Caspase 3 and 7 staining in K562 and PC3 cells subjected to ERG 
overexpression. ......................................................................................................................... 156 
Figure 6. 15: Caspase-9 mRNA levels in K562 cells where different ERG isoforms have been 
overexpressed. ........................................................................................................................... 157 
Figure 6. 16: BCL2L1 mRNA levels in K562 cells where different ERG isoforms have been 
overexpressed. ........................................................................................................................... 158 
Figure 6. 17: Caspase-9 mRNA levels in PC3 cells where different ERG isoforms have been 
overexpressed. ........................................................................................................................... 159 
Figure 6. 18: BCL2L1 mRNA levels in PC3 cells where different ERG isoforms have been 
overexpressed. ........................................................................................................................... 160 
Figure 6. 19: Caspase 3 and 7 staining in MG63 cells where ERG has been knocked down by 
E4 3′ SSOs. ............................................................................................................................... 162 
Figure 6. 20: Caspase-9 mRNA levels in SSOs transfected MG63 cells. ............................... 164 
Figure 6. 21: BCL2L1 mRNA levels in SSOs transfected MG63 cells. ................................. 165 
Figure 6. 22: Cellular proliferation and viability in K562 and PC3 cells after overexpression 
of ERG isoforms. ...................................................................................................................... 167 
Figure 6. 23: Cellular proliferation and viability in MG63 cells transfected with siRNA ERG 
and splice switching oligonucleotides. ..................................................................................... 169 
Figure 6. 24: Transwell migration assay of MG63 cells......................................................... 171 
Figure 6. 25: Transwell cell invasion assay of MG63 cells. ................................................... 173 
List of Figures 
      
 
 
 
Page xii 
 
  
Figure 6. 26: Comparison of RNA-seq .................................................................................... 175 
Figure 6. 27: Transcriptional regulation of SRPK1. .................... Error! Bookmark not defined. 
Figure 9. 1 Plasmid preparation. ............................................................................................. 227 
Figure 9. 2 Plasmid Midiprep .................................................................................................. 228 
Figure 9. 3 Wild type SRPK1 promoter. .................................................................................. 229  
Figure 9. 4   Mutant SRPK1 promoter .................................................................................... 230 
Figure 9. 5: Firefly and Renilla Luciferase Reporter Vectors. .............................................. 231 
Figure 9. 6 PGL3 plasmid map ................................................................................................ 232 
Figure 9. 7 Enzymes digests. .................................................................................................... 233 
Figure 9. 8 Restriction digests of BASP1 plasmids ................................................................. 235 
Figure 9. 9 Restriction digests of ERG plasmids .................................................................... 236 
Figure 9. 10: DDK tag western blots ....................................................................................... 237 
Figure 9. 11: WT1-SRPK1 pull down sequencing .................................................................. 238 
Figure 9. 12: WT1-SRPK1 sequencing result; NCBI Nucleotide Blast ................................. 240 
Figure 9. 13: BASP1-SRPK1 pull down sequencing .............................................................. 242 
Figure 9. 14: BASP1-SRPK1 sequencing result; NCBI Nucleotide Blast ............................. 244 
Figure 9. 15: ERG pull down-PCR sequencing; forward primers ......................................... 246 
Figure 9. 16: ERG-SRPK1 sequencing result; NCBI Nucleotide Blast ................................ 248 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
List of Tables 
      
 
 
 
Page xiii 
 
  
VII. List of Tables 
 
Table 2. 1: Individual siRNA components including their target sequences and fluorescent 
labels. .......................................................................................................................................... 36 
Table 2. 2: sequence and concentration of Splice-switching oligonucleotides. ....................... 37 
Table 2. 3: Plasmids used to perform the DLR assay and overexpression experiments. ......... 38 
Table 2. 4: Restriction enzymes and their digested sequence of bases. .................................... 40 
Table 2. 5: Transcriptional regulators cotransfected with SRPK1 promoter. ......................... 43 
Table 2. 6: Primers used for PCR. ............................................................................................. 46 
Table 2. 7: Antibodies used for western blotting. ...................................................................... 51 
Table 9. 1: Results for restriction digests for the wiled type SRPK1 promoter (pMKC130) & 
mutant SRPK1 promoter (pMKC132). .................................................................................... 234 
Table 9. 2: TPM values of RNA-seq of SRPK1, WT1, BASP1 and ERG in K562, PC3 and 
MG63. ....................................................................................................................................... 249 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
      
 
 
 
Page xiv 
 
  
VIII. Abbreviations  
µ 
µg                      Microgram  
µm                     Micrometer  
µM                     Micromolar  
A 
aa                        Amino acid  
Ab                       Antibody 
ABL1                  Abelson murine leukaemia viral oncogene homology 
AD                       Accessory domain 
AKT/PKB           Phosphatidylinositol 3-kinase /Protein kinase B 
AML                    Acute Myelogenous Leukaemia 
AP                        Ammonium Per sulphate 
AS                        Alternative splicing 
B 
BASP1                 Brain abundant membrane attached signal protein 1 
Bcl-xL                  B-cell lymphoma extra large 
BCR                      Breakpoint cluster region 
BLAST                 Basic Local Alignment Search Tool 
bp                          Base pair 
BRG1                    Brahma Related Gene 1 
BSA                       Bovine Serum Albumin 
C 
°C                            Celsius  
CBP                       CREB Binding Protein 
cDNA                     Complimentary Deoxyribonucleic acid 
CRC                       colorectal cancer   
CLKS                     CDC-like kinases 
D 
DDS                       Denys-Drash Syndrome 
DLR                       Dual-Luciferase Reporter Assay 
DMEM                  Dulbeco Modified Eagle Media 
DNA                       Deoxyribonucleic acid 
E 
EC                           Endothelial cells  
E. coli                     Escherichia coli 
EDTA                     Ethylenediaminetetraacetic acid 
EGF                        Epidermal growth factor 
Abbreviations 
      
 
 
 
Page xv 
 
  
ERG                        ETS-related gene 
EMT                       Epithelial to mesenchymal mransition  
et al.                        et alia 
EtBr                        Ethidium Bromide 
F 
FBS                        Foetal Bovine Serum 
FLI1                       Flightless 1 
H 
H2O2                     Hydrogen peroxide 
HDAC                   Histone Deacetylase 
HEK                       Human Embryonic Kidney 
HRP                       Horseradish peroxidase 
I 
IGF-1                     Insulin-like growth factor - 1 
IgG                          Immunoglobulin g 
K 
kb                             Kilobase 
L 
L                                Litre 
LB                             Luria-Bertani 
LHX9                        LIM Homeobox 9 
M 
M                                Molar 
MAPK                       Mitogen-activated protein kinase 
mg                              Milligram 
min                            Minute(s) 
ml                               Millilitre 
mM                             MilliMolar 
mTOR                        Mammalian target of rapamycin 
MYO1C                      Myosin -1C 
N 
NaCl                          Sodium chloride 
NCAM                       Neural Cell Adhesion Molecule 
NCBI                         National Centre for Biotechnology Information 
NSCLC                     Non-small-cell lung carcinoma  
NFW                         Nuclease-free water were 
ng                              Nanogram, 
NLS                           Nuclear Localisation Sequence 
nm                            Nanometer 
Abbreviations 
      
 
 
 
Page xvi 
 
  
P 
PBS                           Phosphate buffered Saline 
PC-3                          Prostate cancer cell line 
PCR                          Polymerase Chain Reaction 
PEST                        Proline, Glutamic acid, Serine, Threonine 
PH                            Pleckstrin homology 
PI                              Protease Inhibitor 
PI3K/Akt                 Phosphatidylinositol-4, 5-bisphosphate 3 Kinase 
PIP2                         Phosphatidylinositol-4, 5-bisphosphate 
PKC                         Protein Kinase C 
PRP8                        pre-mRNA processing 8 
PRPF31                    pre-mRNA processing factor 31 homolog 
PVDF                       Polyvinyidene Fluoride, ii 
R 
RBP                          RNA-binding Proteins 
RLU                          Relative Luciferase Units 
RPMI                        Roswell Park Memorial Institute 
RRM                         RNA recognition motif 
rpm                           round per minute 
RS                             Arginine/serine-rich domain 
Runx1                       Runt-related transcription factor 1 
RUNX1-ETO           Runt-related transcription factor 1- eight twenty-one 
S 
SDS                             Sodium Dodecyl Sulfate 
SE                                Standard Error 
SF1                              Splice factor 1 
SF1                              steroidogenic factor 1   
siRNA                         Small interfering RNA 
snRNP                         Small nuclear ribonucleoprotein 
SOC                            Super Optimal broth with Catabolite repression 
SPHINX                     SR protein Inhibitor X 
SR                               Serine/argenine rich proteins 
SR proteins                 Serine/arginine-rich proteins 
SRPIN340                   Specific serine/threonine protein kinase inhibitor 340 
SRPIN340                   N-[2-(1-piperidinyl)-5-(trifluoromethyl) phenyl] isonicotinamide 
SRPK1                        Serine rich protein kinase-1 
SRSF-1                        Serine rich splice factor-1 
SSO                              Splice switching oligonucleotides 
T 
TAE                          Tris base, acetic acid and EDTA 
Taq                            DNA polymerase from Thermus aquaticus 
TBST                        Tris-buffered saline and Tween-20 
TE                             Tris, EDTA  
Abbreviations 
      
 
 
 
Page xvii 
 
  
TEMED                    Tetramethylethylenediamine 
Temp                         Temperature 
TGF                           Transforming Growth Factor 
TPM                           Transcripts per million 
 
U 
U                                 Unit(s) of enzyme activity 
UV                              Ultraviolet 
V 
V                                Volts 
VEGF                        Vascular endothelial growth factor 
W 
WT                            Wild type 
WT-1                       Wilms’ tumour-1 
 
 
  
 
 
 
 
 
 
 
Chapter One: Introduction 
      
 
 
 
 Page 2 
 
 
  
1 Chapter One: Introduction 
 
1.1 Alternative splicing and disease  
1.1.1 Discovery of pre-mRNA splicing 
 
In eukaryotic cells, the initial pre-mRNA transcript must be processed into mature 
messenger RNA (mRNA) required for protein synthesis. Pre-mRNA splicing, which is 
essential for gene expression, is the removal of introns and formation of a final mRNA 
consisting of the remaining sequences, called exons.    
Pre-mRNA splicing was first characterised in the 1970s in adenoviruses (Chow et al., 
1977). Six years later, researchers discovered that more than one mRNA could be 
generated from a single immunoglobulin μ gene by a process called alternative splicing 
(Early et al., 1980). There are several modes of alternative splicing (AS). At least 94% 
of human multi-exon genes undergo alternative splicing (Zhou et al 2012). Alternative 
pre-mRNA splicing is a prevalent phenomenon in developed eukaryotic genomes that 
provides a mechanism that increases the complexity of proteins expressed by a genome. 
Alternative splicing plays a significant role in the control of cellular function. Minor 
changes in AS regulation can significantly alter an important cellular process that can 
lead to disease. For example, autosomal dominant forms of retinitis pigmentosa are 
caused by a mutation in the splicing factors PRPF31/U4-61k and PRP8 (Tazi, Bakkour, 
and Stamm, 2009). Altered activity, expression, or subcellular localization of splicing 
factor kinases may be one of the causes of the irregular splicing events linked to cancer 
and other diseases. Through AS, several splice variants can arise from a single gene with 
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different isoforms performing different biological functions. For instance, Troponin I 
(TnI), is a protein that plays an important role in muscular contraction. TnI expressed 
three isoforms in different types of muscle tissue that perform different functions,  (ssTnI 
isoform in the slow skeletal muscle, fsTnI isoform in the fast skeletal muscle and cTnI 
isoform in the cardiac muscle) (Feng et al., 2012 & Yin, Ren, and Guo, 2015). In different 
cell types, alternative splicing gives additional layers for regulating cell-specific gene 
expression.                    
1.1.2 Pre-mRNA splicing catalysed by the spliceosome 
 
A large macromolecular complex, known as the spliceosome, catalyses pre-mRNA 
splicing. This complex consists of five small nuclear ribonucleoprotein particles (U1, U2, 
U4, U5, and U6 snRNPs) and more than 200 auxiliary proteins. It is the relative 
expression and activity of these auxiliary proteins that have a big impact on alternative 
splicing. The activity of the spliceosome is regulated by cis-acting RNA sequence 
elements and trans-acting RNA-binding Proteins (RBP). Regulated reversible 
phosphorylation is vital for modulating the activity of both core spliceosomal 
components and accessory splicing factors. For instance, phosphorylation of the SR 
protein splicing factor SRSF1 modulates its interaction with U1snRNP, consequently 
modulating the assembly of the spliceosome. The function of SR proteins is regulated by 
their phosphorylation or dephosphorylation and splicing can be inhibited by both hypo- 
and hyperphosphorylation (Zhong et al., 2009). For example, dephosphorylation of 
SRSF1 is essential for the catalysis of the first transesterification reaction, while its 
phosphorylation promotes spliceosome assembly. Several important families of splicing 
kinases are involved in pre-mRNA splicing regulation, including the SR protein kinases 
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(SRPKs), the CDC2-like kinases (CLKs) and pre-mRNA splicing 4 kinases 
(PRP4K/PRPF4B). 
1.1.3 Alternative splicing events: types and extent  
 
75% of all human genes undergo cassette exon (exon skipping) events where it greatly 
increases in biodiversity. Therefore, exon skipping is the most common form of 
alternative splicing in eukaryotes (Weatheritt, Sterne-Weiler and Blencowe, 2016). The 
other types include alternative 3′ splice site selection (3′ SS selection), alternative 5′  
splice site selection (5′  SS selection) and intron retention and mutually exclusive exons 
(Keren, Lev-Maor and Ast, 2010).  
Figure 1.1 shows the different AS mechanisms. Exon skipping or cassette exon occurs 
when exons are spliced out from the transcript with flanking introns. Alternative 3′  splice 
site and 5′ splice site selection happen when two or more splice sites are recognised by 
splice factors at the beginning or end of an exon, respectively. Intron retention occurs 
when an intron remains in the mRNA transcript while one of two exon remains in the 
mRNA after splicing, but not both this is known as mutually exclusive exons (Cartegni, 
Chew and Krainer, 2002). 
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Figure 1. 1: Different types of alternative splicing (AS) events.  
Shows different modes of alternative splicing (exon skipping (a), alternative 3′ splice-site selection (b), 
alternative 5′ splice-site selection (c), intron retention (d), mutually exclusive exons (e), alternative 
promoters (f) and alternative polyadenylation (g). by alternative splicing, the same initial transcript could 
be spliced in many ways giving deferent isoforms of the final transcript (figure adapted from Keren, Lev-
Maor, and Ast, 2010)   
 
1.1.4 Regulation of alternative splicing and splice factor kinases 
 
Regulated reversible phosphorylation is vital for modulating the activity of both central 
spliceosomal components and accessory splicing factors. For instance, phosphorylation 
of the splicing factor SRSF1 modulates its interaction with U1snRNP, consequently 
modulating the assembly of the spliceosome. The function of SR proteins is regulated by 
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their phosphorylation or dephosphorylation and splicing can be inhibited by both hypo- 
and hyperphosphorylation.  
Another study demonstrated the importance of AS in regulating histone methylation and 
demethylation in neurons (Fiszbein and Kornblihtt, 2016). It has also been reported that 
suppressing or activating some protein kinases, such as Serine/Arginine splicing factor 
kinase (SRPK1) affects splicing during angiogenesis (Amin et al., 2011 and Wagner et 
al., 2019). Therefore, controlling gene expression through protein kinase activity has 
allowed us to hypothesise that inhibiting SRPK1 and Clk1 could significantly change the 
splicing of different key genes such as VEGF. 
Several important families of splicing kinases are involved in pre-mRNA splicing 
regulation, including the SR-Protein Kinases (SRPKs), the CDC2-like kinases (CLKs) 
and pre-mRNA splicing 4 kinases (PRP4K/PRPF4B). It has been observed that SR 
proteins interact with other proteins, the SR-related proteins, to regulate splicing. SR-
related proteins carry RS domains and RNA binding motifs (PWI), or zinc finger motifs 
(Zn) (Zhou and Fu, 2013). The interaction between SR proteins and SR-related proteins 
occurs through the SR domains of both proteins, thereby initiating splicing (Shepard and 
Hertel, 2009). Some examples of SR-related proteins include both subunits of the U2AF 
heterodimer (U2AF-35 and U2AF-65), U1-70K, and the splicing co-activators SRm 
160/300 (Long and Caceres, 2009). 
PRP4 binds pre-mRNA splicing factors SRSF1 (SRp30a or ASF/SF2), PRP6 and pinin. 
It is an essential kinase that associates with both the U5 snRNP and the N-CoR 
deacetylase complexes. PRP4 manage pre-mRNA splicing with chromatin remodelling 
and transcriptional regulation.  
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1.1.5 Atypical alternative splicing in cancer 
 
Errors in splicing regulation have been shown to contribute to disease states. Figure1.2 
summarize the different types of mutation that can affect splicing. The 5′ and 3′ splice 
site, as well as the branchpoint A, are important for the excision of introns and the joining 
of the exon. Thus any mutation in the splice site can result in mis-splicing. There are 
regulatory sites that contribute to the regulation of AS, exonic and intronic splice 
enhancers and silencers are known as ESE, ESS, ISS and ISE. They play a very important 
role in alternative splicing regulation and mutations in them may lead the trans factors 
such as the SR protein to bind incorrectly or be unable to bind the sequences, thus 
resulting in mis- splicing. Here a few examples are given to illustrate the importance of 
alternative splicing in different tumours.     
 
Figure 1. 2: possible mutations that can occur that affect splicing. 
The regulatory sequences on the pre-mRNA such as the splicing sites, pyrimidine tract, exonic splicing 
enhancer (ESE), Exonic splicing silencer (ESS), intronic splicing enhancer (ISE), and intronic splicing 
silencer (ISS) are important as any mutation will result in the improper binding of the Trans factors 
involved in splicing. This will then lead to mis-splicing. Figure adapted from Baralle, 2005. 
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The Runt-related transcription factor 1 gene (RUNX1), also known as acute myeloid 
leukaemia 1 (AML1) is located on chromosome 21q22. It encodes a crucial 
haematopoietic transcription factor and regulates gene expression by binding to specific 
DNA sequences (Komeno et al., 2014). RUNX1 is essential for haematopoietic 
development (Zhao et al., 2012). The RUNX1 expresses two isoforms through alternative 
splicing of exon 6: Runx1 (with exon 6) and ΔRunx1 (without exon 6). The ΔRunx1 
isoform blocks blood cell differentiation resulting in the massive accumulation of 
immature cells. It has been shown that ΔRunx1 is overexpressed in malignancies 
(Komeno et al., 2014). Acute myeloid leukaemia originates from different chromosomal 
abnormalities, such as t(8;21)(q22;q22) resulting in the fusion of RUNX1-ETO (Runt-
related transcription factor 1- eight twenty-one) genes, the second is t(12;21)(p12;q22) 
resulting in the fusion of TEL-RUNX1 genes, the third is  t(3;21)(q26;q22) resulting in 
the fusion of RUNX1/MDS1/EVI1 genes (Zhao et al., 2012). However, it has been 
reported that rare cases of patients with Philadelphia chromosome-positive (Ph+) are 
detected in AML. However, common cases of Ph+ are found in chronic myeloid 
leukaemia (CML) and they are considered as blast phases due to a rapid expansion of 
immature blood cells (blasts) (Bacher et al., 2011). Therefore, co-expression of RUNX1 
with BCR–ABL1 (fusion gene necessary for the pathogenesis of CML) induces the acute 
myeloid leukaemia (AML) transformation in CML patients (Zhao et al., 2012), 
suggesting the importance of evaluating the effect of combinations of ΔRunx1 expression 
in CML cells. 
Alternative splicing patterns are altered in cancer (Venable 2006). The expression of 
alternative splicing or tumour specific splice variants affects many cellular events that 
are critical in tumorigenesis (Skotheim 2007). For example, KLF6, a member of the 
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kruppel like transcription factor (KLF) family is a known transcription factor and a 
tumour suppressor in colorectal (Reeves et al 2004), lung (Ito et al.,2004) and gastric 
cancer (Cho et al., 2005). The expression of KLF6 is also able to reverse tumorigenic 
phenotypes (Kimmelman et al., 2004). KLF6 can be alternatively spliced to KLF6 SV1 
(Narla et al., 2005). KLF6 SV1 is formed due to the use of an alternatively cryptic splice 
site in exon 2; the resultant protein doesn’t contain the activation and DNA binding 
domain (Narla et al., 2005). KLF6 SV1 is able to compete with wild type KLF6 and 
thereby affect KLF6 function. KLF6 SV1 overexpression leads to tumour aggressiveness 
and poor prognosis for the patient. Also, there is twice as much KLF6 SV1 mRNA 
compared to KLF6 in prostate cancer samples compared to wild type prostate samples 
(Narla et al., 2005). This also has been observed in ovarian cancer. (DiFeo et al., 2006).   
1.2 Splice factor kinase-1 (SRPK1) 
1.2.1 SRPK kinases: structure and function 
 
The SRPK family of kinases is highly specific for the SR family of splicing factors. The 
human genome encodes the SRPK family of kinases which through alternative splicing 
generate SRPK1, SRPK2 & SRPK3. SRPK1 is expressed predominantly (Zhou and Fu, 
2013) and functions as a tumour suppressor or an oncogene in different cell types (Wang et 
al., 2014). SRPK2 and SRPK3 are expressed in the nervous system and muscle cells, 
respectively (Zhou and Fu, 2013). Unless the cell is stimulated by a signal, most of the 
SRPKs are contained in the cytoplasm, However, SRPKs can mobilise to the nucleus 
during the M phase of the cell cycle and stimulate the aggregation of splice factors. For 
example, a number of studies suggest that SRSF1 phosphorylation mediated by SRPK1 
is essential for its nuclear localization and the resulting splicing activity triggered by 
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stimulation of specific signalling pathways (e.g., IGF-1 and EGF growth factor 
treatments). There are other conditions that may contribute to increasing SRPK1 nuclear 
localisation such as cellular stress or osmotic stress. The human SRPK1 gene is located 
on chromosome 6p21.2-p21.3. The SRPK1 protein has two kinase domains separated by 
a spacer sequence. The accessory domain is known to regulate SRPK1 localization as its 
deletion results in limited nuclear localization (Wang et al., 1998; Zhong et al., 2008). 
The accessory domain is essential for protein substrate phosphorylation as well (Plocinik 
et al., 2011). SRPKs phosphorylate specific serine amino acids of proteins rich in 
serine/arginine repeats (RS-domain). The N-terminus and C-terminus of SRPK1 play an 
auxiliary role as their deletion does not inactivate the catalytic activity kinase (Gosh and 
Adam, 2011). 
1.2.2 Regulation of SRPK1 activity  
 
An added layer of complexity comes from the finding that SRPK1 activity is regulated 
by the Akt cell signalling pathway. Akt (v-Akt Murine Thymoma Viral Oncogene)/ PKB 
(Protein Kinase-B) is a serine/threonine kinase that is involved in mediating different 
biological responses, such as inhibition of apoptosis and stimulation of cell proliferation. 
Zhou et al 2012 found that Akt activation plays a major role in EGF-induced splicing in 
HEK 293T cells through modulation of SRPK1 activity. In most cell signalling 
transduction cascades, Akt directly phosphorylates its targets, but in EGF treated cells, 
activated Akt binds and induces SRPK1 autophosphorylation.  Using mass spectrometry 
(Zhou et al 2012) determined four in vitro phosphorylation sites in SRPK1. Two 
autophosphorylation sites (S33 and S309) and two other additional sites (T326 and S587) 
(figure1.3), which are phosphorylated only in the presence of active Akt. Consequently, 
they mutated both sites to alanine either in combination (K1-326A587A) or individually 
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(K1-587A, for S587) and (K1-326A for T326) and the result showed only the double 
mutation eliminated Akt-induced SRPK1 autophosphorylation in vitro. The kinase 
activity of SRPK1 on SR protein substrates such as SRSF1 was not affected by the 
mutation. (figure1.4). 
 
Figure 1. 3: Schematic presentation of SRPK1 domains. 
 Two candidate phosphorylation sites are highlighted in bold (T326 and S587) separated by a spacer 
sequence; an accessory domain (Zhou et al., 2012).  
 
Figure 1. 4: Akt-mediated phosphorylation of SRPK1 at T326 and S587.  
Double Alanine mutations (K1-326A587A) on two phosphorylation sites abolished Akt-mediated 
phosphorylation but had no effect on the kinase activity of SRPK1 on the SR protein SRSF1. There was 
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no major effect on Akt-induced SRPK1 autophosphorylation by individual phosphorylation site mutation 
(K1-587A, for S587) and (K1-326A for T326) (taken from Zhou et al., 2012).  
 
How then does Akt signalling cause changes in the alternative splicing of genes? 
Following Akt signalling, SRPK1 autophosphorylation causes SRPK1 to concentrate in 
the nucleus where it can then phosphorylate nuclear splice factors, thus affecting 
alternative splicing outcomes (Zhou et al 2012). Might this apply in other cancer cells? 
Data suggests that alteration in Akt cell signalling in cancer cells leads to abnormal 
SRPK1 activity through autophosphorylation followed by nuclear accumulation, 
resulting in altered Hsp splicing from Hsp70- to Hsp90-containing complexes. This leads 
to enhanced SRPK nuclear translocation and SR protein phosphorylation in these cells. 
Thus one mechanism through which SRPK1 activity can be regulated is through its 
autophosphorylation. Chaperones which have been identified are the heat shock family 
and co-chaperones Hsp40/Hsp70 and Hsp90/Aha1. While Hsp40 targets region outside 
the accessory domain, Hsp90 targets the accessory domain (Zhong et al., 2008). 
Chaperone complex assembly is initiated by the binding of Hsp40/Hsp70 SRPK1 
followed by the binding of Hsp90 and Aha1 a co-chaperone. Formation of SRPK1-
chaperone-cochaperone complex also ensures the folding of SRPK1 into its active 
conformation as well as protects it from proteasome degradation. This model has been 
validated as inhibition of the chaperone Hsp90 ATPase activity has resulted in 
dissociation of the chaperone complex and SRPK1 nuclear localization (Pratt and Toft, 
2003; Zhong et al., 2008).  
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Figure 1. 5: Summary of EGF signalling through the Akt-SRPK-SR axis to regulate 
alternative splicing in the nucleus.  
Hsp70 is responsible for inhibiting nuclear import of the splicing kinases, Hsp90 knocks off Hsp70 to 
facilitate nuclear import, and 14-3-3 functions to prevent excessive accumulation of the splicing kinases in 
the nucleus while PPases enzyme regulates the SRs phosphorylation (Adapted from Zhou et al 2012). 
 
1.2.3 Molecular interactions of SRPK1 
 
Like other protein kinases, SRPK1 interacts with several molecules which serve as a 
substrate or control its association with substrates. Such interactions result in the 
propagation of cellular function by the substrate or regulation of their activity either 
directly or indirectly. The SR-protein family of splice factors are its best-known substrate, 
especially SRSF1 (previously known as ASF/SF2). SR-proteins are a family of splice 
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factor which is characterised by the presence of at least one amino-terminal RNA 
recognition motif (RRM) and a C-terminal rich in RS peptides. SR proteins play an 
important role in the regulation of pre-mRNA splicing, mRNA nuclear export, translation 
and non-sense mediated RNA decay (Long and Caceres, 2009; Plocinik et al., 2011; 
Corkery et al., 2015). Phosphorylation of SR proteins by SRPK1 results in nuclear import 
of SR proteins and their localization into nuclear speckles (thought to be sites of splice 
factor storage). SRSF1 is a member of the SR protein family which has been extensively 
studied and to be strongly phosphorylated by SRPK1. SRSF1 has two RNA recognition 
motifs (RRM) and an RS domain of about 50 amino acids in length. It is known that 
SRPK1 interacts with about 10-12 amino-acid of the RS domain; an interaction which 
produces high-affinity binding and considered critical for the regulation of the extent to 
which SRSF1 is phosphorylated (Ngo et al., 2007; Plocinik et al., 2011). Phosphorylation 
of SRSF1 by SRPK1 has been shown to be in C- to N-terminal direction irrespective of 
the presence (SRPK1-FL) or absence of N-terminal (SRPK1ΔN) and spacer domain 
(SRPK1ΔS).  
Furthermore, SRPK1 has been shown to regulate epidermal growth factor (EGF) 
activation of multiple signal transduction pathways such as JAK/STAT pathway.  EGF  
is a proto-oncogene known to be up-regulated in tumour cells and also able to activate 
several oncogenic pathways in several cancers. This study suggests that EGF can be 
activated by SRPK1 via the phosphatidylinositol-3-kinase/protein kinase-B (PI3/Akt) 
pathway other than the well-known downstream mammalian target of rapamycin 
(mTOR) pathway to induce an alternative splicing events that result in series of re-
arrangements with molecular chaperones and other regulatory factors to regulate the 
cellular distribution of the splicing kinases. in the nucleus (Zhou et al., 2012). Supporting 
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this finding is a mass spectrometry analysis of SRPK1phosphopeptides showing multiple 
phosphorylation sites which could be induced by EGF or Akt (Zhou et al., 2012). Since 
SRPK1 has been shown to have both cytoplasmic and nuclear localization, it is thought 
that SRPK1 may have other substrates which underpin its cellular functions. 
1.2.4 SRPK1 expression in malignancies 
 
Abnormal SRPK1 expression is observed in epithelial malignancies, such as pancreatic 
carcinoma in which SRPK1 levels are increased (Bullock and Oltean, 2017). Hayes et al 
2007 showed that SRPK1 levels are similarly upregulated in breast and colon tumours, 
with SRPK1 expression increases with tumour grade. Thus, SRPK1 could be used as a 
marker for tumour progression. Increased apoptosis in breast and colon tumour cells is 
associated with lower expression of SRPK1. In breast cancer cells, Xing-hua Li et al 
2014 described that SRPK1 is up-regulated at both mRNA and protein level. The same 
up-regulation of SRPK1 at the mRNA and protein level was shown in non-small cell lung 
cancer (Liu H et al 2016), prostate cancer (Mavrou et al., 2014), glioma (Wu et al., 2013) 
and hepatocellular carcinoma (Zhou et al., 2013). Down-regulation of SRPK1 has been 
reported with tumours of germinal origin (ovarian cancer) where elevated expression of 
UCA1 RNA was identified which is linked to cisplatin resistance (Wang et al., 2014). 
SRPK1is also expressed in normal human retinal tissue where it might play an important 
role in the regulation of proliferation, migration, differentiation, and maturation of 
neurons and neuronal synapses of retinal tissue. Reduction in cells positive for SRPK1 
protein was noticed in advanced and large retinoblastoma tumours as well as recurrences 
or metastases. Low levels of SRPK1 protein could be relevant to drug resistance 
mechanism in RB (Krishnakumaret et al., 2008; Wang et al., 2014). Thus both the 
upregulation and downregulation of SRPK1 might be oncogenic, in different contexts. 
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SRPK2 has also been reported to be upregulated in multiple types of cancers. In clinical 
colon cancer samples, SRPK2 was found to be up-regulated although its contribution to 
colon cancer is not yet clear. SRPK2 overexpression enhanced growth and migration of 
colon cancer cells (HCT-15 and HT-29) while SRPK2 knockdown resulted in inhibition 
of growth, migration and tumorigenicity of colon cancer cells (Wang et al., 2016).  
1.2.5 SRPK1 as a therapeutic target 
 
Therapeutic intervention targeting SRPK1 represents a promising approach to treating 
cancers in which SRPK1 is involved. In pancreatic cancer cell lines Capan-1, Capan-2, 
MiaPaCa2, Panc1, BxPC3, and Su86.86, siRNA-mediated down-regulation of SRPK1 
resulted in a dose-dependent decrease in proliferation and an increase in apoptosis and 
an improved sensitivity of tumour cells to gemcitabine and/or cisplatin, suggesting that 
SRPK1 is a new potential target for ductular pancreatic cancer treatment (Hayes GM et 
al 2006). In metastatic melanoma, the existing treatment doesn’t target angiogenesis, 
which is a vital part of any tumour progression. The current therapies for melanoma target 
either cancer mutations driving growth or immune-based therapies. Gammons et al 2014 
suggested inhibiting splice-site selection with SRPK1 inhibitors (e.g. SRPIN340) to alter 
VEGF splicing, reducing expression of the pro-angiogenic VEGF165 isoform, thereby 
repressing angiogenesis in the context of melanoma. Accordingly, SRPK1 inhibitors may 
be used as therapeutic agents. In prostate cancer (PCa) Mavrou et al 2014 showed that in 
PC-3 cells with SRPK1 knockdown, or using SRPK1 inhibitors that were administrated 
intraperitoneally in an orthotopic mouse model of PCa, VEGF splicing switched toward 
anti-angiogenic splice isoform, VEGF165b. This resulted in tumours that developed 
more slowly in xenografts with reduced vascular density. In PC-3 cells in which SRPK1 
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was knocked-down by RNA interference, no effects were observed on growth, migration, 
proliferation and invasion abilities of PC-3 cells in vitro. These results could provide the 
basis for anti-angiogenic therapeutic strategies that target SRPK1 inhibition in prostate 
cancer.  
1.3 The Wilms tumour suppressor (WT1)   
1.3.1 WT1; background 
 
The tumour suppressor gene WT1 was cloned in 1990 due to its association with WAGR 
syndrome (Wilms tumour, aniridia, genital anomalies and intellectual disability; Rose et 
al., 1990). WT1 is a zinc finger protein that is essential for the development of multiple 
different mammalian tissues including the mesothelium, gonads, heart, blood vessels, 
blood, spleen, nervous system, eyes, lungs, liver and kidneys. Knockout of the WT1 gene 
in mice is embryonically lethal and the mice fail to develop kidney and gonads thus 
indicating that WT1 is important in urogenital development (Kreidberg et al., 1993). In 
adult humans, WT1 is highly expressed in the spleen, smooth muscle and kidney as well 
as both male and female reproductive systems. Mutations in WT1 are associated with 
Wilms’ tumour, in Denys Drash Syndrome, and Frasier Syndrome (Barbaux et al., 1997; 
Klampt et al., 1998). DDS is characterised by childhood nephrotic syndrome, glomerular 
sclerosis, end-stage renal failure and Wilms tumours. Frasier Syndrome is very similar to 
DDS and is characterized by focal glomerular sclerosis, male to female sex reversal and 
gonadal dysgenesis (Moorty et al., 1987).     
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1.3.2 WT1 in cancer  
 
Leukaemias, melanomas and breast cancers are all examples of adult cancers which, in 
some cases, can be WT1-dependent. In adult cancers in which WT1 is implicated, WT1 
often exhibits oncogenic activity. WT1 can even be found to be expressed in adult cancers 
of tissues in which WT1 would not normally be expressed. Adult cancers which have 
been found to be WT1-dependent in some cases include leukaemias, melanomas, renal 
cancers and breast cancers.  WT1 is overexpressed in as many as 80% of cases of some 
subsets of leukaemia which indicates that WT1 can also have oncogenic activity (Inoue 
et al., 1997). In addition, WT1 mutations can also be associated with poor prognosis such 
as in both adult and childhood cases of acute myelogenous leukaemia (AML) (Paschka 
et al., 2008 and Hollink et al., 2009). WT1, therefore, is a highly complex, context-
specific transcription factor with multiple different functions and mutations in different 
cancer types. WT1 has even been found to be overexpressed in some leukaemia cases 
whereas there is loss of function mutations in others (Artibani et al., 2017 and Lee et al., 
2017). 
1.3.3 WT1 structure and function  
 
WT1 can exhibit a range of different activities and functions, in part due to the alternative 
splicing of the WT1 gene. The WT1 gene spans 50kb on chromosome 11p13 and it 
encodes a transcription factor that contains four zinc fingers domain used for DNA 
binding; it is structurally homologous to the early growth response (EGR) family of 
transcription factors (Rauscher et al., 1993). In addition, the N-terminus of WT1 contains 
a putative RNA recognition motif and also a proline/glutamine-rich region involved in 
transcriptional transactivation or repression domain. There is a self-dimerization domain; 
however, the significance of the ability of WT1 to dimerise remains unclear (reviewed in 
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Scholz and Kirschener 2005). WT1 is also alternatively spliced as there are several 
different isoforms of WT1 following post-transcriptional modifications (including 
alternative splicing and alternative upstream CUG translation start site). The four main 
splice variants of WT1 arise from either including or excluding exon 5 from the mature 
mRNA, and this results in proteins that contain or lack a 17 amino acid sequence 
(between the N-terminus and the zinc finger domains) and a three amino acid insertion 
of lysine, threonine and serine (KTS) due to an alternative 5′ splice site in exon 9 
(between the third and fourth zinc fingers domain). The –KTS isoforms have strong DNA 
binding capacities and act as a transcriptional regulator while the +KTS isoforms have 
been found to be active post-transcriptionally and are able to bind to RNA. The +KTS 
isoform is also able to bind to the splice factor U2AF65 (Davies et al., 1998) and localise 
to nuclear speckles (Larsson et al., 1995). +/-KTS ratios are conserved in evolution and 
disruption of the ratio from 2:1 to 1:2 results in Frasier Syndrome (Klamt et al., 1998). 
(figure1.6).  
 
Figure 1. 6: structure of the WT1 protein.  
WT encodes four zinc fingers, annotated as ZF in the figure, and is alternatively spliced into four major 
isoforms. The four major isoforms are formed due to the inclusion or exclusion of 17 amino-acids encoded 
by cassette exon five and the amino acids KTS that arise from an alternative 5′ splice site in exon nine. 
(Adapted from Roberts, 2005). 
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1.3.4 The BASP1-WT1 interaction  
 
Brain acid-soluble protein (BASP1) is a transcription co-repressor that interacts directly 
with WT1.  In human embryonic kidney (HEK) cells, BASP1 was shown to translocate 
to the nucleus where it regulates WT1 to exert its effect on WT1 target genes. The 
mechanism of transcriptional regulation by BASP1 involves the recruitment of a large, 
repressive protein complex containing histone deacetylase. BASP1’s nuclear localisation 
sequence (NLS) allows it to translocate to the nucleus where it binds to WT1 at the 
promoters of WT1 target genes (Carpenter et al., 2004). 
 
 
 
Figure 1. 7: BASP1 acting as a transcriptional co-suppressor for WT1. 
a) WT1 (Wilms tumour 1) binds to target genes and recruits CBP (CREB binding protein), resulting in 
histone acetylation and activation of transcription. b) BASP1 binding to WT1 results in the dissociation of 
CBP and the recruitment of HDAC1 (Histone Deacetylase) resulting in deacetylation of histones and 
repression of transcription. BASP1 binding of PIP2 (phosphatidylinositol 4, 5 bisphosphate) allows the 
recruitment of HDAC (Adapted from Toska et al., 2012). 
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The N-terminal myristoyl group of myristoylated BASP1 allows the recruitment of 
phosphatidylinositol 4, 5 bisphosphate (PIP2) to the BASP1-WT1 complex located at the 
WT1 target gene promoter (figure1.7a). BASP1 binding of PIP2, in turn, allows the 
recruitment of histone deacetylase 1 (HDAC1) (12). HDAC1 is a histone remodelling 
factor that removes the acetyl side chain from a histone lysine residue (H3K9) resulting 
in chromatin condensation. The recruitment of HDAC1 to a WT1 target gene results in 
local condensation of chromatin and thus transcriptional repression of the target 
(figure1.7b). BASP1 is also able to recruit prohibitin, another transcriptional co-
repressor. Prohibitin, in turn, recruits ATP dependent chromatin remodelling factors such 
as Brahma related gene 1 (BRG1) which results in the dissociation of CREB binding 
protein (CBP) from the promoter (Toska et al., 2012). CBP has histone acetyltransferase 
activity (results in relaxation of chromatin structure) and is a scaffold protein for the 
transcriptional complex (Ogryzko et al., 1996). The dissociation of CBP, therefore, 
results in further transcriptional repression of WT1 target genes. BASP1 is, therefore, 
able to convert WT1 activity from a transcriptional activator to a transcriptional repressor 
of WT1 target genes. 
1.3.5 Regulation of SRPK1 transcription by Wilms’ tumour gene-1 (WT1)  
 
Several studies have linked WT1 to the regulation of SRPK1 transcription. Up-regulation 
in SRPK1 expression has been observed in a wide variety of tumours such as 
hepatocellular carcinoma (Zhou et al., 2013), lung adenocarcinoma, squamous cell lung 
carcinoma (Gout et al., 2012), pancreatic, colon and breast cancer. Moreover, expression 
of SRPK1 was noticed to be increased in Denys Drash Syndrome (DDS) podocytes, 
epithelial cells of the visceral layer of a renal glomerulus. DDS is a rare disorder 
consisting of the triad of congenital nephropathy, Wilms tumours, and intersex disorders. 
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DDS podocytes harbour a mutated WT1 gene. WT1 was found to bind and represses 
SRPK1 promoter and downregulate its expression in normal podocytes, but is unable to 
repress SRPK1 in DDS podocytes (Amin et al., 2011). Upregulation of SRPK1 has been 
linked to hyperphosphorylation of SRSF1, leading to increases in the nuclear import of 
SRSF1 and hence a splice shift in VEGF to favour the proangiogenic isoform in DDS. 
The cellular interactions of SRPK1 with SRSF1 have become a major pathway through 
which SRPK1 affects angiogenesis. Recent research has shown that SRPK1 and its best 
-studied substrate, SRSF1 form an essential pathway responsible for the regulation of the 
alternative splicing of vascular endothelial growth factor (VEGF) pro/antiangiogenic 
isoform in renal epithelial cells (podocytes) (Amin et al., 2011) and in colon carcinoma 
cells (Oltean et al., 2012). The latter study further demonstrated that a knockdown of 
SRPK1 increased levels of VEGF anti-angiogenic isoform as well as prevents tumour 
growth in xenograft by a reduction in microvessel density. Similar findings have been 
observed in a study using the prostate cancer cell line PC3 (Mavrou et al., 2014). 
A recent study has observed the transcriptional regulation of SRPK1 by WT1 in a 
different context, making use of SRPK1 promoter: luciferase reporters designed in the 
Ladomery laboratory, (Amin et al., 2011). Wagner et al., 2019 has revealed that WT1, 
SRPK1, SRSF1, and the angiogenic VEGF isoform were highly expressed in tumour 
endothelium compared to normal lung endothelium. An inducible conditional vessel-
specific knockout of WT1 reduced WT1, SRPK1, and SRSF1 expression in endothelial 
cells and induced a shift towards the antiangiogenic VEGF isoform. WT1 (-KTS) isoform 
directly binds and activates both the promoters of SRPK1 and SRSF1 better than WT1 
(+KTS) isoform in endothelial cells. This suggests that WT1, potentially, has the ability 
not only to repress SRPK1 but also to activate its transcription. 
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1.4 Brain abundant membrane attached signal protein 1 
(BASP1)  
1.4.1 BASP1; background  
 
Brain acid-soluble protein 1 (BASP1) is a multifunctional protein found in many different 
tissues and cell types throughout the human body. The RNA and protein expression levels 
of BASP1 are particularly high in the brain and are found across a vast array of cell types 
within multiple areas of the brain including neuronal cells and glial cells of the cerebral 
cortex, hippocampus and caudate, endothelial cells and neuropils of the cerebral cortex 
and cells of both the granular layer and the molecular layer of the cerebellum (The Human 
Protein Atlas. 2018). BASP1 was first characterised in the axonal termini of neuronal 
cells as a member of the GAP-43 family, a group of proteins which were known to be 
involved in axon growth and memory formation (Mosevitsky et al., 1994). However, 
BASP1 has since been identified in a vast array of different organs, tissues and cell types 
throughout the body including but not limited to those of the endocrine tissues, bone 
marrow, lungs, stomach, kidneys and skin, as well as both male and female reproductive 
tissues (H. P. Atlas. 2018). Depending on the cell type and location, BASP1 has been 
proposed to perform a range of different context-specific activities and functions 
(Mosevitskiĭ et al., 1996). 
1.4.2 BASP1 in cancer  
 
BASP1 has been shown to exhibit various tumour suppressive activities in acute 
myelogenous leukaemia cell lines including proliferation inhibition and increased 
apoptosis. In addition, the BASP1 promoter is methylated and silenced by the AML1-
ETO fusion protein in AML cells (Zhou et al., 2018). As WT1 is overexpressed in many 
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cases of AML it is possible that BASP1 exerts its tumour suppressor activity by co-
repression of WT1 target genes. Similarly, BASP1 has been shown to be downregulated 
by DNA methylation in some hepatocellular carcinoma cases (Moribe et al., 2008). 
BASP1 has also been shown to have reduced expression in thyroid cancer cells compared 
with normal tissue, and restoration of BASP1 resulted in inhibition of cell growth and 
migration (Guo et al., 2016). These reports show that BASP1 can act as a tumour 
suppressor in multiple cancer types and is often a target of repression in cancer cells. 
However, one exception has been demonstrated in cervical cancer cells. In the latter 
context, BASP1 expression was shown to promote cancer cell proliferation, colony 
formation efficiency and tumourigenicity as well as being associated with increased stage 
progression and poor prognosis (Tang et al., 2017). 
However, in breast cancer, BASP1 acts as a tumour suppressor (Marsh et al., 2017). In 
addition to exhibiting tumour suppressor activity, BASP1 expression has been associated 
with increased breast cancer patient survival. Interestingly, BASP1 was also found to 
colocalise with several components of the nuclear actin network including β-actin, 
gelsolin, myosin-1C (MYO1C) and flightless 1 (FLI1). These nuclear actin network 
proteins are known to interact with ERα, the hyperproliferative hormone receptor protein 
target of the breast cancer drug tamoxifen (Ambrosino et al., 2010). In the same study, 
BASP1-ERα colocalisation was then observed and it was shown that BASP1 colocalises 
with ERα in the nucleus, suggesting BASP1 as an ERα cofactor. Subsequent investigation 
of the effect of BASP1 expression on tamoxifen action was conducted and it was shown 
that 40% of the genes regulated by tamoxifen in MCF7 cells were BASP1-dependent. 
BASP1 expression was also found to enhance the inhibitory effects of tamoxifen on cell 
proliferation and colony formation (Marsh et al., 2017). 
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In summary, in most contexts, BASP1 appears to act as a tumour suppressor. In terms of 
its interaction with WT1, the implication is that where BASP1 is active, WT1 acquires 
tumour suppressor functions; whereas when BASP1 is absent, WT1 is more oncogenic. 
1.4.3 BASP1 structure  
 
The primary structure of BASP1 is highly conserved between species and in most cases, 
BASP1 knockdown is lethal in animal models (Carpenter et al., 2004). Notable structural 
motifs of BASP1 are its PEST (Proline, Glutamic acid, Serine, Threonine) sequences, 
phosphorylation sites, nuclear localisation sequence and N-terminal myristoylation motif 
(Mosevitsky et al., 1997 and Khan et al., 2003) (figure 1.8). 
 
 
 
 
Figure 1. 8: Structure of human BASP1  
Notable regions are denoted by MM (Myristoylation motif), NLS (Nuclear Localisation Sequence), P-site 
(phosphorylation sites) and PEST (PEST motifs). Residue number is indicated by a scale above the 
diagram. Many more phosphorylation sites have now been proposed but only the four most referenced sites 
were included. (Adapted from Roberts, 2005). 
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PEST motifs are regions of protein rich in proline, glutamic acid, serine and threonine 
that are strongly associated with a fast protein turnover rate (Mosevitskiĭ et al., 1996). 
The multiple phosphorylation sites can be targeted by protein kinases such as protein 
kinase C (PKC) which can affect BASP1 activity and membrane binding capability 
(Maekawa, H Murofushi and Nakamura, 1994). The N-terminal myristoylation motif 
allows BASP1 to anchor to lipid membranes with some specificity for certain lipids such 
as neutral phosphatidylcholine (Khan et al., 2003). Once bound to the membrane, BASP1 
is able to modify the lipid makeup of the membrane in close proximity by accumulating 
cholesterol at the site, in some cases to such an extent that cholesterol crystals can form 
(Epand, Epand and Maekawa, 2003). The N-terminal myristoyl motif provides BASP1 
with some hydrophobic character, despite it being a mostly hydrophilic protein 
(Mosevitskiĭ et al., 1996). N-terminal myristoylation of this motif is required for many 
of BASP1s functions (Korshunova et al., 2008 and Toska et al., 2012).  
1.4.4 BASP1 functions  
 
BASP1 can have many different functions depending on the tissue environment, cell type 
and presence of other cofactors and transcription factors. Within neurons, BASP1 has 
been proposed to have a range of functions that include involvement with synaptic signal 
transmission, neuronal signal transduction, neurite growth, regeneration and memory 
formation. BASP1 has been shown to be upregulated following multiple forms of nerve 
injury in several neurone subtypes and this upregulation is associated with neuron 
regeneration (Mason et al., 2002). Increased expression of BASP1 has also been shown 
to promote both NCAM (neural cell adhesion molecule) independent neurite outgrowth 
and nerve sprouting. This is an essential process in the development of proper brain 
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structure, particularly in the later stages of development. It is now known that BASP1 
likely has additional functions in other cell types. BASP1 has been shown, in the presence 
of WT1 to be capable of altering K562 myelogenous leukaemia cell’s properties to 
differentiate into cells with neuron-like morphology (Goodfellow et al., 2011). BASP1 
also likely has roles in the development of other tissues, such as the kidneys. BASP1 is 
expressed during kidney nephrogenesis and continues to be expressed into adulthood, 
with expression being limited to the podocyte cells (Carpenter et al., 2004). This 
expression pattern seen in kidney development is shared by the transcription factor WT1 
that is essential for proper kidney development (Kreidberg et al., 1993). The co-
expression of WT1 and the co-repressor BASP1 is consistent with the ability of WT1 to 
repress SRPK1 in podocytes (Amin et al., 2011). 
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1.5 ERG (ETS-related gene)  
1.5.1 ERG (ETS-related gene) 
 
The oncogene ETS‑related gene (ERG) was first described in 1987 in the context of 
colorectal cancer (Reddy, Rao and Papas, 1987). ERG is a member of the E-26- 
transformation-specific (ETS) family of transcription factors. This family play an 
important biological role in the human body such as bone development, angiogenesis and 
haematopoiesis. ERG has been proposed to perform a range of different context-specific 
activities and functions. Recently ERG was found to be highly associated with several 
malignancies as it plays transcriptional regulatory roles. In several cancers, ERG has been 
used as a marker to evaluate the tumorigenicity and prognosis. Thus it has become a 
target for multiple therapeutic approaches (Adamo and Ladomery, 2016).             
1.5.2 ERG in cancer   
 
Acute T-lymphoblastic leukaemias and prostate carcinomas are all examples of adult 
cancers in which ERG is overexpressed. For instance, ERG overexpression is a sign of 
poor prognosis as the relapse rate of acute T-lymphoblastic leukaemias cases with ERG-
positive T lymphoblast is four times higher (Baldus et al., 2006). In prostate carcinoma, 
overexpression of ERG result from a gene fusion with the androgen-driven promoter of 
the TMPRSS2 gene (Tomlins et al., 2005) ERG is not normally expressed in prostate 
epithelia (Deramaudt, Remy and Stiegler, 2001) but in the malignant prostate cancer, 
ERG is one of the most overexpressed oncogenes, in as many as 50% of cases (Vanaja et 
al., 2003 and Tomlins et al., 2008). Poor prognosis in prostate cancer is associated with 
ERG overexpression as the tumour stage, metastasis and high Gleason score shorter 
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survival times is the characters of prostate cancer with up-regulated ERG (Tomlins et al., 
2005).  
ERG is considered to be a prognostic marker for prostate cancer and AML. In prostate 
cancer patients, a higher rate of TMPRSS2: ERG fusion protein is associated with an 
increase in the possibility of recurrence compared to patients without the fusion protein 
(Nam et al., 2007).  In AML, for instance, ERG expression was proven to be a useful 
negative prognostic factor and provided more information about the stage of the AML 
with the additional established molecular markers (Metzeler et al., 2009).     
1.5.3 ERG structure and regulation 
 
Full-length ERG protein is a 486 amino-acid 54kDa and the ERG gene is located on 
chromosome 21q22.3 cancer (Reddy, Rao and Papas, 1987). The ETS DNA-binding 
domain (EBD) is the main identifiable structural character of the ETS family of 
transcription factors. EBD is important in defining ERG activities and functions. The 
EBD is a domain of 85 amino-acids with DNA recognition and binding activity. ERG is 
alternatively spliced as there are several different isoforms following is post-
transcriptional modifications. Exon skipping is a common splicing event that alters the 
splicing of the cassette exon 7b. There are several documented alternative splicing events 
involving ERG pre-mRNA that generate at least 15 protein variants.  
The regulation of ERG transcription and expression is not fully understood. However, 
hypermethylation in cancer regulates the activity of the ERG promoter (Schwartzman et 
al., 2011). The hypermethylation of ERG promoter leads to transcriptional repression of 
ERG expression in T-lymphoblastic leukaemia. Downstream of ERG’s promoter, the 
ERG +85 enhancer region is highly active in T-cell acute lymphoblastic leukaemia (T-
ALL) in mice. In contrast in human T-ALL cell lines, the binding of ERG +85 enhancer 
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region to ETS transcription factors results in ERG overexpression and increased 
leukaemic cell proliferation (Thoms et al., 2011). In prostate cancer, ERG was described 
to transactivate its transcription as a result of feedback in which ERG binds to ETS motifs 
present in its own promoter. This is usually associated with highly invasive prostate 
cancer cells (Mani et al., 2009 and Mani et al., 2011).    
1.5.4 ERG function   
 
ERG perform several biologically important roles throughout the human body. ERG 
knockout in mice leads to embryonic lethality associated with vascular defects (Birdsey 
et al., 2015). ERG protein expression and RNA levels are particularly high in the 
embryonic neural crest and embryonic mesoderm and endothelium where it is important 
for the synthesis of urogenital and vascular systems (Birdsey et al., 2008 and Vijayaraj 
et al., 2012). During vascular development, ERG levels decrease but still play a vital role 
in regulating angiogenesis, the pluripotency of hematopoietic stem cells and the 
homeostasis of endothelial cells (McLaughlin et al., 2001). ERG is expressed in bone and 
soft tissue neoplasms where it regulates cartilaginous differentiation and bone 
development (Shon, Folpe and Fritchie, 2014). Moreover, ERG was described by (Thoms 
et al., 2011) to be essential for the maintenance of normal blood platelet numbers, 
haematopoiesis, and normal hematopoietic stem cell function. Since B and T cell 
lymphocytes both arise from hematopoietic stem cells, ERG was found to be expressed 
in both pre and mature lymphocytes while ERG expression in T lymphocytes was only 
detected transiently during T-lineage specification but not in mature T-lymphocytes 
(Anderson et al., 1999). In the case of acute lymphoblastic leukaemia, abnormal ERG 
expression in T-cells promotes the accumulation of immature lymphoblasts (Thoms et 
al., 2011).  
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Our laboratory has had an active interest in the ERG transcription factor since 2008. 
Inspection of the SRPK1 promoter (figure 1.9), from sequence -499 to +100, looking for 
the core ETS binding site, GGA(A/T) (so, therefore (A/T)TCC on the complementary 
strand), suggests the presence of at least nine potential binding sites. This core sequence 
could be recognised by different ETS transcription factors (ERG’s precise target 
sequences are not yet clear; Adamo and Ladomery 2016); but it is tempting to speculate 
that ERG, alongside WT1, might transcriptionally regulate SRPK1. 
 
GGGTCACAGGTTCTTTCCTTCCAGTCTTTTTGTGTTGCTCCCACTCCCTTTTCTTTCT
CACATGTAATTTTTTTCCATTTTCTTTAAATAGTATCTCAACTGGGCTCACAATAGCT
CAGGGAAGGAGAAACTGGGACATGCCTGATTAATCCATTTTACAGGCCAGGAAACTGA
GGCAGATCCCAGTTGCCTCCGAAGCTCTGACTCAGCAGCATGCAGAGAGCCCTGCCGC
TCTCTGCGCCTTTTCTAAACAAATAGAACAAAACTAACCTTGCCAGGTTTCCAAGCTT
GGATCTCTAACACTCCTTCAACGTTCACCCCGGCGTTCCTCCCCGCTGCGCCCCCTCC
CTCTCCTTGCCGCCCCCTCCTCGGGAGCAGGTGGTAGGCTCCGCGCCCAACGCGCAAG
CGCGCGGCATCGTGGGGCGGGGGTGGGGCGGGACTGAGGGCGGAGTGTGAGCGGGCTC
GGTTTTGGGCCGCGGCGGGAGCGGGAGTCGCCGCCACTCGAGTGCGCAGGCGCCTGGC
GATTACCGGTCTCACCATGGAGCGGAAAGGTGAGCGGTGGAGCGGCCTCCGCCACGAG
GGGCAATGGTCGCCGGGGCG 
 
Figure 1. 9: Human SRPK1 promoter sequence  
Putative core ETS binding sites are indicated in bold (GGAA or TTCC)  
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1.6 Hypothesis and aims 
1.6.1 Hypothesis 
 
In summary, based on the published work showing the involvement of SRPK1 in cancer 
pathology, it is important to understand in further details how SRPK1 expression and 
activity is regulated in cancer cells. Could SRPK1 expression be regulated by the WT1 
transcription factor in cancer cells? Are other WT1 transcriptional cofactors such as 
BASP1 involved in the regulation of SRPK1? Do other transcription factors such as ERG 
contribute?  
1.6.2 Aim and objectives of the project  
 
The overall aim of this project was to investigate the potential regulation of SRPK1 
transcription in cancer cells by WT1, BASP1 and ERG with a view to gaining a better 
understanding of how SRPK1, and the alternative splicing events downstream of it, might 
be regulated. Prostate cancer cells (PC3), osteosarcoma (MG63) and leukaemia (K562) 
cell lines were used as a model system to address this aim. The specific objectives were 
as follows: 
o Objective 1) Confirm the effect of SRPK1 inhibition on cancer cell biology 
properties. 
o Objective 2) Determine whether or not the transcription factor WT1 contributes 
to the regulation of SRPK1 transcription in cancer cell lines.  
o Objective 3) Investigate whether or not WT1’s effect on SRPK1 transcription in 
cancer cell lines can be modified by the co-repressor BASP1. 
o Objective 4) Determine whether or not the transcription factor ERG contributes 
to the regulation of SRPK1 transcription in cancer cell lines. 
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2 Chapter Two: Material and Methods 
2.1 Tissue culture  
2.1.1 K562 and B-K562 cells 
 
The K562 cell line (ATCC® CRL-3344) which grows in suspension was cultured using 
RPMI-1640 culture medium with L-glutamine both purchased from Sigma Aldrich 
(product code: R8758). Culture medium was further supplemented with 10% foetal 
bovine serum (FBS) and 5ml of 10mg/ml of a penicillin/streptomycin mixture which was 
used to prevent cell infection. Both foetal bovine serum (FBS) (F9665/lot: 045M3318) 
and antibiotics were purchased from Sigma Aldrich (Lot: P4333/025M4818V). Cells 
used were between passage six to nineteen. Sub-culturing of K562 cells involves the 
collection of the cell suspension into a tube then centrifugation at 1000rpm for 5mins 
(Allegra™ X-22R Benchtop Centrifuge), remove the media and resuspended the pellet 
in a fresh media. Cells were seeded at the density of 0.3-0.5x105 in a T75 flask and sub-
cultured every 48-72hours. B-K562 cells (obtained from a collaborator at the University 
of Bristol) were grown in similar conditions except for 2 mg/ml G418 (Sigma) was added 
to the media to maintain selection for BASP1-expressing K652 cells.  
2.1.2 PC3, DU145 and MG63 cells 
 
PC3, DU145 human prostate cancer cells and MG63 osteosarcoma cells between passage 
7 and 10 were used for this study. Cells were purchased from ATCC (PC-3, ATCC® 
CRL-1435™, DU 145, ATCC® HTB-81™ and ATCC® CRL-1427). These cells lines are 
adherent and were cultured in DMEM (Sigma Aldrich) supplemented with 10% foetal 
bovine serum (BSA) (Sigma Aldrich) and a final concentration of 10mg/ml of a 
penicillin-streptomycin mix (PS) (Sigma Aldrich). Using this media, cells were seeded 
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at densities of 0.3-0.5x105 in a T75 flasks and were sub-cultured every 48-72hours, 
detached from flasks using trypsin EDTA. 
2.1.3 Cell line thawing and freezing  
 
To defrost cells, cryovials were removed from liquid nitrogen and thawed at 37°C for 1 
minute; they were centrifuged at ≥13,000 × g for 3 minutes and cultured in 3 mL of 
appropriate media in a T25 flask. 
To freeze the cells, cells re-suspended in freeze medium (75% RPMI-1640, 20% FBS 
and 5% dimethyl sulfoxide (DMSO) at > 1 × 106 cells/mL, and transferred to cryogenic 
vials. They were then stored at -80°C in a Mr Frosty (Nalgene® Mr Frosty, Sigma-
Aldrich, UK), a slow freezing chamber with isopropanol, for 24 hours before being 
transferred to liquid nitrogen for long term storage. Adherent cells densities of > 2 × 106 
cells/mL were re-suspended in 85% FBS and 15% DMSO and treated as above. 
2.1.4 Plasmid transfections 
 
PC3, DU145, K562 and MG63 cells were seeded in 24 well plates at 5 x 104 per well and 
left for 24 hours before transfection. 24 hours after plating, cells were transfected with a 
ratio of transfection reagent (Lipofectamine™ 2000) to plasmid DNA of 4:1 (2μg/100μl). 
Transfection was performed according to the standard manufacturer’s protocol. 
According to Lipofectamine™ 2000 (life technologies) protocol 7.5μl of the transfection 
reagent was mixed with 2500 ng of plasmid DNA and Opti-MEM® Medium (Gibco) 
then incubated for 20 minutes prior addition to the cells.  Following that Opti-MEM® 
Medium and culture media were added to the cells then the cells were incubated for the 
desired amount of time (48-72 hrs) at 37°C. (See appendix for plasmid maps) 
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2.1.5 Overexpression of WT1, ERG and BASP1 
 
Plasmid transfections were carried out as detailed in section 2.1.4. To detect the effect of 
the overexpression of WT1 on SRPK1 at the transcriptional level, (+/- KTS) WT1 
isoforms were transfected at a range of different concentrations (e.g. titrating 0μg, 1μg, 
1.2μg, 1.5μg, 2.0μg and 2.5μg) into K562, PC3 and DU145 cells with constant 
concentrations of Renilla expressing plasmid and SRPK1 promoter: luciferase constructs, 
wild-type and mutant (table2.3), then the promoter’s activity was monitored through 
DLR assay (for details see section 2.3). To observe the effect of WT1 overexpression on 
SRPK1 at the protein levels, K562, PC3, and DU145 were transfected with either with 
WT1 (-KTS) or (+KTS) separately, and the cells were lysed after 48 hours and prepared 
for western blotting (section 2.12). For experiments involving BASP1, two different 
concentrations (0.5-1.5µg) of BASP1-expressing plasmid (table 2.3) was transfected and 
the effect was monitored through DLR and western blotting. To detect the effect of ERG 
overexpression on SRPK1, plasmid constructs that contain +/- 7b ERG or different 
concentration (0μg-2.5μg) of full-length ERG (Table 2.3) were transfected into cells and 
the effect was monitored through the DLR assay and western blotting. ERG plasmids 
express DDK as epitope tag which was used for validation by western blot using ANTI-
FLAG® M2 antibody against DDK (see appendix; fig 9.10). All plasmids containing 
expression or reporter constructs were transfected to the cells following the same protocol 
in section (2.1.4).     
2.1.6 siRNA mediated knockdown of SRPK1, WT1 and ERG  
 
Fluorescein-labelled siRNAs targeting WT1, GL2 luciferase control siRNA and ERG 
were described at (Jamie et al., 2003) and (Urbinati et al., 2016) respectively. siRNAs 
were produced by Eurofins Genomics (Table 2.1). siRNA against SRPK1 was used as 
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well to evaluate the effect of SRPK1 on cell biology. siRNA targeting SRPK1 was as 
described by ( Zhao et al., 2018). Lipofectamine RNAiMAX was used as a transfection 
reagent (Life Technologies). All the surfaces where the experiment was conducted were 
cleaned using RNaseZAP (Sigma) to get rid of RNase. The cells were seeded at least for 
24 hours before transfection to achieve around 80% confluence. After 24 hours, cells 
were transfected with 10nM or 50nM or 100nM final concentrations siRNA with 
Lipofectamine RNAiMAX following manufacturer’s instructions. 
 
Table 2. 1: Individual siRNA components including their target sequences and fluorescent 
labels. 
 
2.1.7 Small molecule inhibitor (SPHINX)  
 
K562 or PC3 cell lines were treated with either SRPK1 specific small molecule inhibitors 
5-methyl-N-[2-(morpholin-4-yl)-5-(tri-fluoromethyl) phenyl] furan-2-carboxamide 
(SPHINX), a chemical inhibitor of SRPK1 purchased from Enamine (Kiev, Ukraine). 
SPHINX was dissolved in 100% sterile dimethyl sulfoxide (DMSO) (Sigma; code: 
101546280/ lot: SHBF7360V). A further 10μM dilution was prepared in 1%DMSO. In a 
typical experiment, 4.0x106 cells were in a sterile T25 flask. To each well, aliquot of 2mls 
of the appropriate concentration of SPHINX was made up in an individual culture media 
(RPMI or DMEM) containing 2.0x106 cells and then incubated for the desired amount of 
time at 37°C.    
 
siRNA Target sequence Fluorescent label 
WT1- 1180 AATGCATGACCTGGAATCAGA 
 
FAM 
ERG  GCAGGAACUCUCCUGAUGAAU CY5 
SRPK1  UUAAUGACUUCAAUCACUCCAUUGC FAM 
GL2 control CGTACGCGGAATACTTCGATT CY5 
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2.1.8 Splice-switching oligonucleotides (Vivo-Morpholinos) 
 
Splice-switching oligonucleotides were used as a different approach to verify the 
findings. MG63 and PC3 cells were exposed to Vivo-Morpholinos that induce skipping 
of Exon4 and 7b in the ERG gene as well as blocking the splicing of exon 3 of the WT1 
gene. In this study, SSOs were designed against 3′ splice sites by Gene Tools, LLC 
(Philomath, OR, USA. Table 2.2). Stocks of each vivo-morpholino were prepared in WFI 
(Gibco™ water for injection for cell culture) at a concentration of 0.5mM. 7x105 cells 
were seeded into compartments of a 6-well plate and cultured at 37°C overnight. The 
media was replaced with 1ml fresh media where the required SSO concentration was 
added directly. Vivo-morpholinos are fused with octaguanidine dendrimer moiety that 
enhances cellular uptake. After 48-72 hours of vivo-, morpholino treatment, cells were 
harvested for the subsequent analysis. 
Description Sequence Concentration 
Vivo-Morpholino EWING-
7b-3'SS 
 
CTGCACCCCCTGCAGACAAAAGGAA 400 nmol 
Vivo-Morpholino EWING-
4-3'SS 
 
GCTTCCTGAATGCCCAAAGAAACAC 400 nmol 
Vivo-Morpholino WT1 
103 SS   
GCGTCCTCAGCAGCAAAGCCTG 
 
400 nmol 
Scrambled control  GACAATATAGGACGCCACCGCAACC 400 nmol 
 
Table 2. 2: sequence and concentration of Splice-switching oligonucleotides.  
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2.2 Plasmid constructs to study SRPK1 transcriptional 
regulation 
The SRPK1 promoter was cloned into a pGL3 luciferase vector (Promega) allowing in 
vitro transcription assays to be performed (Amin et al., 2011). These assays were 
performed in PC3 and DU145 human prostate cancer and K562 chronic myeloid 
leukaemia cell lines models. Using the SRPK1 promoter-luciferase reporter construct we 
tested the effect of WT1 binding to the SRPK1 promoter on SRPK1 expression. The 
presumed WT1 binding site (GGGGCGGGGG) located -119 bp to -110 bp upstream of 
the SRPK1 transcription start site in the SRPK1 promoter was also mutated. The effect 
on SRPK1 transcription was measured using the Dual- Luciferase Renilla (DLR) assay.  
2.2.1 Plasmid preparations  
 
The following plasmids were cloned into E. coli strain TOP10 and maintained in LB 
media with 100 mg/L ampicillin (Table 2.3).  
pMKC130 
 
pGL3 basic vector with firefly luciferase gene 
under the control of 511 bp (-391 relative to WT1 
binding site) wild-type human SRPK1 promoter)  
pMKC132 
 
pGL3 basic vector with firefly luciferase gene 
under the control of511 bp (-391 relative to 
WT1) mutant human SRPK1 promoter  
pRL-TK Plasmid containing Renilla luciferase gene 
under the control of a constitutive HSV TK 
promoter.  
pGL3 Basic vector (negative control).  
 P118 CMV -WT1 (+/-) -  Ampicillin - 100µg/ml 
P77 1 to 449 (full-length WT1+KTS) - Vector 
backbone - pCDNA3 - Ampicillin - 100µg/ml 
pCDNA3-BASP1-FH   BASP1 expressing plasmid  
 
ERG 227  ERG+72bp (exon 7b included) pCMV6 
ERG 218  ERG∆72bp (exon 7b skipped) pCMV6 
ERG  pCMV-SPORT6 containing full length ERG 
‘variant 1’ 
 Table 2. 3: Plasmids used to perform the DLR assay and overexpression experiments. 
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To help differentiate between pMKC130 from pMKC132 an additional EcoRI restriction 
enzyme site has been created within the mutagenized WT1 binding site in pMKC132. At 
the time of cloning, there were 2 different versions of SRPK1 promoter. Longer (1668bp) 
and shorter (511 bp) version of the human SRPK1 promoter. For the experiments 
described in this thesis, we used the shorter promoter construct. See appendix for detailed 
plasmid maps.     
2.2.2 Growth of E.coli in Luria Broth 
 
E.coli transformed with various plasmids described above were inoculated into Luria 
broth (LB) agar and incubated at 37°C incubator overnight, then single identifiable 
colonies were picked by a sterilized lube and inculcated into a freshly prepared LB and 
then incubated in a shaking incubator (to allow air exchange) at 37° overnight. LB broth 
recipe: 5g NaCl, 5g tryptone, 2.5g yeast extract, 7.5g agar, add dH2O to 500mL then after 
it dissolved completely, autoclave. One the agar cooled down, ampicillin was added to a 
final concentration of 100 mg/ml to select for transformants. 
2.2.3 Plasmid miniprep   
 
A plasmid DNA Miniprep kit (New England Biolabs) was used to extract the plasmids. 
5 ml overnight cultured samples were processed using a spin anion exchange minicolumn 
according to standard manufacturer’s instructions. At the end of the procedure, 40ul of 
plasmid DNA was eluted with elution buffer. Yield and quality of plasmid DNA 
concentration were measured using a Nanodrop spectrophotometer (Life Technologies). 
Plasmids were restricted with appropriate restriction enzymes (see section 2.2.5) and run 
on agarose gels (1% agarose run in standard Tris-Acetate-EDTA (TAE) buffer). 
HyperLadder™ 1kb DNA marker (Bioline) was used to estimate the sizes of bands.    
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2.2.4 Plasmid Midiprep   
 
Plasmid DNA Midiprep kit (Qiagen) was also used to purify the plasmids when larger 
amounts were needed for transfection into mammalian cell lines. 50 ml overnight 
cultured (bacteria in the logarithmic growth phase) samples were processed according to 
the standard manufacturer’s instructions. At the end of the procedure, 200l containing 
plasmid DNA was eluted with elution buffer. Yield and quality of plasmid DNA were 
checked by Nanodrop spectrophotometer (LifeTechnologies) and agarose gel 
electrophoresis.     
2.2.5 Plasmid restriction digestion 
 
The identity of the plasmids was confirmed through restriction digestion. Restriction 
enzymes cleaved each DNA molecule at a specific sequence of bases (Table2.4). 
Different combinations of KpnI, XbaI, Hind III, Nco I, Bam HI and EcoRI  (New England 
Biolabs) using the appropriate restriction enzyme buffers were used. HyperLadder™ 
were used to estimate the fragment size. (See appendix fig 9.1, 2&7) 
Enzyme  sequence digestion  
KpnI 7G-GTACC 
XbaI 2173-TCTAG-A 
HindIII 265-AAGCT-T 
Nco I 517-CCATG-G 
BamHI 2435-GGT-C- 
EcoRI 400-GAATT-C 
XhoI 5000-CTCGAG 
SalI 
 
2000-GTCGAC 
 
Table 2. 4: Restriction enzymes and their digested sequence of bases.  
Plasmids were digested by corresponding restriction enzymes (KpnI, XbaI, HindIII, Nco I, BamHI, EcoRI, 
XhoI and SalI). Numbers and sequences corresponds to the digestion sites used in the cloning. Restriction 
digest reaction was optimized according to the manufacturer’s instructions (Fermentas). 1-5μg DNA was 
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cut at restriction sites using restriction enzymes in 76.5μl reaction incubated at 37 °C for 40minutes. 
Suitable pH and salt concentration were used using the buffer solution provided by the manufacturer.  
2.2.6 Bacterial transformation 
 
Since DH5 alpha E.coli is the competent strain for both P77& P118 plasmids, Competent 
DH5 alpha E.coli cells were prepared as per manufacturer instruction 
(Invitrogen™Lot#18258012). To prevent low transformation efficiency plasmids DNA 
were diluted to the concentrations of 50ng/μl before adding 5μl to 50µl of DH5 E.coli. 
The transformation vials were chilled on ice for 30 minutes before heat shocking them in 
a water bath at 42°c for 30sec. the mix was briefly incubated on ice before adding 250μl 
of pre-warmed S.O.C rich medium to it, then the mix was incubated at a 37° shaking 
incubator for 1 hour at 225rpm to allow the cells to express the ampicillin resistance gene. 
20-200μl of these samples were spread onto LB agar plates containing ampicillin as a 
selective medium (described in section 2.2.2) then incubated overnight at 37°c. The next 
morning, single identifiable colonies of the transformed cells were inoculated into LB 
broth to obtain an overnight culture in preparation for plasmid midiprep (section 2.2.4).   
 
2.2.7 Plasmid DNA and cell strains storage  
 
For short-term storage, the plasmid DNA was stored in sealed 1.5 ml Eppendorf tubes at 
-20°c and at -80 °c for longer-term storage. Top10 and DH5 alpha E.coli bacterial strains 
were kept at 4°c as colonies on LB agar plates that contain 100 mg/ml ampicillin. Stocks 
of plasmids containing bacterial strains were stored at -80 for long-term storage. 
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2.3 Dual luciferase reporter assay 
The dual luciferase reporter (DLR) assay was used to evaluate regulated specific gene 
expression, in this case, of the SRPK1 gene. The system depends on two different 
reporters, firefly (Photinus pyralis) and renilla (Renilla reniformis) luciferases to make 
this evaluation. As a control for normalizing the assay, the sequence encoding firefly 
luciferase reporter gene (luc+) is fused to a promoter and integrated into the pGL3 
plasmid. Renilla luciferase works as an internal control for normalizing the activity of 
the experimental reporter. The DLR assay was performed by consecutively measuring 
the firefly and renilla luciferase activities of the same sample using GloMax® 20/20 
Luminometer. The results are expressed as the ratio of firefly to renilla luciferase activity 
(relative luciferase units, RLU). The results reflect the promoter’s activity. 
 
Figure 2. 1: SRPK1 promoter structure.  
Black= promoter region. Grey=WT1 binding site (GCG GGG GCG) silver=5′UTR, white=coding 
sequence of exon 1. Arrows=primer locations. Numbers are bp relative to the transcription start site (TSS). 
siRNA GL2  Nonspecific Control siRNA  
siRNA WT1  WT1 targeting siRNA   
WT1(+KTS)  Plasmid encodes +KTS WT1 
isoform  
WT1(- KTS) Plasmid encodes -KTS WT1 isoform  
SPHINX  SRPK1 chemical inhibitor  
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Table 2. 5: Transcriptional regulators cotransfected with SRPK1 promoter.   
 
2.4 RNA extraction from cell lines 
Cell pellets were collected after treatments from human prostate cancer cell lines; (PC-3, 
ATCC® CRL-1435™), (MG63 ATCC® CRL-1427™) cells human osteosarcoma cell 
line and K562 (ATCC® CCL-243™)-a human erythroleukemic cell line. RNA extraction 
was performed using the Agilent absolute RNA miniprep kit following the standard 
manufacturer’s protocol for isolation of total RNA. Cell pellets were collected in a 1.5ml 
micro-centrifuge tube followed by lysing in a solution made up by 1:100 dilutions of 
Lysing buffer and 7μL β-mercaptoethanol. Purified RNA was eluted in an appropriate 
amount of elution buffer. The RNA yields were quantified using the Nanodrop and the 
samples then stored at -20 °C for short term storage and at -80 °C for long term storage. 
WT1 SSOs Splice switching oligos that induce 
exon 3 skipping in WT1 gene     
siRNA SRPK1  SRPK1 targeting siRNA   
pCDNA-BASP1 Plasmid encodes BASP1  
pCMV6-ER227 Plasmid encodes ERG (+7b) 
isoform  
pCMV6-ER218 Plasmid encodes ERG (-7b) isoform 
ERG pSPORT  Plasmid encodes full length ERG  
siRNA ERG ERG targeting siRNA   
Control SSOs Nonspecific Splice switching  
oligos 
E4 3′  SSOs Splice switching oligos that 
induces exon 4 skipping in ERG 
gene     
E7b 3′  SSOs Splice switching oligos that 
induces exon 7b skipping in ERG 
gene     
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2.5 cDNA synthesis 
A New England Biolabs kit was used for cDNA synthesis. Up to 2μg of RNA was added 
to 1ml micro-centrifuge tube where 2μl of 40,000U/ml random primers (Promega) and 
2μl of 2.5mM deoxynucleotide triphosphate (dNTP) (Sigma Aldrich) were added and 
brought to a final volume of 16μl with nuclease-free water (Qiagen; Lot: 
129115/151034210). On each tube, 2μl of 40,000U/ml random primers (Promega; cat; 
A5000) were added and incubated at 70°C for 5mins. The RNA with primers was spun 
down and placed immediately on ice. While on ice, 2μl of 10x M-MLV reverse 
transcriptase buffer (NEB; Lot: B0253S/0101505), 1μl of 2x reverse transcriptase (NEB: 
Lot: M0253S/0271503) and RNA inhibitor (NEB: Lot: M0307S/ 0321410) respectively 
was added to the tubes followed by incubation at 42 °C for one hour, followed by enzyme 
inactivation at 90 °C for 10mins. The final products were quantified using the Nanodrop 
and stored at -20 °C. 
2.6 Assessment of RNA and cDNA yield  
RNA and cDNA purity and concentration was assessed using a Nanodrop 1000A UV 
spectrophotometer (Thermo Fisher Scientific, USA). 1μL of each sample was used and 
the degree of purity assayed by calculating the ratio of the sample absorbance at 260/280 
nm (A260 /A280), where a ratio of 2.0 denotes pure RNA.  
2.7 Polymerase chain reaction (PCR)  
Following treatment and transfections, PCR was carried out to evaluate the effect of 
SRPK1 transcriptional manipulations and chemical inhibition on the alternative splicing 
of genes of interest which included caspase-9, and BCL2L1. The alternative splicing of 
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ERG after subjecting the cells to SSOs that induce exon 4 and 7b skipping was also 
evaluated through PCR. Screening the cancer cell lines for the possibility of the presence 
of the SRPK1 splice variant (SRPK1a) was also performed via PCR. Beta actin (β-actin) 
was amplified and used to determine the quality of the cDNA as well as a loading control. 
Table 2.6 describes all primer sequences used for standard PCR. The master mix for PCR 
was prepared following the New England Biolabs protocol (Hot Start Taq 2X Master Mix 
lot: M0496S). In a sterile, thin-walled PCR tube, 1μl of 10µM Forward Primer, 1μl 10 
µM Reverse Primer, 2μl of Template DNA, 25μl of Hot Start Taq 2X Master Mix and 
21µl Nuclease-free water were mixed then placed in MJ Research MiniCycler PTC-150 
Thermal Cycler for amplification.  
Gene name Primer sequence/ length 
5′ – 3′ 
Alignment  Amplicon length 
(bp) 
SR protein kinase 1 
(SRPK1) NM_003137 
F: CGCGCAAGCGCGCGGCATCGT 
(21) 
R: CTGCGCACTCGAGTGGCGGCG  
(21) 
F :1329 – 1353  
R :1430 – 1403 
102 
SRPK1a 
NM_003137 
F:GGTCTCACCATGGAGCGGAAA  
(21) 
R: CTTCCTGCTCTGGTAGATCAC 
(21) 
F :1326 – 1349  
R :1426 – 1399 
120 
Beta – actin (β-actin) 
NM_001101 
F:  TTAAGGAGAAGCTGTGCTACG  
(21) 
R: GTTGAAGGTAGTTTCGTGGAT  
(21) 
F: 719 – 739  
R: 924 – 904 
206 
BCL2 like 1 (BCL2L1)xl  
NM_138578 
F:  CATGCCAGCAGTGAAGCAAG  
(20) 
R:  GCATTGTTCCCGTAGAGATCC 
 (21) 
F: 627 – 646 
R: 977 – 957 
351 
Caspase-9  
NM_001229 
F: GCTCTTCCTTTGTTCATCTCC (21) 
R: CATCTGGCTCGGGGTTACTGC 
(21) 
 
F: 1248 – 1251 
R: 1436 – 1458 
742 
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GAPDH 
NM_002046 
F: CAATTCCCCATCTCAGTCGT  
(21) 
R: TAGTAGGCCGGGCCCTACTTT 
(21) 
 
F :1239 – 1349  
R :1230 – 1303 
100 
ERG (Exon 4 skipping) 
NM_182918 
F: TTTGGAGACCCGAGGAAAGC 
(20) 
R: AGAGAAGGATGTCGGCGTTG 
(20) 
F: 637 – 656 
R: 937 – 959 
300 
200 
ERG (Exon 7b skipping) 
NM_182918 
F:GAATATGGCCTTCCAGACGTCAAC 
(24) 
R:GGTGGCCGTGACCGGTCCAGGCTG 
(24) 
 
F: 640 – 659 
R: 940 – 962 
300 
200 
 
Table 2. 6: Primers used for PCR. 
2.8 Agarose gel electrophoresis 
For sonication optimisation and PCR amplicons, DNA fragment size was measured using 
agarose gel electrophoresis. Following sonication and PCR, 20μL of each sample was 
added to 5μL 5X DNA loading dye (NEB, UK) and resolved on an agarose gel alongside 
gene ruler low range DNA ladder (NEB, UK). The agarose gel was made up of 1% (w/v) 
agarose (Fisher). Gels were electrophoresed in 1X Tris-Acetate-EDTA (TAE) buffer at 
100V for approximately 45minutes in a BIO-RAD Mini-sub Cell GT. Gels were stained 
with 0.01% of 10µg/ml ethidium bromide (Sigma Ltd, UK). Gels were imaged using the 
LI-COR Odyssey FC imaging system (USA) at 600nm. 
2.9 Chromatin immunoprecipitation assay 
Chromatin immunoprecipitation was performed on PC3, K562, B-K562 and MG63 cells 
using the Imprint Chromatin Immunoprecipitation Kit (Sigma; lot# CHP1-24RXN). 
Briefly, according to the manufacturer protocols, 1x 106 cells were incubated for 10 
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minutes with 1% (w/v) formaldehyde at RT to allow DNA to be cross-linked to the 
protein. The cells were then lysed and DNA sheared to about 1000bp using a sonicator 
for 6x at 15seconds at 50% for PC3 and MG63, 30% for a minute for K562 and B-K562 
power output followed by incubation on ice for 60 seconds after each pulse. The DNA-
protein mixture was incubated with 3μg of WT1, ERG and BASP1 antibodies or with 
1μg RNA Polymerase II antibody (positive control) or 1μg nonspecific IgG (negative 
control) coated on a well at room temperature for 3 hours, then washed 6 times with the 
IP wash buffer. The cross-linked DNA-transcription factor complexes were released 
using Proteinase K at 65°C for 15mins. The DNA was cleaned up and eluted using 
GeneElute Binding Colum (Sigma). The eluted DNA was subsequently used in a PCR to 
detect the genomic regions of SRPK1 and GAPDH promoter regions that were being 
pulled down by the antibodies. Using the primers on (table 2.6),  PCR was performed at 
95°C initially for 2mins followed by 95°C for 1 minute, 55°C for 1 min and 72°C for 1 
minute for 35 cycles followed by a final elongation at 72°C for 5 minutes for GAPDH, 
but for WT1 PCR was performed at 95°C for 2mins followed by 95°C for 1 minute, 68°C 
for 1 min and 72°C for 1 mins for 15 cycles followed by 95°C for 1 mins, 60°C for 1 min 
and 72°C for 1 mins for 20 cycles followed by a final elongation at 72°C for 5 minutes. 
2.10 Gel extraction and purification of PCR products 
To sequence the chIP assay products (from section 2.9) a gel extraction kit (Monarch 
DNA gel extraction kit Lot#T1020) was used to purify and collect the products. Bands 
were cut out of the gel above a UV light keeping the amount of gel around the bands as 
little as possible. As per the manufacturer’s instructions, 4 volumes of the gel dissolving 
buffer were added to each gel slice before incubating the samples at 40 °C. Samples were 
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vortexed periodically during the incubation period until the gel slices were dissolved 
completely. Then the samples were passed through columns to get rid of the agarose. The 
columns were placed into collection tubes then the DNA was washed with the provided 
buffer twice. After that, DNA was eluted out of the columns In 1.5 ml Eppendorf tubes 
with nuclease-free water (Ph7-8.5). The concentration of the yield was measured using 
the Nanodrop (described in section 2.6). The collected DNA was concentrated up to 10 
ng/μl (for purified PCR product 1-10 ng/μl) at the volume of 15μl. 1ng/μl of each sample 
was mixed with 10 pmol/μl of forward and reverse primers then the samples were sent to 
Eurofins MWG Operon (Germany) to be sequenced. 
2.11 Protein extraction and quantification 
After treatments and transfections, 5 x 104 cells at 80% confluence from each well were 
lysed using ice-cold RIPA buffer containing 10 mM Tris-Cl pH 7, 140 mM NaCl, 0.1% 
(w/v) SDS and protease inhibitor tablets (Roche). Lysates were passed through a 21mm 
needles, then centrifuged at 1000rpm/4°C for 15 minutes. The supernatant was collected 
into a fresh microcentrifuge tube and the pellet discarded. The protein concentration in 
the supernatant was measured using the Bradford reagent (Sigma). Briefly, 1μl of protein 
extract was added to 200μl of Bradford reagent and measured at OD595nm for its 
absorbance using a fluorstar machine (BMG labtech). The protein concentration was 
calculated using a slandered curve of known amounts of BSA.    
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2.12 Western Blotting  
Western blots were performed with the whole cell samples mixed with Laemmli buffer 
(Sigma; code: 1001521749/lot: SLBG2398V). Cells were lysed with RIPA buffer on ice 
then the appropriate volume of Laemmli buffer was added and the samples were then 
heated to 95°c for 5 minutes.  
SDS-PAGE gels consisted of a resolving gel and a stacking gel. For 10% acrylamide 
resolving gel, gels were poured in an aired lamina flow hood due to the toxicity of 
acrylamide, AP and TEMED, 3mls of 30% acrylamide (Sigma; SLBM3534) was added 
to 2.5ml of 1.5M resolving buffer (18.17g Tris and 100ml dH2O; pH 8.8), 4.1ml of 
nuclease-free water, 100μl of ammonium persulphate (AP) (Sigma; 20 MKBN6480V) 
solution and tetramethylethylenediamine (TEMED) (Sigma; 101360618/BCBL1646V) 
then dispensed immediately to a pre-assembled gel casts using a pasture pipette. The 
resolving gel was allowed to polymerise for approximately 25 minutes. After that, a 
stacking gel was prepared by adding 670μl of 30% acrylamide to 500μl of 1M stacking 
buffer (6.17g tris 100ml dH2O; pH 6.6), 2.4ml of nuclease-free water, and 100μl of AP 
and 40μl of TEMED then added immediately and was allowed to polymerise, with a gel 
comb inserted, for approximately 20 minutes. The gels were then placed in a BIO-RAD 
Mini-tank (BIORAD) which was filled with 10X SDS PAGE running buffer (25mM Tris, 
190mM glycine and 0.1% (w/v) SDS with adjusted pH of 8.3). To each well, 10-15μL of 
cell samples were added and resolved against 8μL of prestained protein marker (Cell 
Signaling Technology). Gels were electrophoresed at 70V for 20 minutes and then at 
100V for approximately a further 50 minutes. 
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Proteins were transferred from the gel to a (PVDF) membrane (Thermo) using a BIO-
RAD tank. In a transfer cassette, gels were placed on a membrane soaked in methanol, in 
between three pieces of filter papers (Thermo) and sponges soaked in transfer buffer 
(25mM Tris, 190mM glycine and 20% methanol). After that, the cassette was placed in 
the transfer tank containing cold transfer buffer. A magnetic stirrer and an ice pack are 
placed in the tank to maintain the cold temperature. Transfers were done for 3hrs at 70V. 
Post-transfer, membranes were blocked in 10mL blocking buffer (3% non-fat dry milk 
and 1xTBST; 1x Tris-buffered saline 20mM Tris pH 7.5, 150mmNaCl, 0.1% (v/v) 
Tween20) on a rocking platform for an hour. The membranes were then incubated with 
antibodies of choice (Table 2.7) on a rocking platform at 4°C overnight. Antibody buffer 
was removed and the membranes were washed in (3x) in 10ml of TBST for about 15 
mins. Membranes were then incubated with 20mL blocking buffer containing 1/5000 
HRP-linked secondary antibody on a rocking platform for 1 hour. Membranes were then 
washed a further 3 times in TBST to remove unbound secondary antibodies. Membranes 
were placed in HPR-substrate (Millipore; cat: WBLUF0100/lot: 151223) for 2 mins prior 
to visualization using LI-COR Odyssey FC imaging system (USA) at 600nm and 
chemiluminescent channels. 
 
Antibody/ 
Specie 
Concentration Dilution 
used 
Source Secondary 
antibody used 
Anti-β-actin 
(Mouse) 
1mg/ml 1:5000 Abcam Horse anti-mouse 
IgG) 
Anti-SRPK1 
(Mouse) 
200µg/ml 1:500 Santa Cruz 
Biotechnology 
HRP-linked  
antibody (Cell  
Anti-
VEGF165b 
(Mouse) 
100µg/ml 1:200 R&D system Signalling) 
(1:1000) 
Anti-DDK 
flag (Mouse) 
200µg/ml 1:50 Sigma  
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Table 2. 7: Antibodies used for western blotting. 
 
2.13 Cell biology assays 
2.13.1 MTT Assay; cell proliferation and viability 
 
Cell proliferation and viability were assessed by monitoring the transformation of MTT 
to formazan. The conversion of water-soluble MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) compound to an insoluble formazan product is catalysed 
by mitochondrial dehydrogenase enzymes. Briefly, cells (200μl/well) were seeded at 
seeding densities of 1x105 into 96 well plates and allowed to adhere for overnight except 
for cells grow in suspension. Following subjecting the cells to the proper treatments and 
transfections, the media was removed, then 50μL of serum-free media and 50μL of MTT 
solution (ab211091, Abcam, Cambridge, MA) were added to each well. After incubation 
at 37 °C for 3 h, 150μL of MTT solvent was added to each well. The absorbance at 
OD=590 nm was measured and used for cellular proliferation and cell viability was 
calculated using the following formula: Cell viability = control- absorbance of treatment 
wells/absorbance of control well ×100%.  
 
 
Anti-
VEGF165 
(Goat) 
100µg/ml 1:25 R&D system Donkey Anti-
Goat IgG HRP-
linked antibody 
(Abcam) (1:1000) 
Anti-WT1 
(Rabbit) 
100µg/ml 1:1000 Abcam Horse anti-Rabbit 
IgG) 
Anti-BASP1 
(Rabbit) 
100µg/ml 1:1000 Abcam HRP-linked 
antibody (Cell  
Anti-ERG 
(Rabbit) 
100µg/ml 1:1000 Abcam Signalling) 
(1:1000) 
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2.13.2 Transwell cell migration and invasion assay 
 
Assays were performed in an insert for 24 well plates (Greiner Bio-One; 8 μm pore size 
662638) according to the manufacturer’s protocol. For cell migration, cells (2.5–5 × 105) 
were re-suspended in 100μL serum-free medium were plated in the top of each chamber 
insert transwell insert then incubate for 10 minutes at 37 °C and 5% CO2 to allow the 
cells to settle down. For invasion assay, inserts were coated with 50μL of a 1:4 Matrigel/ 
Tris; Sodium Chloride (Corning® Matrigel® matrix 54230) and allowed to solidify at 
overnight in a sterile environment then the same steps were applied. Cells were subjected 
to the proper treatments inside the inserts. The bottom chambers were filled with 500μL 
complete medium containing 10% FBS. Cells were allowed to migrate for 24 h. cells that 
have not migrated on the top surface of the inserts were removed with an ethanol coated 
cotton swab, and the cells that migrated to the bottom side of the inserts were fixed in 4% 
(w/v) paraformaldehyde, washed, and stained with 0.2% (w/v) crystal violet in 2% 
methanol. For each insert, representative images in 3 evenly distributed x20 fields of view 
were captured using a light microscope (Zeiss AX10) and coloured using ImageJ 
software. To quantify the migration of cells, 0.1% SDS in PBS was added to the lower 
chambers and absorbance intensity measured on a plate reader at an excitation of 590 nm. 
Each experiment was repeated in triplicate. 
2.13.3 Analysis of apoptosis signals; caspase-3/7 activity assay 
 
After subjecting the cells to the proper treatments and transfections, cells were labelled 
with 5μM CellEvent™ caspase-3/7 green detection reagent (Life Technologies, Carlsbad, 
CA, USA) in PBS for 30 min at 37 °C in the dark. DAPI (4', 6-diamidino-2-phenylindole 
dihydrochloride) (Thermo Fischer: D1306) was added to the cells for 1 minute as a 
counterstain. The apoptotic cells labelled with green fluorescence were visualized using 
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20x Nikon Plan Fluor Objective Ph1 with FITC Filter Set to visualize FAM Fluorescein 
label. 
2.14 Fluorescence microscopy 
A Nikon Eclipse TE300 Inverted Phase Contrast Microscope was used to verify that the 
fluorescein-labelled siRNAs are inside the cells after the incubation period. The 
fluorescent microscopy was also used to examine caspase activity in apoptotic cells. Each 
plate was visualized using 20x Nikon Plan Fluor Objective Ph1 with FITC Filter Set to 
visualize FAM Fluorescein label, DAPI was used for DAPI staining and TxRed Filter Set 
to visualize CY5 Fluorescein label. 
2.15 Normalisation of western blots and PCR 
To ensure that the changes in the protein and gene expressions have resulted from 
different treatments and transfections, PCR gels and WB membranes were analysed using 
image studio lite software (LiCOR Odyssey) that measures the densities of bands and the 
generated data were exported to Excel sheets and GraphPad software. The graphs 
depicted the relative expression of splice variants of different genes or proteins from 
different cells lines, such as VEGF165a/b ratios. Data were presented as mean ± SE. 
Statistical differences between treatments groups were compared using one-way 
ANOVA calculate the P values that show the Statistical significance of a given treatment. 
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3 Chapter Three: Effect of SRPK1 inhibition and 
knockdown on SRPK1 expression and cell biology   
3.1 Background  
SRPK1 has been shown to phosphorylate SR proteins that contain serine-arginine-rich 
domains. SR proteins act like substrates to the kinase and act as key regulators of mRNA 
AS (alternative splicing). SRPK1 interacts with several molecules which serve as a 
substrate or control its association with substrates. Such interactions result in the 
propagation of cellular function by the substrate or regulation of their activity either 
directly or indirectly. SRSF1 is one of the best-studied SR proteins and is phosphorylated 
by SRPK1. SRSF1 has two RNA recognition motifs (RRM) and an RS domain consisting 
of about 50 amino-acids (rich in serine and arginine). It is known that SRPK1 interacts 
with about 10-12 amino-acid of the RS domain; an interaction which produces high-
affinity binding and is considered critical for the regulation of the extent to which SRSF1 
is phosphorylated (Ngo et al., 2007; Plocinik et al., 2011). Amin et al., 2011 and Mavrou 
et al., 2015 have shown that the SRPK1 and its main substrate, SRSF1 forms an essential 
pathway responsible for the regulation of the alternative splicing of vascular endothelial 
growth factor (VEGF) mRNA to produce pro/antiangiogenic isoforms in renal epithelial 
cells (podocytes), colon and prostate carcinoma cells. SRPK1 knockdown increases the 
levels of VEGF anti-angiogenic isoform and thereby prevents tumour growth in 
xenografts through the reduction in microvessel density. A similar finding has been 
observed in a study using a prostate cancer cell line (Mavrou et al., 2015). 
Since SRPKs are overexpressed in several tumours, there has been an increased interest 
in targeting SRPKs for the management of several cancers. Batson et al., 2017 described 
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a selective SRPK1 inhibitor with moderate potency known as SPHINX, 5-methyl-N-[2-
(morpholin-4-yl)-5-(tri-fluoromethyl) phenyl] furan-2-carboxamide, that induce an 
alteration in the splicing of VEGF isoforms through SRPK1 inhibition. This alteration 
involves a splicing switch from pro to antiangiogenic VEGF isoform which could cause 
a significant change in the extent of angiogenesis supporting the growth of several 
tumours. 
 A novel isoform of SRPK1, SRPK1a, has been described as being expressed in testes 
and leukemic cells; it has not been widely studied. The properties of the SRPK1a isoform 
are similar in terms of subcellular localization, substrate specificity and in their ability to 
induce alternative splicing of target genes (Sanidas et al., 2010). They are structurally 
different since SRPK1a results from the retention of 513bp interionic segment and 
contains an additional 171 amino acids in its N-terminal domain.  SRPK1 is the most 
highly expressed isoform in chronic myeloid leukaemia K562 cells; the global patterns 
of SRPK1a expression are yet to be studied. Sanidas et al., 2010 studied the impact of 
SRPK1/SRPK1a ratio on erythroid differentiation. They found that the ratio of SRPK1 
to SRPK1a is critical in determining K562 cell fate, with SRPK1 favouring proliferation 
and SRPK1a favouring differentiation. However, since the latter report, there have not 
been any further publications on SRPK1a and therefore its significance remains 
controversial. 
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3.2 Aims and objectives   
 
 Aim 1: To obtain evidence of SRPK1a isoform expression in cancer cell lines.  
 Aim 2: To investigate the possibility of SRPK1 auto-regulation through  
a. siRNA mediated SRPK1 knockdown.  
b. chemical inhibitor (SPHINX) treatment 
 Aim 3: To investigate the effect of SRPK1 knockdown or of chemical inhibition 
on: 
- The alternative splicing of VEGF-A. 
- The alternative splicing of apoptotic factor; BCL2L1 and  
caspase 9 
- Cell migration, invasion, viability, and proliferation. 
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3.3 Results 
3.3.1 Expression of the SRPK1a splice isoform  
 
Multiple cancer cell lines were tested to look for SRPK1a isoform expression by PCR 
Specific primers were used to detect SRPK1a based on the primers used by previous 
publications studying the expression of this isoform in K562 cell lines (Sanidas et al., 
2010); actin was also amplified as a cDNA control. Whereas overall SRPK1 expression 
was confirmed in all cell lines tested (PC3, DU145 and VCaP prostate cancer cell lines 
and TK6 and K562 leukemic cell lines), SRPK1a was not detected by PCR in any of the 
cell lines (Figure.3.1a &b).  
 
Figure 3. 1 a: Schematic representation of human SRPK1a and SRPK1. 
Splicing in of the 513-bp segment yields SRPK1a isoform, whereas splicing out of a 513-bp segment, 
which is located between the first two exons of the SRPK1 locus, results in the production of SRPK1. 
(Sanidas et al., 2010).  
Figure 3. 1 b: PCR products electrophoresis. 
SRPK1 isoforms amplified from cDNA from five different cell lines.  For SRPK1a (120 bp amplicon), S1; 
sense primer:  5'-CTCCACATTCGCCCTTCATC-3', A1; antisense primers: 5'-
CCTCGGTGCTGAGTTTCAGAT-3', probe: ATCCCTCTCTCCTGCAGTG. For SRPK1 (100 bp 
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amplicon), S2; sense primer: 5'-CACCATGGAGCGGAAAGTG-3', A2; antisense: 5'-
GCCTCGGTGCTGAGTT TCAG-3', probe: CCCGAAAGAAAAGGACCA. Arrows point to the SRPK1 
band (100bp) and the expected location of SRPK1a band (120bp). Quick-load Purple 50bp DNA Ladder 
was used to estimate the band sizes.  
 
3.3.2 Effect of siRNA mediated SRPK1 knockdown on SRPK1 expression 
 
The splice factor kinase CLK1 is involved in an autoregulatory loop. When it is inhibited 
its expression increases (Duncan et al., 1997).  More recently, its inhibition in PC3 and 
DU145 prostate cancer cells has been shown to alter CLK1’s own alternative splicing, 
favouring the production of more full length CLK1 (Uzor et al. 2018). It is conceivable 
that SRPK1 is also involved in an autoregulatory loop. This was examined in PC3 and 
K562 cell lines. Cells were transfected with siRNA that target SRPK1 (Table 2.1) 
previously described in (Zhao et al., 2018), alone at first to verify that the knockdown 
occurred, then the siRNA were co-transfected with SRPK1 promoter constructs fused to 
luciferase reporter (Amin et al., 2011) to see whether or not the knockdown would have 
an effect on the promoter’s activity. A western blot was performed on protein lysates 
prepared from the cell lines following the siRNA knockdown (Figure.3.2.A &B). 
Significant reduction on SRPK1 levels was observed at higher concentrations of the 
siRNA (50&100nM) confirming that the siRNA is effective. The next step was to 
examine the impact of the higher siRNA concentration on SRPK1 transcription through 
co-transfecting the siRNA with wild type/mutant SRPK1promoters (Figure.3.2.C). The 
activity of the promoter showed no significant change after SRPK1 knockdown which 
suggests that SRPK1 might not be involved in an autoregulatory loop.   
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Figure 3. 2 Effect of SRPK1 knockdown on SRPK1 expression. 
K562 (A) and PC3 (B) cells were transfected with increasing concentration of SRPK1 siRNA (10nM, 
50nM, and 100nM) or control GL2 siRNA for 48 hours. A&B. Western blots of protein lysates collected 
after SRPK1 siRNA knockdown. Membranes were blotted with anti-SRPK1 or anti-beta actin antibodies 
as a loading control. Graphs represent relative expression determined by densitometric measurement of the 
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bands and are expressed relative to actin. Bar-graph shown is the average of three independent experiments. 
**= p<0.0016 and *** p= 0.0001 significant change compared to control using a one way ANOVA test.  
(C) DLR assay of SRPK1 promoter activity in PC3 cells transfected with siRNA SRPK1. Measurement of 
SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. WT/mutant SRPK1 promoters were 
co-transfected with 100nM SRPK1 siRNA or control siRNA into PC3 cells. Data expressed as relative 
luciferase units (RLU). Data presented as mean ± S.E. for independent experiments n=3. The figure shows 
no significant reduction using a one way ANOVA test in the activity of the promoter where SRPK1 has 
been knocked down. 
 
3.3.3 Effect of the SRPK1 inhibitor SPHINX on SRPK1 protein levels and 
transcription 
 
As discussed, CLK1, another splice factor kinase that phosphorylates SR protein in the 
nucleus, is involved in its auto-regulation; inhibition of CLK1 results in increased CLK1 
expression (Duncan et al., 1997; Uzor et al., 2018). Thus it was of interest to determine 
whether or not this is applicable following SRPK1 inhibition. The expression of SRPK1 
after subjecting the cells to SPHINX treatment, a specific SRPK1 chemical inhibitor, 
treatment was assessed by western blotting. Western blot was performed on cell lysates 
harvested from K562 and PC3 cells after 72 hrs of SPHINX treatment. The blot shows 
that SRPK1 inhibition using 10μM SPHINX resulted in decreased levels of SRPK1 
protein (Figure 3.3 A&B). That suggests the possibility of SRPK1 inhibition might also 
result in decreased SRPK1 protein expression through a feedback loop. Cells were also 
transfected with wild type/mutant SRPK1 promoters while treated with 10μM SPHINX 
to test the inhibitor’s treatment on SRPK1 transcription. The wild-type promoter’s 
activity was reduced suggesting that SPHINX does cause a reduction in SRPK1 
transcription in K562 and PC3 cell lines (Figure 3.3C&D).     
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Figure 3. 3 Effect of SPHINX on SRPK1 protein levels and transcription 
 A&B Protein levels of SRPK1 in SPHINX treated K562 (A) and PC3 (B) cells. Western blot of protein 
lysate collected from K562 and PC3 cells Subjected to 10µM SPHINX for 72 hours. Membranes were 
C D 
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blotted with anti SRPK1 or anti-beta actin antibodies as a loading control. Graphs represent relative 
expression determined by densitometric measurement of the bands and are expressed relative to actin. Bar-
graph shown is the average of three independent experiments. Although there is a slight reduction in 
SRPK1 levels, this reduction is not statically significant using unpaired t test. Three independent repeats 
are shown in each case.   
 C&D DLR assay of SRPK1 promoter activity in K562 and PC3 cells treated with SPHINX. Measurement 
of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. WT/mutant SRPK1 promoters 
were transfected into cells treated with 10µM SPHINX. Data are expressed as relative luciferase units 
(RLU). Data presented as mean ± S.E. for independent experiments n=3. *** p<0.0005 and * p<0.0178, 
are statistically significant using a one way ANOVA test. Figures show a reduction of the promoter’s 
activity in cells treated with SPHINX. 
 
3.3.4 Effect of SPHINX treatment on VEGF-A alternative splicing 
 
Numerous studies showed that different SRPK1 inhibitors (SRPIN340, SPHINX) induce 
vascular endothelial growth factor VEGF-A (VEGF) splice switching from pro to anti-
angiogenic isoforms in vitro causing anti-angiogenic effects in vivo. Mavrou et al., 2014 
has demonstrated that SRPK1 inhibition with SPHINX in PC3 cells causes a similar 
splice switch in VEGF. Therefore, it was of interest to observe changes in VEGF splicing 
following SPHINX treatment. To determine whether or not SPHINX treatment induced 
a splicing change in VEGF, PC3 cells were treated with 10μM SPHINX followed by 
protein extraction. The whole cell protein extracts were immunoblotted. The protein band 
shown in Figure 3.4 at 22kDa corresponds to the isoforms VEGF165b and total 
VEGF165. The western blot showed regular VEGF165 expression and an increase in the 
anti-angiogenic isoform VEGF165b following SPHINX treatment which suggests that, 
as expected, the inhibition of SRPK1 by SPHINX results in a splicing switch from pro- 
to anti-angiogenic VEGF isoforms in PC3 cells. 
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Figure 3. 4: Inhibition of SRPK1 by SPHINX results in a splicing switch from pro- to anti-
angiogenic VEGF isoforms in PC3 cells.  
Western blot analysis of VEGF165 and VEGF165b isoforms in PC3 cells after exposure to 10µM SPHINX. 
The blots were re-probed with actin which was used as a loading control. Three independent repeats are 
shown in each case. The graph represents relative expression determined by densitometric measurement of 
the bands and is expressed relative to VEGF 165. The bar graph shown is the average of three independent 
A 
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experiments. (**P= 0.0076) a significant change of VEGF Splicing compared to untreated using unpaired 
t test. 
3.3.5 Effect of SPHINX treatment on the alternative splicing of apoptotic genes 
BCL2L1 and CASPASE-9 
 
 Wang et al., 2017 demonstrated that knocking down SRPK1 with siRNA result in 
increased splicing of the cleaved caspase‑3 and other pro-apoptotic splice isoforms of 
PARP and p53. Specifically, the study suggests that knocking down SRPK1 by siRNA 
allows the activation of the PARP- caspase3 pathway and helps to limit the proliferation 
rate in K562 cells.  
To investigate whether SRPK1 inhibition using a chemical inhibitor would result in any 
change in the splicing of other caspase family members such as caspase-9 and another 
apoptotic factor such as BCL2L1, mRNA was extracted from the K562 and PC3 cells 
following 10μM SPHINX treatment. Then a PCR was performed using the primers listed 
in Table 2.6. PCR bands show that the splicing ratio (PSI-Ψ) of caspase-9a/caspase-9b 
(Figure 3.5) and Bcl-xl/Bcl-xs (Figure 3.6) was significantly higher in the SPHINX 
treated group than in the control group in K562 cells. The splice ratio of caspase-9a/9b 
isoform in the control was 0.67 while in SPHINX treated cells 0.87 (**P= 0.0025 using 
unpaired t-test) in PC3 cells, caspase-9a/9b splicing ratio of the control was 0.48 while 
0.83 in (*P= 0.0351 using unpaired t-test). The expression ratio Bcl-xl/xs isoform in the 
control was 0.83 while in SPHINX treated cells 0.94 (**P= 0.0012 using unpaired t-test). 
On the other hand, in PC3 cells there was no significant change in the ratio of Bcl-xl/Bcl-
xs isoforms following SPHINX treatment (figure 3.7 and 3.8). Taken together, these 
experiments do clearly show that SPHINX causes changes in the alternative splicing of 
apoptosis-associated genes. 
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Figure 3. 5: Caspase-9 mRNA levels in SPHINX treated K562 cells.  
A 
B  
C 
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K562 cells treated with 10μM of SPHINX for 72hrs followed by RNA extraction and cDNA synthesis. 
PCR was performed using Caspase-9 specific primers. (A). Representation of Caspase-9 PCR amplicon 
sizes and (B) Showing band intensity and size and corresponding loading control, β-actin. (C). 
Densitometry showing caspase-9a/9b PSI-Ψ values for 72hrs. The result shows significance in splice ratio 
of caspase-9 (PSI-Ψ, **P= 0.0025) using unpaired t test.  n=3. Three independent repeats are shown in 
each case.    
  
 
 
                             
0.0
0.2
0.4
0.6
0.8
1.0
R
at
io
 o
f 
B
cl
x/
s 
m
R
N
A
 (
P
SI
-Ψ
)
**
10µM SPHINX
control
 
Figure 3. 6: BCL2L1 mRNA levels in SPHINX treated K562 cells.  
B 
C  
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K562 cells treated with 10μM of SPHINX for 72hrs followed by RNA extraction and cDNA synthesis. 
PCR was performed using Bclx-specific primers. A. Representation of Bclx PCR amplicon (B) PCR gel at 
72hrs showing band intensity and size and corresponding loading control, β-actin. (C). Graph showing 
relative densitometry of Bcl-xl/s PCR bands 72hrs after SPHINX treatment. There was a significant change 
in splice ratio of caspase-9 (PSI-Ψ, **P= 0.0012) using unpaired t test.  n=3. Three independent repeats 
are shown in each case. 
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Figure 3. 7: Caspase-9 mRNA levels in SPHINX treated PC3 cells.  
A 
B 
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PC3 cells treated with 10μM of SPHINX for 72hrs followed by RNA extraction and cDNA synthesis. PCR 
was performed using Caspase-9 specific primers. (A) Showing caspase-9a and b band intensity and size 
and corresponding loading control, β-actin. (B). Graph of relative densitometry showing caspase-9a/9b 
PSI-Ψ values for 72hrs.  The result shows significance in splice ratio of caspase-9 (PSI-Ψ, *P= 0.0351) 
using unpaired t test. n=3. Three independent repeats are shown in each case.    
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Figure 3. 8: BCL2L1 mRNA levels in SPHINX treated PC3 cells. 
PC3 cells treated with 10μM of SPHINX for 72hrs followed by RNA extraction and cDNA synthesis. PCR 
was performed using Bcl specific primers. (A) PCR gel at 72hrs showing band intensity and size and 
corresponding loading control, β-actin. (B). Densitometry showing Bcl-xl/s PSI-Ψ values for 72hrs. The 
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result shows no significance in the splicing ratio of caspase-9 using unpaired t test. n=3. Three independent 
repeats are shown in each case.   
 
 
3.3.6 The Effect of SRPK1 chemical inhibition and siRNA knockdown on cellular 
viability and proliferation 
 
Slower cellular growth was observed in K562 and PC3 cells when SRPK1 was inhibited 
with SPHINX and siRNA SRPK1. An MTT assay was performed to evaluate the 
proliferation and viability of K562 and PC3 (figure 3.9 C&D) cells following siRNA 
transfections and SPHINX treatments (Ren et al., 2010). Cells were subjected to 100nM 
siRNA and 10μM of SPHINX for 48hrs and 72hrs respectively. The results suggest that 
SRPK1 inhibition suppresses cellular proliferation and viability compared to the group 
where SRPK1 was not subjected to any inhibition. A similar effect of SRPK1 inhibition 
was described by (Wang et al., 2017) for K562 and (Mavrou et al., 2014) for PC3 cells.  
In K562 (figure 3.9 A&B) cellular proliferation rate was similar after SRPK1 inhibition 
using siRNA and SPHINX (*p = 0.0125 and 0.0176, two-way ANOVA). Cell viability 
was the lowest in cells treated with SPHINX (***p = 0.0003 two-way ANOVA). For 
PC3 cells (figure 3.9 C&D), the cellular proliferation rate was similar after SRPK1 
inhibition using siRNA and SPHINX (**p = 0.0032 and 0.0019, two-way ANOVA). PC3 
cellular viability was reduced in a similar way following SRPK1 inhibition using siRNA 
and SPHINX (****p < 0.0001 two-way ANOVA).  
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Figure 3. 9: Cellular proliferation and viability in K562 and PC3 cells after SRPK1 inhibition 
by siRNA and SPHINX treatment.  
MTT assay was used to analyse the effect of siRNA induced SRPK1 knockdown for 48 hrs and SPHINX 
treatment for 72hrs on cellular proliferation and viability in K562 (A&B) and PC3 (C&D) cells. The 
absorbance of each well was measured at 590 nm using a plate reader. Results represent the mean ± SEM 
of three experiments and are presented as graphs after normalizing to the respective controls. Cell viability 
A B 
C D 
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was calculated using the following formal: viability= control- absorbance of treatment wells/absorbance of 
control well ×100%. (*p = 0.0125 and 0.0176, ****p < 0.0001 using two-way ANOVA)   
 
3.3.7 The effect of SRPK1 chemical inhibition and siRNA knockdown on cellular 
migration and invasion 
 
SRPK1 inhibition modifies VEGF splicing causing antiangiogenic effects (Mavrou et al., 
2014). However, genes involved in other hallmarks of cancer, such as those involved in 
migration and invasion (metastatic phenotypes) could be affected. So it was of interest to 
evaluate how the cellular invasion and migration ability are affected by SPHINX 
treatment and siRNA SRPK1 knockdown. At first, cellular migration and invasion were 
assayed using Transwell migration and invasion assay (Mavrou et al., 2014). (Figure 3.10 
& 3.11) shows an observed difference in the number of migrating and invasive cells 
between SPHINX treated PC3 and the untreated control groups (*p=0.0211 and 
**p=0.0089 unpaired t-test) respectively. In another experiment, SRPK1 was knocked 
down in the cells and the potential of the cells to migrate and invade was determined 
using the same assay. (Figure 3.12 &13) shows an observed difference in the number of 
migrating and invasive cells between PC3 SRPK1-KD PC3 and the control siRNA and 
the un-transfected cells groups (**** p<0.000, unpaired t-test). These data considered 
together suggest that SRPK1 inhibition using a chemical compound or siRNA 
knockdown significantly suppress PC3 capacity to migrate and invade.                  
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Figure 3. 10:  Transwell migration assay of PC3 cells. 
PC3 cells treated with 10μM of SPHINX for 72hrs (A). Representation of the transwell insert used to 
measure cell migration and invasion. (B). Representative Pictures of PC3 cell transwell migration. Serum-
free medium was added to the lower chamber as the negative control. After cell migration and staining 
with crystal violet, pictures of the migrated cells were captured by Nikon Eclipse TE300 Inverted Phase 
Contrast Microscope using a 20x objective (scale bare = 50μM). (C) Quantification of cells migrating 
toward the FBS sublimated medium (Average of 5 picture fields at 100x total magnification). *P=0.0211 
using unpaired t test. Three independent repeats are shown in each case. 
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Figure 3. 11: Transwell cell invasion assay of PC3 cells. 
PC3 cells treated with 10μM of SPHINX for 72hrs. (A). Representative Pictures of PC3 cell transwell 
invasion. The transwell membrane was coated with Matrigel and then the cell- Serum-free medium was 
added on top of the Matrigel. After cell invasion and staining with crystal violet, pictures of the migrated 
cells were captured by Nikon Eclipse TE300 Inverted Phase Contrast Microscope using a 20x objective 
A 
B 
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(scale bare = 50μM). (B) Quantification of invasive cells moving to the FBS supplemented medium 
(Average of 5 picture fields at 100x total magnification). **P=0.0089 using unpaired t test. Three 
independent repeats are shown in each case.    
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Figure 3. 12: Transwell migration assay of PC3 cells.  
PC3 cells transfected with 100nM SRPK1 siRNA or GL2 control siRNA for 48hrs. (A). Representative 
Pictures of PC3 cell transwell migration. After cell migration and staining with crystal violet, pictures of 
the migrated cells were captured by Nikon Eclipse TE300 Inverted Phase Contrast Microscope using a 20x 
objective (scale bare = 50μM). (B) Quantification of cells migrating toward the FBS sublimated medium 
(Average of 5 picture fields at 20x total magnification). ****P<0.0001 using unpaired t test. Three 
independent repeats are shown in each case.    
 
B 
Chapter Three: Effect of SRPK1 inhibition and knockdown on SRPK1 expression and 
cell biology 
 
      
77 
 
 
 
A 
Chapter Three: Effect of SRPK1 inhibition and knockdown on SRPK1 expression and 
cell biology 
 
      
78 
 
0
200
400
600
800
C
el
ls
 /
 2
0
x
 F
ie
ld
control
GL2-siRNA control
100nM SRPK1 siRNA
****
 
 
Figure 3. 13: Transwell cell invasion assay of PC3 cells.  
PC3 cells transfected with 100nM SRPK1 siRNA or GL2 control siRNA for 48hrs. (A) Representative 
Pictures of PC3 cell transwell invasion. The transwell membrane was coated with Matrigel and then the 
cell- Serum-free medium was added on top of the Matrigel. After cell invasion and staining with crystal 
violet, pictures of the migrated cells were captured by Nikon Eclipse TE300 Inverted Phase Contrast 
Microscope using a 20x objective (scale bare = 50μM). (B) Quantification of invasive cells moving to the 
FBS sublimated medium (Average of five picture fields at 20x total magnification). ****P<0.0001 using 
a one way ANOVA test. Three independent repeats are shown in each case.  
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3.4 Summary  
The results in this section have confirmed the expression of SRPK1 in a range of cancer 
cell lines. The presumed SRPK1a isoform was not detectable in the cell lines, at least not 
by standard PCR (fig.3.1). The SRPK1a isoform has only been described in a single 
publication where SRPK1/SRPK1a ratio on erythroid differentiation was studied. The 
existence of this isoform needs to be corroborated by other studies. It was not detected in 
this study. It is conceivable that SRPK1a is expressed at very low, barely detectable levels 
in these specific cell lines.  
Evidence for an autoregulatory loop involving SRPK1 was examined. The siRNA 
knockdown of SRPK1 apparently did not affect the transcription of SRPK1. The 
chemical inhibition of the kinase activity did, however, appear to affect levels of SRPK1. 
In summary, in K562 and PC3 cells, inhibition of SRPK1 using siRNA knockdown 
reduced SRPK1 protein levels as expected. The SRPK1 inhibitor (SPHINX) did, 
however, appear to reduce protein levels of SRPK1, and the transcription of the SRPK1 
gene (fig.3.2&3), suggesting that an autoregulatory loop may exist. Conceivably, SRPK1 
might be involved in regulating the activity of factors that regulate SRPK1 transcription. 
The chemical inhibition of SRPK1 in K562 and PC3 cells resulted in the alteration of the 
splicing of a panel of key apoptotic genes. Specifically, SRPK1 inhibition resulted in a 
change in the splicing of the apoptotic factors such as BCL2L1 and CASPASE-9 splicing 
toward the pro-apoptotic isoforms in the same cell lines (fig.3.5, 6&7). A shift in the 
splicing of VEGF165 was clearly observed in this study as SRPK1 inhibition using 
SPHINX induced a splicing switch toward the anti-angiogenic isoform VEGF165b 
(fig.3.4).  
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Cellular proliferation, viability, migration and invasion were also affected by SRPK1 
inhibition. Following SRPK1 inhibition using siRNA and SPHINX, the proliferation and 
viability of K562 and PC3 cells were significantly reduced (fig.3.9). A similar reduction 
was observed in the migration and invasive ability of both cell lines in response to SRPK1 
inhibition (fig.3.10, 11, 12 &13). Together these results are consistent with SRPK1 
exerting pro-oncogenic effects. It is, therefore, necessary to examine how SRPK1 
expression might be activated in cancer cells. The next chapter considers whether or not 
the transcription factor WT1 (Wilms’ tumour) is involved in the regulation of SRPK1 
transcription. 
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4 Chapter Four: SR protein kinase 1 (SRPK1) 
regulation by WT1 
4.1 Background 
As highlighted in the previous chapter, SRPK1 is a protein kinase that phosphorylates 
serine/arginine-rich proteins (SR-proteins) which are responsible for regulating 
constitutive and alternative mRNA splicing. Studies have linked high SRPK1 levels to 
tumour proliferation, growth, and metastatic ability (Zhou et al., 2013). The 
overexpression of SRPK1 has been associated with pancreatic, breast and colorectal 
cancer (Hayes et al., 2007). However, the regulation of SRPK1 expression is not well 
understood. This suggests that its inhibition might result in limiting tumour growth, 
increasing therapy responsiveness by modulating alternative splicing of key cancer 
genes. One of these key genes is vascular endothelial growth factor (VEGF) which 
regulates angiogenesis and other vital cellular pathways.  
VEGF is highly expressed in the podocytes of the kidney glomerulus (Ermina and 
Quaggin 2004). The development and function of the podocytes might be linked to this 
high expression. In the development of the kidney, the interaction of the epithelial 
ureteric bud with metanephric mesenchyme, a histologically distinct patch of cells in the 
urogenital ridge, leads to condensation of the mesenchymal cells around the branching 
ureteric bud. This results in the subsequent induction of a mesenchymal-to-epithelial 
transformation of the condensed mesenchyme into a tubular structure known as a nephron 
(Saxen, 1987). Gao et al., 2005 have shown that this developmental process is mediated 
by WT1 and VEGF. 
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The Wilms tumour suppressor WT1 was previously shown to repress the transcription of 
SRPK1 in normal podocytes and indirectly serine/arginine-rich splicing factor 1 (SRSF1) 
activity, thus altering VEGF splicing because of SRSF1 drives the expression of pro-
angiogenic VEGF. SRPK1 expression was significantly elevated in Denys Drash 
Syndrome podocytes harbouring a WT1-activating mutation in the zinc finger domain 
(Amin et al. 2011). A recent study Wagner et al., 2019; (see appendix) has demonstrated 
that WT1, SRPK1, SRSF1, and the angiogenic VEGF isoform are highly expressed in 
tumour endothelium compared to normal lung endothelium. Inducible conditional vessel-
specific knockout of WT1 reduced WT1, SRPK1, and SRSF1 expression in endothelial 
cells and induced a shift towards the antiangiogenic VEGF isoform. WT1 (-KTS) isoform 
directly binds and activates both the promoters of SRPK1 and SRSF1 better than WT1 
(+KTS) isoform in endothelial cells.  
This suggests that WT1 activates SRPK1 and SRSF1 and induces expression of 
antiangiogenic VEGF isoforms in tumour endothelium. The ability of WT1 to either 
activate or repress its target genes in different contexts is well known. Whether or not 
WT1 contributes to the transcriptional regulation of SRPK1 in other cancer cells, has not 
yet been determined. 
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4.2 Aims and objective 
1. To investigate the transcriptional regulation of the splice factor kinase gene 
SRPK1 by WT1 in K562, DU145 and PC3 cancer cell lines by assaying binding 
of WT1 to SRPK1 promoter.  
2. To evaluate the impact of WT1 knockdown or overexpression on the following:   
- Transcription and protein levels of SRPK1 in K562, PC3, and DU145 cells. 
- The alternative splicing of apoptotic factors; BCL2L1 and caspase 9 
- On cellular migration, invasion, viability, and proliferation. 
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4.3 Results  
4.3.1 WT1 binds the SRPK1 promoter 
 
Since WT1 is a well-established transcription factor and given the fact that WT1’s (-
KTS) isoforms are efficient at DNA-binding (Laity et al., 2000), the ability of WT1 to 
bind the SRPK1 promoter was investigated. (Amin et al., 2011) analysed the open reading 
frame of SRPK1 and indicated that the putative core promoter sequence is located 
between -178 and + 40 relative to the ATG start codon in the open reading frame (the 
actual transcriptional start site is unclear; figure 4.1.A) WT1 is known to bind to the 9 
base pair early growth response 1 (EGR-1) consensus sequence (GCG GGG GCG) 
(Rauscher et al., 1990; Bickmore et al., 1992); a similar sequence is apparently close to 
the presumed SRPK1 transcription start site. WT1 has already been shown to bind to the 
putative SRPK1 promoter region of the gene in glomerular podocytes (Amin et al., 2011). 
In this study, chromatin immunoprecipitation (ChIP) was performed on sheared cross-
linked chromatin collected from K562 and PC3 cells (figure 4.2). Primers specific to the 
SRPK1 promoter (table 2.6) were used based on Amin et al. 2011 and PCR was 
performed to detect the genomic regions around 100bp being pulled down by the 
antibodies. Figure 4.2. Shows that WT1 is binding to the SRPK1 promoter in these cell 
lines. Rabbit monoclonal antibody against WT1 was used in the chip or anti- polymerase 
II antibody as a positive control. Normal Mouse IgG served as a negative control. Input 
DNA was used as an additional positive control for subsequent PCRs on the SRPK1 
promoter and the respective sequence. For additional confirmation, the amplicon was 
extracted from the gel and verified by sequencing (see Appendix)
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Figure 4. 1: Sonicated DNA smear for PC3 and K562 cells in preparation for Chromatin 
Immunoprecipitation assay.  
A. Position of the WT1 binding site in the SRPK1 core promoter. Black, promoter region; grey, WT1 binding site 
(B) Chromatin fragments resolved by agarose gel following sonication with varying sonication times, the cells 
were lysed and DNA sheared using a sonicator A. K562 cells were sheared at 30% power output for a minute for 
K562 followed by incubation on ice for 60 seconds after each pulse. B. 50% power output for 15seconds for PC3 
followed by incubation on ice 
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Figure 4. 2: WT1 binds the SRPK1 promoter. 
Chromatin immunoprecipitation (ChIP), A. PCR assay for ChIP product for K562 cells using primers to detect 
the region around the SRPK1 transcriptional start site (TSS) and GAPDH promoters. Representative agarose gel 
photographs of semi-quantitative ChIP PCR experiments for the SRPK1 and GAPDH promoters. Data are 
expressed as means ± S.E.M. **** indicates p < 0.0001 which is statically significance (n = 3) using a one way 
ANOVA test. B. PCR assay for ChIP product for PC3 cells using primers to detect the region around the SRPK1 
transcriptional start site (TSS) and GAPDH promoters. Representative Agarose gel photographs of semi-
quantitative ChIP PCR experiments for the SRPK1 and GAPDH. 
PC3 
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4.3.2 WT1 activates SRPK1 transcription in PC3, DU145 and K562  
 
The previous experiment suggests that WT1 binds to SRPK1 promoter. In a previous study 
(Amin et al., 2011), the binding of WT1 to the SRPK1 promoter results in the repression of 
transcription of SRPK1 by WT1 in glomerular podocytes. The aim here was to determine 
whether or not WT1 might contribute to SRPK1 transcriptional regulation in cancer cells. As a 
model system, the leukemic cell line (K562) and prostate cancer cell lines (PC3 and DU145) 
were used. These cancer cell lines are known to express both WT1 and SRPK1. The results 
show that the ratio of Luciferase to Renilla was almost four times greater in K562, PC3 and 
DU145 cells (Figures 4.3) when cell lines were transfected with wild type promoter while when 
transfected with the mutated promoter the ratio was greatly reduced. In all of the three 
transfection repeats in all of the cell lines mutation of the GC-rich WT1 binding site disrupted 
SRPK1 promoter activity. Therefore, findings support the hypothesis that WT1 is binding to 
the SRPK1 promoter in these cell lines activating its transcription. 
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Figure 4. 3: DLR assay of SRPK1 promoter activity in K562 (A), PC3 (B) and DU145(C) cells. 
Measurement of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. An SRPK1: Luciferase 
construct (cloned into a pGL3 vector), with or without a mutation in the WT1 binding site in the SRPK1 promoter 
(GGGGCGGGGG to GAATTCAAAA) was transfected into the cell lines with a Renilla expressing vector as a 
transfection control. Data are expressed as relative luciferase units (RLU). Data presented as mean ± S.E. for n=3. 
B 
C 
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**** indicates p<0.0001 which is statistically significant using a one way ANOVA test. Figures show a reduction 
of promoter’s activity in cells when transfected with the mutant promoter and high activity when transfected with 
wild type promoter.  
 
4.3.3 Effect of WT1-siRNA knockdown on SRPK1 transcription and protein level 
 
So far, the experimental outcomes in this study suggest that WT1 binds to the SRPK1 promoter 
and activates its expression. In order to investigate further the involvement of WT1 in SRPK1 
transcriptional regulation, it was necessary to establish siRNA-mediated knock-down of WT1 
in K562 and PC3 cell lines. The same WT1 siRNA (human specific) and the GL2 control 
sequences (table 2.1) previously described in (Davies et al., 2003) were used in this study. To 
verify the transfection efficacy, siRNA were tagged with different fluorescent labels such as 
FAM & CY5 (Figure.4.4.A). At first, to verify that the knockdown occurred siRNA were 
transfected alone to the cells and western blot was performed on protein lysates prepared from 
the cell lines following the siRNA knockdown (Figure.4.4.B &C). Significant reduction on 
both WT1 and SRPK1 levels was observed at higher concentrations of the siRNA (50 and 
100nM) which suggests that knocking down WT1 resulted in a reduction in SRPK1 expression 
in K562 and PC3 cell lines.  
The next step was to evaluate the effect of WT1 knockdown on SRPK1 transcription by co-
transfecting the highest concentration of siRNA WT1 with SRPK1 wild-type and mutant 
promoters. Figure.4.6.D&E shows that the activity of the wild type promoter significantly 
decreased in K562 cells (*p= 0.0014) (Figure.4.6.D) and PC3 cells (*p< 0.0001) when co-
transfected with WT1 siRNA (Figure.4.7.E). The mutant promoter showed no change in the 
activity in response to WT1 siRNA transfection.
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Figure 4. 4: Effect of WT1 knockdown on SRPK1 levels in K562 and PC3 cells. 
(A). representative fluorescence microscopy images of siRNA transfected PC3 cells where the GL2 control 
siRNA was tagged with CY5 and the WT1 targeting siRNA was tagged with FAM fluorescent tags. 
Pictures were captured by Inverted phase contrast microscope using a 20x objective (scale bare = 50μM). 
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Western blot of protein lysate from K562 (B) and PC3 (C) cell lines subjected to increasing concentration 
(10nM, 50nM, and 100nM) of WT1 siRNA knockdown control GL2 siRNA for 48 hours.  
Membranes were blotted with anti-WT1 or anti SRPK1 anti-beta Actin antibodies as a loading control. 
Graphs represent relative expression determined by densitometric measurement of the bands and are 
expressed relative to actin. Bar-graph shown is the average of 3 independent experiments. **** = p<0.0001 
significant change compared to control using 2-way ANOVA test.  DLR assay of SRPK1 promoter activity 
after a knockdown of WT1, using siRNA in K562 (D) and PC3 (E) cells. Measurement of SRPK1 promoter 
activity using a dual luciferase reporter (DLR) assay. WT or mutant SRPK1: Luciferase construct, was co-
transfected with 100nM WT1 siRNA into the cell lines. Data is expressed as relative luciferase units (RLU). 
Data presented as mean ± S.E. for n=3. * indicates p=0.0014, **** p<0.0001, which is statistically 
significant using one way ANOVA test. Figures show reduction in the promoter’s activity in cells where 
WT1 has been knocked down. 
                          
4.3.4 Effect of splice switching oligonucleotide-mediated WT1 knockdown on    
SRPK1 promoter activity 
 
Splice-switching oligonucleotides (SSOs) new emerging molecular tool that has been 
recently used to change the way that exon segments of RNA are spliced (joined) together 
and result in inclusion or exclusion of a given exon. In chapter 6 SSOs, based on 
morpholino chemistry, are used to modify ERG splicing thereby diminishing ERG 
expression. Since the previous section shows that knowing down WT1 impacted the 
transcription and expression of SRPK1, we tested a WT1-specific SSO to see if we could 
confirm the results obtained with a siRNA. 
Gene tools (SSOs’ manufacturer) were approached with the idea to synthesis a 
morpholino that targets the human WT1 oncogene. The idea was to target the 3' and 5′ 
splice site of a constitutive, early exon on the WT1 gene. They proposed a sequence (table 
2.2). That is complementary to WT1 exonic splice junction as a target as shown in figure 
4.5.A.  
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The self-transfecting SSOs were added to PC3 cells followed by western blotting and 
DLR assay to evaluate the possible effect. (Figure 4.5.C) Shows no impact on SRPK1 
transcription (figure.4.5.B) or the protein levels of SRPK1 and WT1, suggesting that the 
SSO was not effective.  
 
 
 
  
 
 
 
            
0
5
10
15
r
e
l.
 l
u
c
if
e
r
a
se
 a
c
ti
v
it
y
mutant SRPK1 promoter
WT SRPK1 promoter
WT SRPK1 promoter +WT1 SSO
 
 
 
Figure 4. 5: Effect of splice switching oligonucleotides mediated WT1 knockdown on SRPK1 
expression.  
(A) Representation of the target sequence for the SSOs on the WT1 gene. (B) Western blot of protein lysate 
from PC3 cell line subjected to 3µM WT1 SSOs for 48 hours. Membranes were blotted with anti-WT1 or 
anti SRPK1 Anti-beta Actin antibodies as a loading control. There wasn’t any noticeable difference in the 
bands between the controls and WT1 SSOs transfections. Three independent repeats are shown in each 
case. DLR assay of SRPK1 Promoter’s activity (C) Measurement of SRPK1 promoter activity using a dual 
luciferase reporter (DLR) assay. Where WT or mutant SRPK1: Luciferase construct, were co-transfected 
B 
 
C 
 
A 
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with 3µM WT1 SSOs into PC3 cell line for 48 hrs. Data are expressed as relative luciferase units (RLU). 
Data presented as mean ± S.E. for independent experiments n=3 and shows no significant change in the 
activity of the promoters using one way ANOVA test.  
 
4.3.5 WT1 overexpression and the effect of co-transfection of +/- KTS WT1 
expressing plasmids on SRPK1 promoter activity 
 
 WT1, like other oncogenes, express several splice isoforms. Through alternative splicing, 
the WT1 gene generates several isoforms. This study focused on studying the effect of -
/+KTS isoforms of WT1. These two WT1 variants differ by the presence or absence of 
three amino acids (KTS) in the zinc finger domain of the molecule at the very end of 
zinc-finger three (Haber et al., 1991; Gessler et al., 1992). The results in the previous 
sections of this chapter suggest that WT1 is activating SRPK1 transcription in K562 and 
PC3 cells lines. To determine how (-/+KTS) WT1 isoforms influence the activation of 
SRPK1, WT1 (-KTS) or WT1 (+KTS) expressing plasmids constructs were used for this 
purpose in transient transfections. At first, to examine the degree of WT1 overexpression 
induced by the different isoforms, the constructs were transfected into the K562 and PC3 
cell lines. Western blot was performed on protein lysates prepared from the cell lines 
following the overexpression. (Figure.4.6.A&B) shows a significant increase 
(***p=0.0003) in WT1 bands was noticed with –KTS isoform transfection in K562 cells 
(A) and (**p=0.0052) in PC3 cells (B). +KTS isoform didn’t induce the same significant 
overexpression. No significant change was observed in SRPK1 protein levels in both cell 
lines after overexpression of WT1 isoforms. With the caveat that these are transient 
transfections, it appeared that whereas the –KTS expressing plasmid did increase WT1 
levels, the +KTS expressing plasmid did not, suggesting that the plasmid did not work. 
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Figure 4. 6: Overexpression of WT1.   
Western blot of protein lysates from K562 (A) and PC3 (B) cell lines where WT1 (+/- KTS isoform) 
expressing plasmids were transiently transfected for 48 hours. Membranes were blotted with anti-WT1 or 
anti SRPK1 or Anti-beta Actin antibodies as a loading control. Graphs represent relative expression 
determined by densitometric measurement of the bands and are expressed relative to actin. Bar-graph 
shown is the average of 3 independent experiments. ** = p<0.0052 and ***p=0.0003 significant change 
compared to the control determined by 2-way ANOVA test. Three independent repeats are shown in each 
case. 
 
The next step was to test the effect of the overexpression of WT1 (-KTS) isoform on 
SRPK1 transcription. For that purpose, (-KTS) isoform was transiently co-transfected 
with WT SRPK1 promoter at increasing concentrations into K562 and PC3 cells lines. 
(Figure 4.7) Shows that –KTS isoform significantly stimulated SRPK1 promoter. +KTS 
isoform was excluded from this experiment due to the +KTS plasmid not working.   
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Figure 4. 7: Overexpression of WT1 (-KTS) isoform significantly enhances SRPK1 promoter’s 
activity.  
Plasmid encoding wild-type WT1 (- KTS isoform) were co-transfected with the WT SRPK1 promoter: 
Luciferase and Renilla expressing vectors at increasing concentrations, 0-2.5 µg into K562 (A) and PC3 
(B) cells. RLU = relative luciferase units.   
 
4.3.6 Effect of WT1 siRNA knockdown on the alternative splicing of apoptotic 
factors BCL2L1 and CASPASE-9  
 
K Ito, et al., 2017 demonstrated that WT1-specific siRNA induces apoptosis in a caspase-
dependent manner in several leukemic cell lines; the knockdown activated caspase-3 and 
-9 in the intrinsic apoptosis pathway. In this study, caspases 3/ 7 staining was used to 
determine if knocking down WT1 resulted in a change in the apoptotic activity in K562 
and PC3 cell lines. Figure 4.8 A shows that the signal of caspase 3/7 was significantly 
higher (****P<0.0001) in the cells where WT1 has been knocked down compared to the 
A B 
Chapter Four: SR protein kinase 1 (SRPK1) regulation by WT1. 
 
100 
 
untransfected cells. This indicates that reducing WT1 expression induces apoptosis in 
K562 and PC3 cell lines (figure 4.8.A&B).      
To further investigate the possibility of knocking down WT1 would result in any change 
in the alternative splicing of other caspase family members such as caspase-9 and another 
apoptotic factor such as BCL2L1, mRNA was extracted from the K562 and PC3 cells 
following WT1 knockdown. Then a PCR was performed using the primers listed in table 
2.6. PCR shows that the splicing ratio (PSI-Ψ) of caspase-9a/caspase-9b mRNA was 
significantly higher in the siRNA WT1 transfected group compared to the control group 
while no significant change was observed on the splicing ratio Bcl-xl/Bcl-xs in both cell 
lines (figure 4.10 & 4.12). In K562 cells, (figure 4.9), the expression ratio of caspase-
9a/9b isoform in the control was 0.71 siRNA WT1 transfected cells 0.95 (*P= 0.0276 
using unpaired t-test). The expression ratio caspase-9a/9b isoform in the control was 0.69 
while in siRNA WT1 transfected cells 0.80 (*P= 0.0148 using unpaired t-test) in PC3 
cells (figure 4.11) 
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Figure 4. 8: Caspases 3 and 7 staining in K562 and PC3 cells where WT1 has been knocked 
down.  
K562 and PC3 cells were transfected with 100nM WT1 siRNA or GL2 control siRNA for 48hrs followed 
by detection of active caspases 3 and 7 were performed using Caspase 3/7 Green Detection Reagent. A. 
Representative images of the stained PC3 cells taken under a fluorescent microscope. the graph represents 
the number of caspases positive in K562 (B) and PC3 (C) cells which shows significance in the ratio of 
caspase activity in the cells after WT1 KD, ****P<0.0001 using unpaired t-test. n=9. 
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Figure 4. 9: Caspase-9 mRNA levels in K562 cells where WT1 has been knocked down. 
K562 cells transfected with 100nM WT1 siRNA for 48hrs followed by RNA extraction and cDNA 
synthesis. PCR was performed using caspase-9 specific primers. PCR shows band intensity and size and 
corresponding loading control, β-actin. Densitometry showing caspase-9a/9b PSI-Ψ values for 48hrs. The 
result shows a small but significant change in splice ratio of caspase-9 (PSI-Ψ, *P= 0.0276) using unpaired 
t-test.  n=3. Three independent repeats are shown in each case.   
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Figure 4. 10: BCL2L1 mRNA levels in K562 cells where WT1 has been knocked down. 
K562 cells transfected with 100nM WT1 siRNA for 48hrs followed by RNA extraction and cDNA 
synthesis. PCR was performed using Bcl specific primers. PCR gel at 48hrs showing band intensity and 
size and corresponding loading control, β-actin. Densitometry showing Bcl-xl/s PSI-Ψ values for 48hrs. 
There was no significant change in splice ratio (PSI-Ψ) of Bcl using unpaired t-test.  n=3. Three 
independent repeats are shown in each case. 
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Figure 4. 11: Caspase-9 mRNA levels in PC3 cells where WT1 has been knocked down.   
PC3 cells transfected with 100nM WT1 siRNA for 48hrs followed by RNA extraction and cDNA synthesis. 
PCR was performed using Caspase-9 specific primers. PCR shows band intensity and size and 
corresponding loading control, β-actin. Densitometry showing caspase-9a/9b PSI-Ψ values for 48hrs.  The 
result shows a small but significant chance splice ratio (PSI-Ψ, *P=. 0.0148) of caspase-9a/9b using 
unpaired t-test. n=3. Three independent repeats are shown in each case. 
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Figure 4. 12: BCL2L1 mRNA levels in PC3 cells where WT has been knocked down.   
PC3 cells transfected with 100nM WT1 siRNA for 48hrs followed by RNA extraction and cDNA synthesis. 
PCR was performed using Bcl specific primers. PCR gel at 48hrs showing band intensity and size and 
corresponding loading control, β-actin. Densitometry showing Bcl-xl/s PSI-Ψ values for 48hrs. The result 
shows no significant change in the splicing ratio of Bcl using unpaired t-test. n=3. Three independent 
repeats are shown in each case. 
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4.3.7 The Effect siRNA WT1 knockdown and overexpression on cell proliferation 
and viability   
 
Parenti, et al., 2014 has demonstrated that silencing WT1 resulted in limiting cellular 
proliferation in nerve sheath tumour sNF96.2 cell line. This effect was likely a result of 
the interference with the cell cycle progression in which WT1 plays a major role. Hong 
et al., 2017 report that WT1 overexpression in rhabdoid tumour G401 cell Line decreased 
cell proliferation rate. Thus, in this study, the effect of WT1 knockdown and 
overexpression on cellular proliferation and viability of K562 and PC3 cells was 
investigated. siRNA was used to reduce WT1 expression levels while (-KTS) WT1 
isoform expressing plasmid was used to upregulate WT1. The effect of that on the protein 
levels was shown in the previous sections. Transfections were performed, followed by an 
MTT assay. Significant reduction in proliferation and viability occurred 48 h after 
transfections with siRNA and –KTS isoform compared with the control group. 
Additionally, the statistical analysis in (figure 4.13 A&B) indicated that with siRNA and 
–KTS expressing plasmid reduced K562 proliferation and cell viability (***P=0.0010 
and *0.0447, respectively). A significant reduction in PC3 (figure 4.13 C&D) cellular 
proliferation and cell viability. These findings suggest that WT1 affects cell proliferation 
and viability in K562 and PC3 cells.       
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Figure 4. 13. Cellular proliferation and viability in K562 and PC3 cells after overexpression of 
WT1 isoform and WT1 knockdown.  
MTT assays were used to analyse the effect of WT1 (- KTS isoform) or 100nM WT1 siRNA transfections 
for 48hrs on the cellular viability and proliferation in K562 (A&B) and PC3 (C&D) cells. The absorbance 
of each well was measured at 590 nm using a plate reader. Results represent the mean ± SEM of three 
independent experiments and are presented as a bar graph after normalizing to the respective controls. Cell 
A B 
C D 
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viability was calculated using the following formula:  control- absorbance of treatment wells/absorbance 
of control well ×100%. (***P=0.0010, *0.0447 using one way ANOVA test).   
 
4.3.8 Effect of WT1 knockdown on cellular migration and invasion  
 
Yang, et al., 2016 described how WT1 knockdown suppressed migration and invasion of 
two different human NSCLC cell lines. Therefore, in this experiment, the effect of siRNA 
WT1 knock down on the migration and invasion of PC3 cells was determined. WT1 
knockdown was performed on PC3 cells and transwell migration and invasion assay was 
carried out. (Figure 4.14 &15) shows an observed difference in the number of migrating 
(*** p =0.0003) and (**** p<0.0001) invasive cells between PC3 WT1-KD and the 
control siRNA and the un-transfected cells groups. These data considered together 
suggest that WT1 knockdown significantly suppress PC3 capability to migrate and 
invade.                  
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Figure 4. 14: Transwell migration assay of PC3 cells following WT1 knockdown 
B 
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PC3 cells transfected with 100nM WT1 siRNA or GL2 control siRNA for 48hrs. (A) Representative 
Pictures of PC3 cell transwell migration. After cell migration and staining with crystal violet, pictures of 
the migrated cells were captured by  Nikon Eclipse TE300 Inverted Phase Contrast Microscope using a 
20x objective (scale bare = 50μM). (B) Quantification of cells migrating toward the FBS sublimated 
medium (average of 5 picture fields at 20x total magnification). ***P=0.0003 using one way ANOVA test. 
Three independent repeats are shown in each case.    
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Figure 4. 15: Transwell cell invasion assay of PC3 cells following WT1 knockdown. 
PC3 cells transfected with 100nM WT1 siRNA or GL2 control siRNA for 48hrs. (A). Representative 
Pictures of PC3 cell transwell invasion. The transwell membrane was coated with Matrigel and then the 
cell- Serum-free medium was added on top of the Matrigel. After cell invasion and staining with crystal 
violet, pictures of the migrated cells were captured by Nikon Eclipse TE300 Inverted Phase Contrast 
Microscope using a 20x objective (scale bare = 50μM). (B) Quantification of invasive cells moving to the 
FBS sublimated medium (Average of 5 picture fields at 20x total magnification). ****P<0.0001 using one 
way ANOVA test. Three independent repeats are shown in each case.  
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4.4 Summary  
The data presented in this chapter has confirmed the previously described binding of 
WT1 to the SRPK1 promoter. It was the effect of this binding what was different in this 
study. WT1 has been shown to repress SRPK1 in DDS podocytes. In contrast, SRPK1 
transcription appeared to be activated by WT1 in K562, PC3 and DU145 cells (fig.4.2 
&3). The activation of SRPK1 transcription by the –KTS isoform of WT1 is significantly 
higher compared to the activation by +KTS (fig.4.7) which is expected since –KTS 
isoform has been described to be better at binding to its DNA targets (Laity et al., 2000). 
Additionally, –KTS WT1 isoform stimulated WT1 expression at a higher rate compared 
to the +KTS isoform following overexpression of both WT1 isoforms using plasmid 
constructs in  K562 and PC3 cell lines (fig.4.6). Thus, it is possible that the observed 
effect of WT1 on SRPK1 is mediated by –KTS, and not +KTS isoforms. However, it is 
quite possible that the +KTS expressing plasmid was not working optimally; further 
experiments are needed therefore to compare the activity of + and –KTS isoforms in 
relation to regulating SRPK1 transcription. 
The results in this chapter have confirmed that knocking down WT1 impacted the 
transcriptional activity of SRPK1 as its promoter activity was diminished when siRNA 
WT1 was cotransfected with the wild type SRPK1 promoter into K562 and PC3 cell lines. 
Moreover, WT1 inhibition mediated by siRNA resulted in not only in the reduction of 
WT1 protein levels but also of SRPK1 protein levels in both cell lines (fig.4.4).  
WT1 is a major transcriptional regulator; therefore, its inhibition is likely to affect the 
transcription of other genes that play important roles in different cellular pathways 
including the regulation of apoptosis (K Ito et al., 2017). In this study, WT1 knockdown 
was shown to induce an increase in the levels of active caspases 3 and 7 which suggests 
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a higher apoptotic activity in the cells (fig.4.8). This was accompanied by a change in 
alternative splicing of caspase-9 mRNA. Following WT1 knockdown in K562 and PC3 
cells, a splicing switch toward the pro-apoptotic caspase-9a isoform was observed 
(fig.4.9&11).  
Cellular proliferation, viability, migration and invasion seemed to be influenced by WT1 
knockdown. Following WT1 knockdown, the proliferation and viability of K562 and PC3 
cells were significantly reduced (fig.4.13). A similar reduction was observed on the 
migration and invasive ability of both cell lines in response to SRPK1 inhibition 
(fig.4.14&15). It is therefore tempting to speculate that the consequences of knocking 
down WT1 on cell biology are at least in part due to a reduction in the expression of 
SRPK1. 
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5 Chapter Five: Effect of the co-suppressor BASP1 on 
the transcriptional regulation of SRPK1 by WT1   
5.1 Background  
Genes that are involved in growth, differentiation and the regulation of cell division have 
been described to be transcriptionally regulated by WT1.  The last chapter discussed how 
WT1 binds the putative SRPK1 promoter and activates its transcription in K562 cells and 
PC3. This is the opposite of what happens in glomerular podocytes where SRPK1 is 
transcriptionally repressed by WT1. As discussed before, the ability of WT1 to activate 
or repress its target genes is fully dependent on the presence or absence of other 
transcriptional cofactors (Toska & Roberts, 2014). Numerous proteins have been 
described to be interaction partners for WT1. They add more specificity to WT1 function 
and determine whether it acts as a transcriptional activator or repressor (Roberts, 2005).  
Brain-abundant signal protein (BASP1) has been shown to influence transcriptional 
control and tumourigenicity in breast cancer cells, acute myelogenous leukaemia cells, 
hepatocellular carcinoma cells and thyroid cancer cells (Zhou et al., 2018, Guo et 
al., 2016 and Marsh et al., 2017). It also has been described to interact with numerous 
major transcription factors including WT1, c-myc and ERα in a variety of cell types 
(Carpenter et al., 2004 and Marsh et al., 2017). 
Carpenter et al., 2004 revealed that BASP1 translocates into the nucleus of HEK cells 
where it influences WT1 activity and consequently its target genes. BASP1 modulates 
the transcriptional regulation of WT1 through direct binding to WT1 at the promoters of 
its target genes. BASP1 was also found to form a transcriptional complex with WT1 to 
regulate the transcription of WT1 target genes. For instance, Goodfellow et al., 2011 has 
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shown that BASP1 binds to WT1 and converts it from a transcriptional activator to a 
transcriptional repressor of WT1 target genes. BASP1 does this by inducing the 
dissociation of CBP and the recruitment of HDAC1 to the WT1 transcriptional complex.  
Depending on the cell type and location, BASP1 has been proposed to perform a range 
of different context-specific activities and functions. WT1 induces tumour suppressor 
activity in the presence of BASP1. This indicates that in cell lines that express both 
proteins, BASP1 can promote WT1 tumour suppressive activity while the 
downregulation of endogenous BASP1 expression enhances the activation of 
transcription of cancer-associated by WT1. 
5.2 Aims and objectives 
1. To investigate the effect of the transcriptional co-suppression of WT1 by BASP1 
on SRPK1 expression.   
2. To evaluate the impact of the WT1 / BASP1 interaction on the following: 
- Expression of SRPK1 in K562, B-K562 (BASP1-overexpressing), 
PC3, and DU145 cells. 
- VEGF alternative splicing in PC3 cells. 
- The effect of BASP1 overexpression on cellular viability, and 
proliferation. 
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5.3 Results  
5.3.1  BASP1 binds to the SRPK1 promoter (ChIP)  
 
The previous chapter examined the involvement of WT1 in the transcriptional regulation 
of SRPK1. The manner in which WT1 is involved in the transcriptional regulation of 
SRPK1 appeared to be cell line dependent. WT1 activates SRPK1 in several cell lines 
while repressing its transcription in DDS podocytes. Several studies have suggested that 
this difference in regulating the transcriptional activity of the same target gene depends 
not only on the type of the cell line but also on the presence or absence of other 
transcriptional regulators. However, in both cases, there was a physical binding of WT1 
to SRPK1 promoter which confirmed by chromatin immunoprecipitation. 
Since BASP1 had been identified as WT1 transcriptional co-suppressor (Carpenter et al., 
2004), another study considered investigating the possible presence of a WT1/BASP1 
transcriptional complex that represses WT1 target genes. Green et al., 2008 revealed that 
WT1 and BASP1 bind the promoter of the podocalyxin, Bak and c-Myc genes in podocyte 
precursor, MPC5 cells. Through performing chromatin immunoprecipitation, they used 
an anti-WT1 and two different anti-BASP1 antibodies to pull down WT1/BASP1 
complexes then amplified the regions of the promoters that contain the proposed WT1-
binding sites. Results show that both WT1 and BASP1 are present at the Bak and c-myc 
promoters.   
In this study, chromatin immunoprecipitation (ChIP) was performed on sheared cross-
linked chromatin was collected from B-K562, a modified K562 cell generated to provide 
a stable K562 cell-line derivative that expresses BASP1 (Goodfellow et al., 2011). 
Primers specific to the SRPK1 promoter were designed and PCR was performed to detect 
Chapter Five: Effect of the co-suppressor BASP1 on the transcriptional regulation of 
SRPK1 by WT1   
      
 
117 
 
the genomic regions being pulled down by the antibodies. Figure 5.1. Shows that BASP1 
binds to the SRPK1 promoter. A rabbit polyclonal antibody against BASP1 was used with 
an anti- polymerase II antibody as a positive control. Total mouse IgG served as a 
negative control. Input DNA was used as an additional positive control for PCR. For 
additional confirmation, the BASP1-SRPK1 pull-down amplicon was extracted from the 
gel and sent for sequencing (see Appendix).  
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Figure 5. 1: BASP1 binds the SRPK1 promoter.  
Chromatin immunoprecipitation (ChIP, n = 3 independent repeats) was performed using a rabbit 
monoclonal antibody against BASP1 or anti- polymerase II antibody as a positive control. Total Mouse 
A 
B 
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IgG served as a negative control. Input DNA was used as an additional positive control for subsequent 
PCRs on the SRPK1 promoter and the respective sequence. PCR assay for ChIP product for B-K562 cells 
using primers to detect the region around the SRPK1 transcriptional start site (TSS) and GAPDH promoters. 
(A) Representative agarose gel photographs of ChIP PCR experiments for the SRPK1 and GAPDH 
promoters. (B) Quantified data are expressed as means ± S.E.M. * indicates p < 0.0426 which is statically 
significant using one way ANOVA test, based on three independent repeats are shown in each case. 
 
5.3.2 Overexpression of the transcriptional co-repressor BASP1 prevents WT1 
from activating SRPK1 transcription 
 
The previous experiment suggests that BASP1 binds to the SRPK1promoter where WT1 
also was previously described to be present (chapter 4).  
Given the fact that for WT1 to act as a transcriptional activator or suppressor depends on 
the presence or absence of other transcriptional regulator, and that Carpenter et al., 2004 
has described that BASP1 can promote WT1 tumour suppressive activity, in this study, 
the overexpression of BASP1 was used to determine whether or not WT1/BASP1 
cosuppression mechanism is applicable in PC3 and K562 cell lines.  
A full-length BASP1 cDNA construct (Carpenter et al., 2004) and B-K562, a genetically 
modified K562 cell line that overexpresses BASP1, (Goodfellow et al., 2011) were used 
for this purpose. At first, the stable expression of BASP1 in B-K562 cells was compared 
to the endogenous BASP1 in regular K562 by western blot. (Figure.5.2. A) shows 
significant expression of BASP1 (****p < 0.0001) in B-K562 cells compared to K562 
cells. To examine the degree of BASP1 expression introduced by the vector, the construct 
was transfected into a PC3 cell line. Western blot was performed on protein lysates 
prepared from the cell line following BASP1 overexpression. (Figure.5.2.B) shows a 
significant increase (**p=0.0064) in BASP1 bands was noticed where BASP1 was 
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overexpressed in PC3 cells (B). While the untransfected group showed lower levels of 
BASP1. 
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Figure 5. 2: Overexpression of BASP1 in B-K562 (A).  
Western blot of protein lysate from B-K562 and K562 cell lines. Membranes were blotted with anti-BASP1 
or anti-beta actin antibodies as a loading control. The graph represents relative expression determined by 
A 
B 
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densitometric measurement of the bands and is expressed relative to actin. Bar-graph quantifies the result 
of three independent experiments. **** = p<0.0001 significant change compared to the control determined 
by the T-test. (B)  Overexpression of BASP1 in PC3 cells. Western blot of protein lysate from PC3 cells 
transfected with plasmids encoding wild-type BASP1. Membranes were blotted with anti-BASP1 or anti-
beta actin antibodies as a loading control. The graph represents relative expression determined by 
densitometric measurement of the bands and is expressed relative to actin. Bar-graph shown is the average 
of three independent experiments. ** = p<0.0064 significant change compared to the control determined 
by T-test. 
 
The next step was to test the effect of the BASP1 overexpression on SRPK1 transcription. 
For that purpose, the BASP1 expressing construct was transiently co-transfected with 
wild-type and mutant SRPK1 promoters. Figure 5.3 shows that BASP1 significantly 
diminished SRPK1 promoter activity (****p < 0.0001) in both cell lines.    
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Figure 5. 3: Effect of BASP1 on SRPK1 transcription 
(A) The transcriptional co-repressor BASP1 prevents WT1 from activating SRPK1 transcription when 
expressed in K562. Relative luciferase activity of the WT and the mutant SRPK1 promoters in B-K562 and 
K562. In B-K562 cells SRPK1 promoter’s activity levels are significantly reduced (**** = p<0.0001) one 
A B 
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way ANOVA test.  (B) Overexpression of BASP1 reduces SRPK1 transcription in PC3. Plasmids encoding 
wild-type BASP1 at two concentrations, 0.5-1µg or empty vector were co-transfected with the WT or 
mutant SRPK1 promoters into PC3 cells. RLU = relative luciferase units. (**** = p<0.0001) determined 
by 2-way ANOVA test. Three independent repeats are shown in each case. 
 
5.3.3 BASP1 expression limits the endogenous protein levels of WT1 and SRPK1 
 
The results in this chapter so far suggest that BASP1 binds to the SRPK1 promoter and 
helps to repress its transcription. BASP1 is known to work as a WT1 co-suppressor; WT1 
expression in K562 cells is high and there is no detectable amount of BASP1. In the 
developing podocytes, BASP1 expression overlaps with WT1 as its expression levels 
decrease while BASP1 levels become more prominent in the latter stages of kidney 
development. (Carpenter et al., 2004). Here in this study, the transcriptional regulation 
of SRPK1 was repressed when BASP1 was overexpressed in PC3 and B-K562 cells while 
it remained unchanged in untransfected K562 cells. To determine if this repression could 
result in the down regulation of the endogenous protein levels of SRPK1 and WT1, 
protein lysates from PC3, DU145, K563 and B-K562 were prepared and western blot was 
carried out. (Figure.5.4.) shows the levels of SRPK1 and WT1 in different cell lines. A 
significant reduction in SRPK1 and WT1 levels combined with elevated BASP1 
expression in B-K562 cells was observed. SRPK1 level was significantly lower in B-
K562 compared to other cell lines (pc3 cells; *p= 0.0362. DU145; **p=0.0032. K562; 
****p<0.0001). WT1 expression was lower in B-K562 as well compared to other cell 
lines (****p<0.0001) while BASP1 was elevated in B-K562 cells compared to other cell 
lines (*p=0.0362).    
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Figure 5. 4 BASP1 expression limits the expression of endogenous WT1 and SRPK1 protein. 
Western blot of protein lysate from PC3, DU145, K562 and B-K562. Membranes were blotted with anti-
BASP1 or anti SRPK1 or anti WT1 or anti-beta actin antibodies as a loading control. The graph represents 
relative expression determined by densitometric measurement of the bands and is expressed relative to 
actin. Bar-graph shown is the average of 3 independent experiments. **** = p<0.0001 represent a 
significant change compared to the control using 2-way ANOVA test.  
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5.3.4 Overexpression of WT1 co-suppressor BASP1 affects VEGF-A alternative 
splicing in PC3 cells  
 
SRPK1 has been described to be a downstream target for WT1 regulation where WT1 
can either activate (Wagner et al., 2019) or repress SRPK1 transcription (Amin et al., 
2011) in different contexts. Data shown in chapter 3 of this study confirmed that the 
alternative splicing of VEGF has changed in response to the inhibition of SRPK1 by the 
chemical inhibitor SPHINX. Recently SRPK1 activation by WT1 in endothelial cells was 
found to enhance the expression of angiogenic VEGF isoforms (Wagner et al., 2019). 
Thus, in this study, it was of interest to investigate whether or not the overexpression of 
WT1 co-suppressor BASP1 caused an alteration in VEGF alternative splicing.  
For this purpose, a western blot was performed on protein lysates prepared from the PC3 
cell lines transiently transfected with full-length BASP1-expressing construct (Carpenter 
et al., 2004). The protein bands shown in (figure 5.5) at 22kda correspond to anti-
angiogenic VEGF165b and total VEGF165 in different membranes. The western blot 
showed baseline VEGF165 expressions and an increase in the anti-angiogenic isoform 
VEGF165b following the overexpression of BASP1. This suggests that the WT1/BASP1 
complex suppresses SRPK1 and therefore, results in a splicing switch from pro- to anti-
angiogenic VEGF isoforms in PC3 cells. 
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Figure 5. 5 Overexpression of WT1 co-suppressor BASP1 Affects VEGF alternative Splicing 
in PC3 cells. 
Western blot analysis of VEGF 165 and VEGF 165b isoforms in PC3 cells after BASP1-expressing plasmid 
transfection (pCDNA-BASP1-FH). The blot was re-probed with actin which was used as a loading control. 
The graph represents relative expression determined by densitometric measurement of the bands and is 
expressed relative to VEGF 165. Bar-graph shown is the average of three independent experiments. (**P= 
0.0090) a significant change of VEGF alternative splicing compared to the untreated group using unpaired 
t-test. 
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5.3.5 Effect of BASP1 overexpression on cell proliferation and viability 
 
Guo et al., 2016 demonstrated that BASP1 overexpression in vitro in KMH-2 
cells and BHT101 resulted in limiting cellular proliferation and reducing cell viability. In 
vivo, BASP1 overexpression showed inhibitory activities against proliferation and 
tumorigenicity. In multiple tumours, WT1 plays a major role in tumour cell proliferation 
and inhibiting apoptosis (Sugiyama, 2010). 
The described co-suppressive activity of BASP1 could play a role in limiting cellular 
proliferation and viability through suppressing WT1 target genes. Therefore the effects 
of BASP1 overexpression on the proliferation and viability of K562 and PC3 cells was 
investigated in this study.  
BASP1 expressing plasmid was transfected into both cell lines followed by the MTT 
assay. Significant reductions in proliferation and viability occurred 48 h after transfection 
compared with the control group. Additionally, the statistical analysis in figure 5.6 
indicates that BASP1 overexpression reduced K562 proliferation and cell viability 
(*P=0.0360 and *0.0015, respectively). A significant reduction in PC3 (figure 5.6 C&D) 
cellular proliferation and cell viability (**P 0.019 and ***=0.0002, respectively) was also 
observed. These findings suggested that BASP1 overexpression inhibits the proliferation 
and cell viability in K562 and PC3 cells.   
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Figure 5. 6 Cellular proliferation and viability in K562 and PC3 cells after overexpression of 
BASP1.  
MTT assays were used to analyse the effect of BASP1 expressing plasmid transfections for 48hrs on the 
cellular viability and proliferation in K562 (A&B) and PC3 (C&D) cells. The absorbance of each well was 
measured at 590 nm using a plate reader. Results represent the mean ± SEM of three experiments and are 
presented as a bar graph after normalizing to the respective controls. Cell viability = control- absorbance 
A B 
C D 
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of treatment wells/absorbance of control well ×100%. (*P=0.0360,*0.0015, **P 0.019, ***=0.0002 using 
unpaired t-test).   
 
5.3.6  Effect of BASP1 overexpression on SRPK1 promoter activity in WT1 
negative MG63 cells 
 
As previously described, BASP1 has been identified as a WT1 transcriptional co-
suppressor as the WT1/BASP1 transcriptional complex binds and represses transcription 
of its target genes. The collective evidence in this part of the study suggests that BASP1 
influences SRPK1 transcription through a co-suppressive mechanism that involves WT1.  
To provide further evidence for this mechanism, and as a further control, BASP1 was 
expressed in a WT1 negative cancer cell line, MG63 (osteosarcoma). MG63 cells were 
transiently co-transfected with full-length BASP1 expressing construct and the WT 
SRPK1 promoter: luciferase reporter. BASP1 overexpression alone has no significant 
impact on SRPK1 transcription (Figure 5.7).     
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Figure 5. 7: Overexpression of BASP1 doesn’t repress SRPK1 transcription in MG63.   
Plasmid encodes wild-type BASP1 was co-transfected with the WT SRPK1 promoters into MG63 cells. 
RLU = relative luciferase units. No significant change was observed using unpaired t-test. Three 
independent repeats are shown in each case. 
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5.4 Summary   
Data in preceding chapters have shown that WT1 binds to SRPK1 promoter and activates 
it. This was the opposite of what has been described before in podocytes wherein WT1 
binds and represses SRPK1 expression. This could be attributed to the fact that WT1 
interacts with other transcriptional cofactors that determine whether it works as a 
transcriptional activator or repressor of its target genes. Previous publications have 
identified that BASP1 is a WT1 co-suppressor that forms a transcriptional complex with 
WT1 and induces transcriptional repression of its target genes. 
Given that WT1 binds to the SRPK1 promoter and regulates its transcription, it is possible 
that BASP1 might be present at the SRPK1 promoter and modulate its transcription in 
genetically engineered BASP1 expressing K562 cells. Via ChIP analysis of cross-linked 
chromatin harvested from B-K562 cells, the experiments first confirmed that BASP1 is 
associated with the SRPK1 promoter (fig.5.1)  
Furthermore, overexpression of BASP1 in PC3 and K562 cells using a plasmid construct 
increased the levels of BASP1 in the cells (fig.5.2) and reduced the transcriptional 
activity of SRPK1 (fig.5.3). This raises the possibility that BASP1 might be present at 
the SRPK1 promoter by itself or in the form of a complex with WT1. 
Western blot for endogenous BASP1, WT1 and SRPK1 in K562, B-K562, DU145 and 
PC3 cells suggests that when BASP1 is overexpressed, both WT1 and SRPK1 are 
downregulated. The downregulation of SRPK1 is consistent with BASP1 turning WT1 
into a transcriptional repressor; the change in WT1 levels could be a result of BASP1 
affecting an autoregulatory loop since WT1 is known to be able to regulate its own 
transcription (fig.5.4).  
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We also examined the effect of SRPK1 repression through BASP1 on the alternative 
splicing of VEGF. In podocytes, in which WT1 represses SRPK1 in the presence of 
BASP1, anti-angiogenic VEGF165b is expressed. BASP1 overexpression in PC3 
resulted in a similar increase in levels of the anti-angiogenic isoform VEGF165b 
(fig.5.5). Furthermore, the overexpression of BASP1 also resulted in a reduction in 
cellular proliferation and viability of K562 and PC3 cells (fig.5.6). The modest changes 
are consistent with the fact that in transient transfections only a proportion of cells will 
have taken up the BASP1-expressing plasmid. Finally, in MG63 cells, which is not a 
WT1 expressing cell line, BASP1 overexpression did not affect SRPK1 promoter activity 
(fig.5.7).   
Taken together, the results presented in this chapter indicate that BASP1 is able to 
modulate the activity of WT1 on the transcriptional regulation of SRPK1. Results also 
confirm that BASP1 has the characteristics of a tumour suppressor. The latter could in 
part be mediated by the interaction of BASP1 with WT1, making it repress oncogenic 
splice factor kinases such as SRPK1. 
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6 Chapter Six: Effect of the ERG transcription factor 
on SRPK1 transcription.  
6.1 Background 
SR proteins are essential for the regulation of alternative splicing of pre-mRNA. They 
play critical roles in the initiation of spliceosome assembly on pre-mRNA substrates. 
Each SR protein is characterised by substrate specificity towards specific pre-mRNAs. 
Hypo and hyperphosphorylation of SR proteins inhibit splicing; therefore, the 
phosphorylation of SR protein must be strictly regulated at the cellular level. The 
mechanisms through which SR protein phosphorylation is regulated are not yet fully 
explored. However, SRPK1 has been shown to phosphorylate these SR proteins utilizing 
their serine-arginine-rich domains as a substrate. SRPK1 and its best-studied substrate, 
SRSF1 are part of an essential pathway responsible for the regulation of the alternative 
splicing of vascular endothelial growth factor (VEGF) pro/antiangiogenic isoforms in 
renal epithelial cells (podocytes) and in colon carcinoma cells (Amin et al., 2011 and 
Oltean et al., 2012). 
WT1 regulates the expression of SRPK1 in different contexts, repressing it in podocytes 
(Amin et al., 2011) yet activating it in vascular endothelial cells (Wagner et al., 2019). 
Results described in previous chapters show that WT1 activates SRPK1 transcription in 
K562 and PC3 cells; this activation is however prevented by the co-repressor BASP1. 
This finding has clear significance given the involvement of WT1 in many cancers. 
However, it is likely that other transcription factors contribute to SRPK1 regulation. 
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The ETS-related gene (ERG) has been described by several studies to regulate several 
cancer-associated target genes. ERG also plays a key role in regulating the anti-
inflammatory response (Yuan et al., 2009). They have shown that, through direct binding, 
ERG suppress the activity of IL-8 promoter. Birdsey et al., 2012 demonstrated that ERG 
also downregulates the expression of HDAC6 by interacting directly with its promoter in 
the HUVEC cell line. ERG is involved in the development of the vascular system, and in 
bone and blood development (Adamo and Ladomery, 2015). Therefore it was of interest 
to investigate whether or not ERG regulates SRPK1 transcription.   
6.2 Aims and objectives 
1. To investigate the transcriptional regulation of the splice factor kinase gene 
SRPK1 by ERG.  
2. To evaluate the impact of ERG knockdown or overexpression on the following:   
- Transcription and protein levels of SRPK1 in K562, PC3 and 
MG63 cell lines. 
- The alternative splicing of apoptotic factors BCL2L1 and   
caspase 9 
-  On cellular migration, invasion, viability, and proliferation. 
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6.3 Results 
6.3.1 ERG binds the SRPK1 promoter 
 
The ERG oncogene encodes an ETS family transcription factor. ERG can bind a specific 
ETS site, with a core GGAA target sequence. Yuan et al., 2009 described how ERG 
associates with the IL-8 promoter and downregulates its transcription in the HUVEC cell 
line. Furthermore, ERG transcriptionally represses the tumour suppressor PTEN (Adamo 
et al., 2017). Chromatin Immunoprecipitation (ChIP) was performed on sheared cross-
linked chromatin collected from the ERG-positive MG63 osteosarcoma cell line (figure 
6.1). Primers specific to the SRPK1 promoter used in previous chapters were used and 
PCR was performed to detect the genomic regions being pulled down by the antibodies. 
Figure 6.2. Suggests that ERG is binding to the SRPK1 promoter. A rabbit monoclonal 
antibody against ERG was used; together with an anti- RNA polymerase II antibody as a 
positive control. Normal Mouse IgG served as a negative control. Input DNA was used 
as an additional positive control for subsequent PCRs. For additional confirmation, the 
amplicon was extracted from the gel and sent for sequencing (see Appendix).  
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Figure 6. 1: Sonicated DNA smear for MG63 cells in preparation for Chromatin 
Immunoprecipitation (ChIP) assay. 
Chromatin fragments resolved by agarose gel following sonication with varying sonication times, the cells 
were lysed and DNA sheared to about 1000bp using a sonicator. 6X of 50% power output for 15seconds 
followed by incubation on ice for 60seconds. The sizes of the generated DNA smears are between 200-
1000bp which is optimal for the ChIP assay. 
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Figure 6. 2: ERG binds the SRPK1 promoter  
Chromatin immunoprecipitation (ChIP, n = 3) was performed using a rabbit monoclonal antibody against 
ERG or anti- polymerase II antibody as a positive control. Normal Mouse IgG served as a negative control. 
Input 5% is the diluted sonicated chromatin which was used as an additional positive control for subsequent 
PCRs on the SRPK1 promoter and the respective sequence. A. PCR assay for ChIP product for MG63 cells 
using primers to detect the region around the SRPK1 transcriptional start site (TSS) and GAPDH promoters. 
Representative Agarose gel photographs of semi-quantitative ChIP PCR experiments for the SRPK1 and 
GAPDH promoters. Data are expressed as means ± S.E.M. *** indicates p < 0.0005 which is statically 
significance using one way ANOVA test. 
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6.3.2 ERG suppresses SRPK1 transcription  
 
The previous experiment suggests that ERG binds to the SRPK1 promoter. The next 
question is to determine whether or not ERG might contribute to SRPK1 transcriptional 
regulation in cancer cell lines. As a model system, the leukemic cell line K562 prostate 
cancer cell lines PC3 and osteosarcoma cell line MG63 were used for this purpose. Those 
K562 and PC3 cells are known to express SRPK1 but not ERG. MG63, on the other hand, 
is known to express both ERG and SRPK1. Cells were transfected with the wild-type 
SRPK1: Luciferase construct alone or cotransfected with a plasmid that expresses full 
length ERG. The results show that the SRPK1 wild type promoter remained active when 
transfected alone but when ERG is overexpressed, the ratio of Luciferase to Renilla was 
significantly reduced in K562 (**p<0.0049), PC3 (***p<0.0005) and MG63 
(**p<0.0021) cells (Figures 6.3). There was a trend in all of the three transfection repeats 
in all of the cell lines in which ERG overexpression appears to repress SRPK1 promoter 
activity. RLU luminescence values are ± SE of experiments performed in triplicate. 
Therefore, findings support the hypothesis that ERG is binding to the SRPK1 promoter 
and contributes to regulating its transcription specifically repressing it. 
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Figure 6. 3: DLR assay of SRPK1 promoter activity in MG63 (A), PC3 (B) and K562 (C) cells. 
Measurement of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. An SRPK1: 
Luciferase construct was transfected alone or cotransfected with a plasmid that expresses full length ERG. 
Plasmids were transfected into the cell lines with a Renilla expressing vector or empty vector as transfection 
control. Data are expressed as relative luciferase units (RLU). Data presented as mean ± S.E. for n=3. 
**p<0.0021 or ***p<0.0005 or **p<0.0049 for MG63, PC3 and K562 respectively which is statistically 
significant using one way ANOVA test. Figures show a reduction of promoter’s activity in cells when 
cotransfected with full length ERG and high activity when only transfected with wild type promoter.     
C 
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ERG, like other oncogenes and major transcriptional regulators, express several splice 
isoforms. In the current study, the focus was on studying the effect of (-/+7b) isoforms 
and the full length ERG on the regulation of SRPK1. These two ERG variants differ by 
the presence or the absence of a short cassette exon 7b that adds, in the frame, 24 amino-
acids to the transcriptional activation domain. Exon 7b has been shown to be included at 
a higher rate in advanced prostate cancer (Hagen et al, 2014).  
At first, to test which isoform suppresses SRPK1 activity the most, different ERG 
isoforms were cotransfected with the SRPK1 wild type promoter into the cells and DLR 
was carried out. The results suggest that all ERG isoforms equally suppressed SRPK1 
promoter activity. The statistical analysis in figure (6.4 A&B) shows.  (+7b *p<0.0254 
in K562 cells or ***= 0.0005 in PC3 cells) (-7b *p<0.0230 in K562 cells or ***= 0.0004 
in PC3 cells) (Full length ERG *p<0.0403 in K562 cells ****<0.0001 in PC3 cells)      
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Figure 6.4 A&B: Transcriptional repression of SRPK1 promoter by different ERG isoforms in 
K562 and PC3 cells.  
Measurement of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. WT SRPK1 
promoter transfected alone or with +/- 7b and full length ERG isoforms expressing plasmids into K562 
A B 
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cells for 48 hours (A). Data are expressed as (RLU) and presented as mean ± S.E. for n=3. (B) Shows the 
same transfections into PC3 cells. Data are expressed as (RLU) and presented as mean ± S.E. for n=3. P 
values were obtained using one way ANOVA test. 
 
The next step was to test the effect of the overexpression of full length ERG isoform, also 
+exon 7b, expressed from a different plasmid vector, on SRPK1 transcription. For that 
purpose, full length ERG isoform was transiently co-transfected with WT SRPK1 
promoter at increasing concentrations into MG63 cells line. (Figure 6.4.C) Shows that 
the full length ERG isoform significantly reduced SRPK1 promoter in a dose-dependent 
manner.  
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Figure 6.4 C: Transcriptional repression of SRPK1 promoter by full length ERG (+exon 7b) 
in MG63 cells. 
Wild-type SRPK1 promoter transfected alone or with an increasing concentration (0-1.5 µg) of a plasmid 
that expresses full length ERG (+exon 7b) in MG63. Data are expressed as relative luciferase units (RLU). 
Data presented as mean ± S.E. for n=3. The figure shows a reduction of the promoter’s activity in cells 
when cotransfected with full length ERG and high activity when only transfected with wild type.  
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6.3.3 Effect of ERG overexpression on SRPK1 protein levels 
 
Data obtained suggest that ERG interacts with the SRPK1 promoter and represses its 
transcription. Adamo et al., 2017 described how ERG represses the transcription of 
PTEN in DU145 cells; so it is capable of working as a transcriptional repressor. The 
effect of the transcriptional repression of SRPK1 by ERG on SRPK1 protein levels was 
investigated. For this objective, at first, K562 cells (SRPK1 positive and ERG negative) 
were transiently transfected with -7b and +7b full-length ERG expressing plasmids 
separately. A western blot was performed on protein lysates prepared from the cell lines 
following the overexpression. (Figure.6.5.A &B) shows a significant decrease in SRPK1 
bands following ERG isoform overexpression in K562 cells (**p=0.0057 for full length 
and ***p=0.0003 -7b). 
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Figure 6.5 A&B: Repression of SRPK1 protein levels by -7b and full-length ERG isoforms in 
K562 cells.  
Western blot of protein lysates from K562 cells. Cells were transiently transfected with - 7b or full length 
ERG (+7b) isoforms expressing plasmids for 48 hours. Membranes were blotted with anti-SRPK1 or anti-
beta actin antibodies as a loading control. Graphs represent relative expression determined by densitometric 
measurement of the bands and are expressed relative to actin. The bar-graph shown is the average of three 
independent experiments. A significant reduction in SRPK1 levels as a result of overexpressing ERG. P 
values were obtained using unpaired t-test.  
 
The next step was to transfect PC3 cells (SRPK1 positive and ERG negative) with -7b 
and +7b full-length ERG. A western blot was performed on protein lysates prepared from 
the cell line following the overexpression. (Figure.6.5.C&D) shows a significant decrease 
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in SRPK1 protein levels with ERG isoform overexpression in transfected PC3 cells 
(*p=0.0440 for +7b full-length) and (***p=0.006 for -7b).   
 
 
 
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 e
x
p
r
e
ss
io
n
 S
R
P
K
1
/a
c
ti
n
 control
full lengh ERG
*
 
 
 
 
 
 
D 
C 
Chapter Six: Effect of the ERG transcription factor on SRPK1 transcription  
142 
 
0.0
0.5
1.0
1.5
R
e
la
ti
v
e
 e
x
p
r
e
ss
io
n
 S
R
P
K
1
/a
c
ti
n
untransfected control
-7b ERG
***
 
 
Figure 6.5 C& D: Repression of SRPK1 protein levels by +/- 7b ERG isoforms in PC3 cells. 
Western blot of protein lysates from PC3 cells. Cells were transiently transfected with - 7b or full length 
ERG isoforms expressing plasmids for 48 hours. Membranes were blotted with anti-SRPK1 or anti-beta 
actin antibodies as a loading control. Graphs represent relative expression determined by densitometric 
measurement of the bands and are expressed relative to actin. Bar-graph shown is the average of three 
independent experiments. A significant reduction in SRPK1 levels was observed as a result of 
overexpressing ERG. P values were obtained using unpaired t-test. 
 
6.3.4 Effect of ERG -siRNA knockdown on SRPK1 transcription and protein 
levels  
 
The data obtained so far indicate that ERG binds to SRPK1 promoter and repressed its 
expression. To further investigate SRPK1 regulation by ERG, siRNA-mediated knock-
down of ERG was performed in the MG63 cell line. The same ERG and GL2 control 
siRNA sequences (table 2.1) previously described in (Urbinati et al., 2016) were used in 
this study. To verify the transfection efficacy, ERG siRNA was tagged with CY5 
fluorescent labels (Figure.6.6.A). At first, to verify that the knockdown has occurred, 
siRNA were transfected alone into the cells and western blot was performed on protein 
lysate was prepared from the MG63 cells following the siRNA knockdown (Figure.6.6.B 
Chapter Six: Effect of the ERG transcription factor on SRPK1 transcription  
143 
 
&C). Significant reduction in ERG protein was observed at higher concentration of the 
siRNA (100nM) which suggested that ERG knockdown was achieved.  
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 Figure 6.6: ERG knockdown in MG63 cells. 
(A) Representative fluorescence microscopy images of CY5 tagged-ERG targeting siRNA transfected into 
MG63 cells (bright and fluorescent fields). MG63 cells were transfected with increasing concentration of 
ERG siRNA (10nM, 50nM and 100nM) (B) or 100nM siRNA alone (C) or control GL2 siRNA for 48 
hours. B&C. Western blot of MG63 protein lysate after ERG siRNA knockdown. Membranes were blotted 
with anti-ERG or anti-beta actin antibodies as a loading control. Graphs represent relative expression 
determined by densitometric measurement of the bands and are expressed relative to actin. Bar-graph 
shown is the average of three independent experiments. **= p<0.0129 and ****= p<0.0001 significant 
change compared to control using 1 way ANOVA test and unpaired t test respectively.  
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The next step was to evaluate the effect of ERG knockdown on SRPK1 transcription via 
co-transfecting the highest concentration of siRNA ERG with the WT SRPK1 promoter 
reporter. (Figure.6.7.) shows that the activity of the wild type promoter significantly 
increased in MG63 cells (**** p<0.0001). 
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Figure 6.7: DLR assay of SRPK1 promoter activity following siRNA mediated ERG 
knockdown in MG63 cells.  
Measurement of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. WT SRPK1 
promoter was co-transfected with 100nM ERG siRNA into the cells. Data are expressed as relative 
luciferase units (RLU). Data presented as mean ± S.E. for n=3. **** p<0.0001, which is statistically 
significant using unpaired t test. The figure shows a reduction of the promoter’s activity in cells where 
ERG was knocked down. 
 
6.3.5 The effect of ERG Exon 4 skipping through splice switching   
oligonucleotides on SRPK1 transcription and protein levels 
 
Splice-switching oligonucleotides (SSOs) are a new emerging molecular tool that has 
been recently used to change the way that exon segments of pre-mRNA are spliced 
(joined) together. They can be used to influence the rate of inclusion of a given exon. 
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So far, the experimental outcomes in this study suggest that ERG is an SRPK1 
transcriptional repressor that binds to the SRPK1 promoter and downregulates its 
expression. Increased ERG expression reduces SRPK1 levels, and conversely ERG 
knockdown increases SRPK1 levels.  
To verify this conclusion using a different approach, two different splice-switching 
oligonucleotides that manipulate ERG pre-mRNA was used. The vivo-morpholino -7b-
3'SS induces skipping of cassette exon 7b within the ERG pre-mRNA (Jumbe et al., 2019) 
while vivo-morpholino 4-3'SS results in skipping of exon 4 which leads to diminishing 
ERG protein levels due to a premature stop codon resulting. Vivo-morpholinos are 
morpholinos with an oligodendromer that facilitates transfection. Sequences and 
concentrations are shown in table 2.2.  
Initially, the E4 3′ –morpholinos were added to MG63 cells followed by an RNA 
extraction to perform a PCR to verify the efficiency of the SSOs. E4 3′ SSOs induced 
ERG exon 4 skipping at the 3′ splice sites (Figure 6.8.A). A PCR was performed using 
the primers listed in (table 2.6). The rate of ERG exon 4 inclusion was measured by 
quantifying the PCR bands and calculating the splicing ratio (percentage spliced in, PSI-
Ψ) (Figure 6.8.B&C). A control SSO (scrambled exon 7b SSO sequence) was included 
in addition to untreated cells as controls. The most efficient exon skipping was observed 
with the E4 3′ SSO at 3μM (0.31 PSI-Ψ), where Ψ is the proportion of exon inclusion, 
compared to the control SSO that did not cause any significant changes to ERG exon 4 
skipping 0.84 Ψ and 0.81 Ψ for untreated cells.    
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Figure 6.8: ERG mRNA levels in E4 3′ SSO transfected MG63 cells. 
MG63 cells treated with 3μM of E4 3′ SSO for 48hrs followed by RNA extraction and cDNA synthesis. 
PCR was performed using ERG specific primers. (A) Design of SSOs targeting exon 4 of ERG (B) PCR 
gel at 48hrs showing band intensity and size and corresponding loading control, β-actin. (C) graph of 
densitometry reading showing the percent spliced in (PSI, ψ) ratio at 48hrs data presented as mean ± S.E. 
for n=3. **** p<0.0001 using 1 way ANOVA test. The result shows E4 3′ SSO resulted in near complete 
exon 4 skipping in MG63 cells. Three independent repeats are shown in each case. 
 
Next, the effect of ERG exon 4 skipping on SRPK1 transcription was tested. For this 
objective, The WT SRPK1 promoter was co-transfected with the 3μM E4 3′ SSO 
concentration which induced significant skipping in the previous experiment at for 48 
and 72 hrs. Following that, a DLR assay was carried out (Figure 6.9). A significant 
increase in SRPK1 promoter’s activity was observed after 72 hrs of 3μM E4 3′ SSO 
transfection (**** p<0.0001) and 48 hrs. (**p<0.0022). This indicates that the 
transcriptional activity of SRPK1 increased following ERG exon 4 skipping.            
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Figure 6.9: DLR assay of SRPK1 promoter activity in E4 3′ SSO transfected MG63 cells. 
Measurement of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. WT SRPK1 
promoter, was co-transfected with 3μM of E4 3′ SSO for 48hrs and 72hrs into the cells. Data is expressed 
as relative luciferase units (RLU). Data presented as mean ± S.E. for n=3. **p<0.0022 and **** p<0.0001, 
which is statistically significant using 1 way ANOVA test. Figure shows significant increase of the 
promoter’s activity in cells with ERG-Exon4 skipping.  
 
Given the fact that ERG regulates SRPK1 and represses its transcription, the next part of 
this experiment was to determine if the reduction of ERG by E4 SSOs changes the 
transcriptional downregulation of SRPK1 and restores its expression at a protein level. 
For that aim, MG63 cells were transfected with 3μM of E4 3′ SSO for 48hrs and 72hrs. 
Western blot was performed on protein lysates prepared from the cells following the E4 
SSOs transfection (Figure.6.10). A significant reduction in ERG expression (* = 
p<0.0201 for 48hrs and *=0.0220 for 72 hrs) correlated with a significant increase in 
SRPK1 expression (* = p<0.0214 for 48hrs and **** = p<0.0001 for 72 hrs) which 
suggest that diminishing ERG with E4 3′ SSO resulted in an increase in the SRPK1 
expression in MG63 cell line.          
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 Figure 6.10: Effect of exon 4 skipping on ERG and SRPK1 protein levels. 
MG63 cells were transfected with 3μM of E4 3′ SSO or control SSO for 48hrs and 72hrs. Cells were lysed 
and a Western blot was performed. Membranes were blotted with anti-ERG and anti SRPK1 or anti-beta 
actin antibodies as a loading control. The graph represents relative expression determined by densitometric 
measurement of the bands and is expressed relative to actin. Bar-graph shown is the average of three 
independent experiments. * = p<0.0201 and **** = p<0.0001 represent significant reduction in both ERG 
and SRPK1 levels compared to the untreated control using 2-way ANOVA test. Three independent repeats 
are shown in each case. 
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6.3.6 The effect of ERG Exon 7b skipping through splice switching 
oligonucleotides on SRPK1 transcription and protein levels 
 
Subsequent to the previous findings, the effect of cassette exon 7b Skipping on SRPK1 
transcription and expression was tested in this study. The self-transfecting E7b 3′ –
morpholinos were added to MG63 cells then followed by an RNA extraction to perform 
a PCR to verify the efficiency of the SSOs. E7b 3′ SSOs induced ERG exon 7b skipping 
b steric inhibition of the 3′ splice site (Figure 6.11.A). A PCR was performed using the 
proper primers listed in table 2.6 (ERG; Exon 7b skipping primers). The rate of ERG 
exon 7b inclusion was measured by quantifying the PCR bands and calculating the 
splicing ratio (PSI-Ψ) (Figure 6.11.B&C). A control SSO was included in addition to 
untreated cells as controls. The most efficient exon skipping was observed with the E7b 
3′ SSO at 3μM (0.63 PSI-Ψ), where Ψ is the proportion of exon inclusion, compared to 
the control SSO that did not cause any significant changes to ERG exon E7b 3′ skipping 
0.95 Ψ and 0.96 Ψ for untreated cells.    
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Figure 6.11: ERG mRNA levels in E7b 3′ SSO transfected MG63 cells.  
MG63 cells treated with 3μM of E7b 3′ SSO for 48hrs followed by RNA extraction and cDNA synthesis. 
PCR was performed using ERG specific primers. (A) Design of SSOs targeting Exon7b of ERG (B) PCR 
gel at 48hrs showing band intensity and size and corresponding loading control, β-actin. (C) graph of 
densitometry reading showing the percent spliced in (PSI, ψ) ratio at 48hrs data presented as mean ± S.E. 
for n=3. ** p=0.0016 using 1 way ANOVA test. Three independent repeats are shown in each case. 
 
Next, the effect of ERG exon 7b skipping on SRPK1 transcription was tested. For this 
objective, the WT SRPK1 promoter was co-transfected with the 3μM E7b 3′ SSO 
concentration which induced significant skipping in the previous experiment at for 72 
hrs. Following that, a DLR assay was carried out (Figure 6.12). No significant change in 
SRPK1 promoter activity was observed after 72 hrs of 3μM E7b 3′ SSO. This indicates 
that the transcriptional activity of SRPK1 wasn’t significantly affected by ERG exon 7b 
Skipping.         
C 
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Figure 6.12: DLR assay of SRPK1 promoter activity in E7b 3′ SSO transfected MG63 cells. 
Measurement of SRPK1 promoter activity using a dual luciferase reporter (DLR) assay. WT SRPK1 
promoter was co-transfected with 3μM of E7b 3′ SSO for 72hrs into the cells. Data are expressed as relative 
luciferase units (RLU). Data presented as mean ± S.E. for n=3. No significant change was observed on the 
promoter activity with Exon7b skipping using 1 way ANOVA test. Three independent repeats are shown 
in each case.     
 
The next part of this experiment was to determine whether exon 7b skipping changes 
SRPK1 protein levels. For that purpose, MG63 cells were transfected with 3μM of E7b 
3′ SSO for 72hrs. A western blot was performed on protein lysates prepared from the 
cells following the E7b 3′ transfection (Figure.6.13) Consistent with the DLR data, no 
significant change was observed in ERG and SRPK1 expression, which suggests that 
exon 7b skipping in ERG did not change SRPK1 expression in the MG63 cell line.  
However there was, perhaps, a suggestion of an upward trend in SRPK1 expression.      
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Figure 6.13: Effect of exon7b skipping on ERG and SRPK1 protein levels.  
MG63 cells were transfected with 3μM of E7b 3′ SSO or control SSO for 72hrs. Cells were lysed and 
Western blot was performed. Membranes were blotted with anti-ERG and anti SRPK1 or beta-actin 
antibodies as a loading control. The graph represents relative expression determined by densitometric 
measurement of the bands and is expressed relative to actin. Bar-graph shown is the average of 3 
independent experiments. No significant change was observed in ERG and SRPK1 levels using 1 way 
ANOVA test. Three independent repeats are shown in each case. 
 
 
6.3.7 Effect of ERG overexpression on the alternative splicing of apoptotic factors 
BCL2L1 and caspase 9 
 
Several studies have described how downregulating endogenous ERG in cell lines that 
express it induces apoptosis. Birdsey et al., 2008 for instance, has described that ERG 
inhibition by siRNA in HUVEC cells (ERG positive) resulted in the increased activation 
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of caspase 3 and 7. In a previous chapter of this study, SRPK1 inhibition leads to a 
significant increase in apoptosis. The data in the current part of the study suggest that 
ERG transcriptionally represses SRPK1. Thus, it was of interest to evaluate the effect of 
ERG overexpression in (ERG negative cells) on apoptotic markers e.g. caspase and 
BCL2L1. For that purpose, Caspases 3 and 7 staining was used to determine if 
overexpressing -7b and full-length ERG +7b is going to result in a change in the apoptotic 
activity in K562 and PC3 cell lines. (Figure 6.14) Shows that the activity of Caspase 3/7 
detected by green detection reagent was significantly higher (****P<0.0001) in both cell 
lines where ERG has been overexpressed compared to the untransfected cells. This 
indicates that ERG overexpression induces apoptosis in K562 and PC3 cell lines (figure 
6.14.A.B&C). 
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Figure 6.14: Caspase 3 and 7 staining in K562 and PC3 cells subjected to ERG overexpression. 
K562 and PC3 cells were transfected with -7b and +7b full-length ERG isoforms expressing plasmids for 
48 hours followed by Detection of active caspases 3 and 7 was performed using Caspase 3/7 Green 
Detection Reagent. (A)  Representative images of stained K562 taken under a fluorescent microscope. The 
graph represents the number of active capase3/7 positive cells in K562 (B) and PC3 (C) cell lines which 
shows significance in the ratio of caspase activity in the cells after ERG overexpression, ****P<0.0001 
using 1 way ANOVA test. n=9. 
 
To further investigate the possibility of -7b and full-length ERG overexpression would 
result in any change in the splicing of other caspase family members such as caspase-9 
and another apoptotic factor such as BCL2L1, mRNA was extracted from the K562 and 
PC3 cells following -7b and +7b full-length ERG overexpression. Then a PCR was 
performed using the proper primers listed in table 2.6. (Caspase-9 NM_001229 and BCL2 
like 1 (BCL2L1)xl NM_138578). PCR bands show that the splicing ratio (PSI-Ψ) of 
caspase-9a/caspase-9b mRNA was significantly higher in the ERG overexpression 
group compared to the control group while no significant change was observed in the 
B C 
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splicing ratio Bcl-xl/Bcl-xs in both cell lines (figure 6.15 & 6.17).   In K562, (figure 6.15), 
the expression ratio (PSI-Ψ) of caspase-9a/9b isoform in the control was (0.57 PSI-Ψ), -
7b isoform (0.82 PSI-Ψ) and +7b full-length ERG isoform (0.87 PSI-Ψ) (**P= 0.015 and 
***= 0.0003 one way ANOVA). The expression ratio caspase-9a/9b isoform in the 
control was (0.44 PSI-Ψ) while in -7b isoform (0.80 PSI-Ψ) and full-length ERG isoform 
(0.83 PSI-Ψ) (**P= 0.0050 and **= 0.0032 one way ANOVA unpaired t-test) in PC3 
cells (figure 6.16). 
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Figure 6.15: Caspase-9 mRNA levels in K562 cells where different ERG isoforms have been 
overexpressed.  
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K562 cells transfected with plasmids that express full-length ERG or ERG-7b isoforms for 48 hrs followed 
by RNA extraction and cDNA synthesis. PCR was performed using Caspase-9 specific primers. (A) 
Representation of Caspase-9 PCR amplicon sizes (B) and (C) showing band intensity and size and 
corresponding loading control, β-actin. Densitometry showing caspase-9a/9b PSI-Ψ values for 48hrs. The 
data suggests a significant change in splice ratio (PSI-Ψ) of caspase-9 following ERG overexpression.  P 
values were obtained using one way ANOVA test. n=3.  
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 Figure 6.16: BCL2L1 mRNA levels in K562 cells where different ERG isoforms have been 
overexpressed.  
K562 cells transfected with plasmids that express full-length ERG or ERG -7b isoforms for 48 hrs followed 
by RNA extraction and cDNA synthesis. PCR was performed using Bcl specific primers. A. Representation 
A 
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of Bcl PCR amplicon sizes. (B) PCR gel at 48hrs showing band intensity and size and corresponding 
loading control, β-actin. C. Densitometry showing Bcl-xl/s PSI-Ψ values for 48hrs. The result shows no 
significant change in the splice ratio of Bcl. P values were obtained using one way ANOVA test. n=3. 
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Figure 6.17: Caspase-9 mRNA levels in PC3 cells where different ERG isoforms have been 
overexpressed.  
PC3 cells transfected with plasmids that express full-length ERG or ERG-7b isoforms for 48 hrs followed 
by RNA extraction and cDNA synthesis. PCR was performed using Caspase-9 specific primers. A. and B 
showing band intensity and size and corresponding loading control, β-actin. Densitometry showing 
caspase-9a/9b PSI-Ψ values for 48hrs. The Result shows significance in splice ratio (PSI-Ψ) of caspase-9 
following ERG overexpression. P values were obtained using one way ANOVA test. n=3.  
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Figure 6.18: BCL2L1 mRNA levels in PC3 cells where different ERG isoforms have been 
overexpressed.  
PC3 cells transfected with plasmids that express full-length ERG or ERG -7b isoforms for 48 hrs followed 
by RNA extraction and cDNA synthesis. PCR was performed using BclX-specific primers. (A) PCR gel at 
48hrs showing band intensity and size and corresponding loading control, β-actin. (B)  Densitometry 
showing Bcl-xl/s PSI-Ψ values for 48hrs. The result shows no significance (PSI-Ψ) in splice ratio of Bcl.  
n=3. No significant change was observed using one way ANOVA test. 
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6.3.8 The effect of ERG exon 4 skipping through splice switching oligonucleotides 
on the alternative splicing of apoptotic factors BCL2L1 and caspase 9 
 
Skipping of exon 7b of ERG mRNA is shown in Jumbe et al., 2019 to induce apoptosis 
through increasing the activity of Caspase 3/7 activity in ERG positive VCaP prostate 
cancer cells. ERG inhibition by other means induced a similar effect in HUVEC cells 
(Birdsey et al., 2008). In the previous section, exon 4 skipping in ERG mRNA resulted 
in the reduction of ERG protein and therefore, upregulation of SRPK1. Here we examine 
the effect of skipping of exon 4 on apoptotic markers e.g. caspase and BCL2L1 in MG63 
cells (ERG positive cells). For that purpose, caspases 3 and 7 staining was used to 
determine if exon 4 skipping is going to result in a change in the apoptotic activity in 
MG63 cell line. (Figure 6.19) Shows that the activity of Caspase 3/7 was significantly 
higher (****P<0.0001) in MG63 cell line where ERG expression has been diminished 
by exon 4 skipping compared to the untransfected cells. This indicates that ERG 
inhibition induces apoptosis in MG63 cell line. 
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Figure 6.19: Caspase 3 and 7 staining in MG63 cells where ERG has been knocked down by 
E4 3′ SSOs.  
Cells were transfected with 5μM E4 3′ SSOs for 72hrs followed by detection of active caspases 3 and 7 
was performed using the caspase 3/7 Green Detection Reagent. (A) Representative Images of the stained 
MG63 cells taken under a fluorescent microscope. (B) The graph represents the percentage of caspase 3/7 
positive cells in MG63 which show significance in the ratio of caspase activity in the cells after exon 4 
skipping in ERG, ****P<0.0001 using one way ANOVA test. n=9 
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To further investigate the possibility of exon 4 skipping would result in any change in the 
splicing of other caspase family members such as caspase-9 and another apoptotic factor 
such as BCL2L , mRNA was extracted from the MG63 cells following exon 4 skipping 
SSOs transfection at 1 or 5μM E4 3′ SSOs. Then a PCR was performed using the primers 
listed in table 2.6. PCR bands show that the splicing ratio (PSI-Ψ) of caspase-9a/caspase-
9b mRNA was significantly higher in the exon 4 skipping group at 5μM compared to the 
control group and 1μM while no significant change was observed in the splicing ratio 
Bcl-xl/Bcl-xs in MG63 cells (figure 6.20). (Figure 6.20) shows the expression ratio (PSI-
Ψ) of caspase-9a/9b isoform in the control was (0.55 PSI-Ψ), control SSOs (0.57 PSI-
Ψ), 1μM E4 3′ SSOs (0.60 PSI-Ψ) and 5μM E4 3′ SSOs (0.74 PSI-Ψ) (*P= 0.0014 one 
way ANOVA).  
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Figure 6.20: Caspase-9 mRNA levels in SSOs transfected MG63 cells.  
MG63 cells transfected with (1 and 5μM) of E4 3′ SSOs or ctrl SSOs for 48hrs. Untransfected cells were 
used as control. RNA extraction and cDNA synthesis were performed following transfections. PCR was 
performed using caspase-9 specific primers. (A) Showing band intensity and size and corresponding to the 
loading control, β-actin. (B). Densitometry showing caspase-9a/9b PSI-Ψ values for 48hrs. The result 
shows significance in splice ratio of caspase-9 when transfected with 5μM of E4 3′ SSOs. *P= 0.0014 one 
way ANOVA. n=3. 
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Figure 6.21: BCL2L1 mRNA levels in SSOs transfected MG63 cells. 
 MG63 cells transfected with (1 and 5μM) of E4 3′ SSOs or ctrl SSOs for 48hrs. Untransfected cells were 
used as control. RNA extraction and cDNA synthesis were performed following transfections. PCR was 
performed using Bcl specific primers. (A) PCR gel at 48hrs showing band intensity and size and 
corresponding loading control, β-actin. B. Densitometry showing Bcl-xl/s PSI-Ψ values for 48hrs. The 
result shows no statistically significant change in the splice ratio of Bcl.*P= 0.0014 one way ANOVA. n=3. 
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6.3.9 Effect of ERG overexpression on cell proliferation and viability 
 
The data described in this chapter suggests that ERG is repressing the transcription of 
SRPK1. ERG has been described as driving cellular proliferation In PCa cell line VCaP 
(ERG positive), cellular proliferation and viability were decreased following an ERG 
knockdown (Liu et al., 2016). In this part of the study, the effect of ERG overexpression 
on cellular proliferation and viability of K562 and PC3 cells was investigated. For this 
purpose, -7b and +7b full-length ERG isoforms expressing plasmids were used to 
overexpress ERG followed by MTT assay. A significant reduction in cellular 
proliferation and viability occurred 48 h after ERG overexpression in both cell lines. 
(Figure 6.22.A) shows the significant effect of -7b (*P= 0.0118) and full length +7b ERG 
(**P=0.0057) overexpression on cellular proliferation and viability of K562 cells (Figure 
6.22.C, ****P<0.0001 and ***P= 0.0366 for -7b and full length ERG respectively). For 
PC3 cells, (Figure 6.22.B), a significant reduction in cellular proliferation (**P=0.0025 
and = 0.0048 for -7b and+7b full length ERG respectively) and viability (Figure 6.22.D) 
(*P=0.0219 and *P= 0.061 for -7b and full length ERG respectively) was observed. 
Taken together, the results indicate that ERG overexpression in K562 and PC3 cell lines 
(ERG negative) resulted in a reduction in cellular proliferation and viability.     
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Figure 6.22: Cellular proliferation and viability in K562 and PC3 cells after overexpression of 
ERG isoforms.  
MTT assays were used to analyse the effect of -7b and full length +7b ERG overexpression for 48hrs on 
the cellular viability (C&D) and proliferation (A&B) in K562 and PC3 cells. The absorbance (optical 
density; OD) of each well was measured at 590 nm using a plate reader. Results represent the mean ± SEM 
of three experiments and are presented as a bar graph after normalizing to the respective controls. Cell 
viability = control- absorbance of treatment wells/absorbance of control well ×100%. P values were 
obtained using one way ANOVA test. 
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6.3.10 Effect of splice switching oligonucleotides and ERG knockdown on MG63 
cells proliferation and viability 
 
Skipping of exon 7b reduces cell proliferation (Jumbe et al., 2019) while other studies 
have described how downregulation of ERG resulted in the similar effect on ERG 
expressing cell lines (Liu et al., 2016 and Klezovitch et al.,2008). Therefore, the effect 
of ERG downregulation and exon 7b skipping on cellular proliferation and viability was 
investigated in the MG63 cell line. An MTT assay was performed following transfection 
with ERG siRNA, control SSOs, E4 SSOs and E7b SSOs. Figure 6.23 shows how ERG 
downregulation using siRNA and E4 SSOs as well as skipping of exon 7b resulted in a 
reduction in cellular proliferation and viability of the MG63 cells compared to the control 
SSOs and the untreated groups. Figure 6.23. A Shows a significant reduction in MG63 
proliferation (*p= 0.0153, ***p=0.0005 and **p=0.0056) for siRNA ERG, 7b and E4 
SSOs respectively. Figure 6.23. B shows a significant reduction in MG63 viability 
(*p=0.0153,*p= 0.0420 and **p= 0.0086) for siRNA ERG, 7b and E4 SSOs respectively. 
These findings suggested that overall ERG downregulation, as well as the skipping of 
exon 7b, affected proliferation and cell viability in MG63 cells.                  
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Figure 6.23: Cellular proliferation and viability in MG63 cells transfected with siRNA ERG 
and splice switching oligonucleotides.  
MTT assays were used to analyse the effect of 7b 3′ or E4 3′ or control SSOs or 100nM ERG siRNA 
transfections for 48hrs on the cellular proliferation (A) and viability (B) in MG63 cells. The absorbance of 
each well was measured at 590 nm using a plate reader. Results represent the mean ± SEM of three 
experiments and are presented as a bar graph after normalizing to the respective controls. Cell viability = 
control- absorbance of treatment wells/absorbance of control well ×100%. P values were obtained using 
one way ANOVA test.  
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6.3.11 Effect of ERG inhibition on cell migration and invasion 
 
ERG, which is a major oncogene, plays an important role in cellular migration and 
invasion. The migration and invasion of VCaP cell lines were remarkably reduced 
following siRNA knockdown of ERG (Liu et al., 2016). In this study, the effect of ERG 
inhibition on MG63 cellular migration and invasion was measured. For that purpose, 
transwell migration and invasion assay were carried out following transfection with 
siRNA against ERG or E4 SSOs. (Figure 6.24) shows a significant difference in the 
number of migrating and invasive (Figure 6.25) MG63 cells following the 
downregulation of ERG compared to un-transfected cells groups (**** p < 0.0001). The 
outcome of this experiment demonstrates how ERG knockdown causes a significant 
decrease in MG63 migration and invasive capacity. 
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Figure 6.24: Transwell migration assay of MG63 cells.  
MG63 cells transfected with 3μM E4 3′ SSO or with 100nM ERG siRNA for 48hrs.  A. Representative 
images of MG63 cell transwell migration. After cell migration and staining with crystal violet, pictures of 
B 
A 
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the migrated cells (orange stained) were taken using a microscope with a 10x objective. (B) Quantification 
of cells migrating toward the FBS sublimated medium (Average of 5 picture fields at 100x total 
magnification). ****P=0.0001 using one way ANOVA test. Three independent repeats are shown in each 
case.    
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Figure 6.25: Transwell cell invasion assay of MG63 cells. 
MG63 cells transfected with 3μM E4 3′ SSO or with 100nM ERG siRNA for 48hrs. A. Representative 
Pictures of MG63 cell transwell invasion. The transwell membrane was coated with Matrigel and then the 
cell- Serum-free medium was added on top of the Matrigel. After cell invasion and staining with crystal 
violet, pictures of the migrated cells (orange stained) were taken using a microscope with a 10x objective. 
(B) Quantification of invasive cells moving toward the FBS sublimated medium (Average of 5 picture 
fields at 100x total magnification). ****P=0.0001 using one way ANOVA test. Three independent repeats 
are shown in each case.  
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6.3.12 Cancer Cell Line Encyclopaedia comparison 
 
All the findings in this study suggest that WT1, BASP1 and ERG are involved to some 
degree in regulating SRPK1. WT1 activates SRPK1 in the absence of BASP1. ERG, on 
the other hand, was shown to repress SRPK1. That raised the question about the levels 
of gene expression of SRPK1 related to the expression of WT1, BASP1 and ERG. Through 
RNA sequencing database available in in the expression atlas website 
(https://www.ebi.ac.uk/gxa/experiments/E-MTAB-2770/Results) (Expression, 2009), a 
simple comparison was made to show the expression levels of these genes in K562, PC3 
and MG63 cell lines. Transcripts per million (TPM) is an RNA-seq metric unit that 
should be read as "for every 1,000,000 RNA molecules in the RNA-seq sample, x came 
from this gene/transcript." which reflect the levels of RNA molecules (Arrayserver.com, 
2016). Results show that in K562, BASP1 is totally absent whereas WT1 is higher than it 
is levels in PC3 cells where BASP1 is partially expressed. SRPK1 is the highest in K562 
compared to MG63 and PC3 cell lines and this could be due to the absence of ERG. In 
PC3 cells, a low level of BASP1 is detected while WT1 is very low and SRPK1 present at 
low levels. ERG is expressed in the MG63 cell line where the expression of BASP1 is the 
highest compared to K562 and PC3 cells, WT1 was not detectable in MG63 cells while 
SRPK1 is moderately expressed. Figure (6.26).       
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Figure 6.26: Comparison of RNA-seq 
(A). graph of the Transcripts per million (TPM) values of RNA-seq of SRPK1, WT1, BASP1 obtained from 
encyclopaedia report. (B) Cancer Cell Line Encyclopaedia report. Comparison between SRPK1, WT1, 
BASP1 and ERG expression in K562, PC3 and MG63.  
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6.4 Summary    
ERG expression is not prominent in K562 and PC3 cells; therefore, MG63 cells were the 
cell line of choice since they express ERG. ERG is a well-established transcription factor, 
and here we show that it binds to the SRPK1 promoter and regulates SRPK1 transcription. 
ChIP analysis confirmed that ERG associates with the SRPK1 promoter (fig.6.2). 
Through overexpressing the full-length ERG using a plasmid construct, ERG was found 
to repress the transcription of SRPK1in K562, PC3 and MG63 cell lines (fig.6.3).  
Moreover, full-length ERG, including both isoforms (+/- exon 7b), were shown to reduce 
the transcription of SRPK1 as measured by the luciferase reporter, and also its expression 
at a protein level. A remarkable reduction in the activity of SRPK1 promoter following 
the overexpression of (+/- 7b) ERG isoforms was observed in K562 and PC3 (fig.6.4) 
cells. Furthermore, western blots showed a significant reduction in SRPK1 following 
ERG overexpression in both cell lines (fig.6.5).   
To further investigate SRPK1 regulation by ERG, siRNA-mediated ERG knockdown 
combined with DLR assay was performed. The siRNA knockdown of ERG resulted not 
only in a reduction of ERG expression at a protein level (fig.6.6) and restored SRPK1 
promoter activity (fig.6.7). 
For the purpose of learning more about the effect of ERG on SRPK1 expression, SSOs 
that alter the splicing of ERG mRNA were tested. SSOs that induce exon 4 skipping in 
the ERG mRNA were shown to switch the splicing of ERG at the mRNA level (fig.6.8). 
This particular splice switch diminishes the ERG protein expression by inducing a 
premature stop codon, and therefore the E4 3′ SSO combined with a DLR showed a 
significant increase in SRPK1 promoter activity (fig.6.9). Moreover, following exon 4 
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skipping, western blot showed a reduction in ERG levels combined with a significant 
increase in SRPK1 expression (fig.6.10). Another SSO that induces cassette exon 7b 
skipping was tested.  E7b 3′ SSO caused successful skipping of exon 7b in ERG mRNA 
(fig.6.11) but had no significant effect on SRPK1 expression (other than perhaps a 
marginal increase at the protein level) (fig.6.12 &13).   
ERG is also implicated in the regulation of genes that are important for several biological 
functions of the cells. Genes that are involved in apoptosis are affected by ERG 
expression. For example, Caspase 3 and 7 activity was shown to increase following the 
overexpression of ERG isoforms in K562 and PC3 cells (fig.6.14). This was combined 
with a modest splicing switch favouring the pro-apoptotic caspase-9a isoform in both 
cell lines (fig.6.14, 15&17). Skipping of exon 4 in MG63 cells induced a similar effect 
on the activity of caspases 3 and 7(fig.6.19) and the alternative splicing of caspase-9 
(fig.6.20). 
The overexpression, inhibition and E7b skipping of ERG seemed to impact cellular 
proliferation and viability. A significant reduction in proliferation and viability of K562 
and PC3 cells was observed following ERG overexpression (fig.6.22). A similar effect 
was also observed in MG63 cells following exon 7b skipping and the inhibition of ERG 
with siRNA and E4 SSOs (fig.6.23). 
MG63 cell migration and invasion seemed also to be influenced by exon 7b skipping and 
the inhibition of ERG with siRNA and E4 SSOs. A significant reduction in the migration 
and invasion of the MG63 cells was observed following ERG inhibition and exon 7b 
skipping (fig.4.24&25). 
This thesis is focused on gaining a better understanding of the regulation of SRPK1. The 
main finding is that WT1 is activating SRPK1; it is then surely not coincidental that 
SRPK1 levels are the highest where WT1 is well expressed in K562 cells. The same is 
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noticeable in PC3 cells where there is a detectable amount of BASP1, which is a WT1 
co-suppressor, and perhaps that ties in with lower SRPK1 levels compared to K562. 
However, in most genes multiple transcription factors, and also epigenetic effects 
combine to determine the extent to which a gene is switched on, and so the picture is 
complicated. To complicate the picture, evidence presented here suggests that the 
oncogene ERG surprisingly represses SRPK1. Consistent with this observation, SRPK1 
levels are lower in MG63 where WT1 is absent and ERG is expressed (fig.6.26). If ERG 
is an oncogene, why does it repress SRPK1? The answer is likely linked to the fact that 
the oncogenic properties of any gene are relative to the context in which they operate. 
Perhaps in these cell lines, the set of co-factors that, presumably, cooperate with ERG, 
make it repress SRPK1. It is conceivable, that as is the case with WT1, in other contexts 
ERG might activate SRPK1 transcription. Further research will address these questions; 
what seems clear, is that both WT1 and ERG can contribute significantly to the 
transcriptional regulation of SRPK1. 
The findings in this study suggest that both the transcription factor WT1 and the co-
repressor BASP1 are present on the SRPK1 promoter region. WT1 activates SRPK1 
transcription however, this activation is prevented by the co-repressor BASP1 (fig.6.27 
A&B). The transcription factor ERG was also shown to bind to the SRPK1 promoter and 
represses its transcription. Yang et al., 2003 described that ERG represses the 
transcription of its target genes through interacting with HDAC. ERG may repress 
SRPK1 transcription through a similar mechanism (fig.6.27 C).  
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Figure 6.27: Transcriptional regulation of SRPK1. 
A schematic of the model of the human SRPK1 transcriptional regulation by WT1, BASP1 and ERG. (A) 
WT1 binds to its putative binding site (GGGGCGGGGG) on the SRPK1 promoter and activate SRPK1 
transcription. WT1 stimulates the transcription of its target genes via the recruitment of CBP (CREB 
binding protein), resulting in histone acetylation which relaxes the chromatin (Euchromatin) and activates 
transcription. (B) BASP1 forms a complex with WT1 and initiate the dissociation of CBP and the 
recruitment of HDAC1 (Histone Deacetylase) resulting in deacetylation of histones which condenses the 
chromatin (Heterochromatin) and subsequently represses SRPK1 transcription. PIP2 (phosphatidylinositol 
4, 5 bisphosphate) facilitates the recruitment of HDAC. (C) ERG interacts with the SRPK1 promoter and 
represses SRPK1 transcription by interacting with HDAC and the formation of heterochromatin.   
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7 Chapter seven: General Discussion and future work 
7.1 Discussion  
7.1.1 Detection of the SRPK1a splice isoform and a potential autoregulatory loop 
 
Despite its increasing profile and a growing body of literature on SRPK1, very little is 
known about how its expression is regulated. We began by looking at a potential splice 
isoform of SRPK1. The SRPK1a splice isoform has previously been described and 
detected in K562 leukaemia cells.  Research by Sanidas et al., 2010, suggests that 
SRPK1a associates with ribosomes in K562-SRPK1a cells, thereby suggesting that the 
kinase may have an active role in ribosome function and/or structure. The patterns of 
expression of SRPK1a in normal tissues has not been examined; its physiological 
significance remains unclear. Here, an attempt was made to detect the SRPK1a splice 
isoform in a range of cell lines. However, it could not be detected. It is conceivable that 
SRPK1a is expressed at very low levels, or perhaps the SRPK1a transcript adopts a loop 
structure at the RNA level, with extended double-stranded domains (E.Nikolakaki, 
unpublished observations ) resulting in poor detection by Northern and RT-PCRs. It is 
also possible that in addition to SRPK1a, SRPK1 expresses additional splice isoforms; 
but none have been reported so far in the literature (Sanidas et al., 2010). It is possible 
that SRPK1a might play several additional roles that yet to be identified once it 
extensively investigated but as we failed to detect it, we focused on canonical, full-length 
SRPK1.  
The aim of this study was to gain a better understanding of how SRPK1 is regulated at 
the transcriptional level and this will be addressed later in the discussion. Here it is worth 
mentioning that evidence was found that SRPK1 might regulate its own expression via a 
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feedback loop, much like the splice factor kinase CLK1 does (Uzor et al., 2018). 
SPHINX-mediated inhibition of SRPK1 appeared to repress the transcription and the 
protein level of SRPK1, whereas the knock-down of SRPK1 using siRNA seemed to 
reduce only protein levels rather than transcription Thus SPHINX is inhibiting the 
enzyme and somehow this results in a feedback loop changing the expression of SRPK1. 
SRPK1 is not a transcriptional regulator; it is an enzyme that phosphorylates splicing 
factors but of course could be having an indirect effect because it is changing the 
alternative splicing of other potential SRPK1 regulators. Despite the amount of research 
on SRPK1 in a variety of contexts, there has not been a previous report of this effect. The 
extent to which SRPK1, like CLK1, might influence its own regulation, will be further 
investigated in future research. 
7.1.2 Effect of SRPK1 inhibition with SPHINX on alternative splicing of VEGF-
A, BCL2L1 x and caspase-9 
 
SRPK1 plays an important role in the phosphorylation of SR proteins which are involved 
in the regulation of alternative splicing in development and disease. The ability of SRPK1 
to influence the activity of splice factors is critical in multiple cellular pathways, 
including the regulation of angiogenesis. Angiogenesis is a vital process through which 
tumours form blood vessels and attain essential nutrients. Nevertheless, tumours can be 
very heterogeneous in their metabolism hence their dependency on nutrients and oxygen 
as some of the most aggressive tumours survive and proliferate with minimal energy 
supplies (Hanahan D et al., 2011). In the context of angiogenesis, SRPK1 has been shown 
to phosphorylate the splice factor SRSF1 which then promotes the expression of the pro-
angiogenic splice isoform of VEGF-A.  
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The alternative splicing of VEGF-A was shown to be affected by inhibition of SRPK1 in 
numerous studies. For instance, Mavrou et al., 2014 has shown that by making a stable 
SRPK1 knockdown with shRNA, an increase in anti-angiogenic VEGF165b at the 
protein level was observed in PC3 cells. Through SRSF1, SRPK1 has been described in 
(Amin et al., 2011) to be the most important regulator of VEGF165/VEGF165b splicing 
ratio in glomerular podocytes. On the contrary, up-regulation of SRPK1 was associated 
with higher pro-angiogenic VEGF isoform in several tumours such as hepatocellular 
carcinoma and breast cancer. This solidifies the link between SRPK1 and 
VEGF165/VEGF165b splicing. Here with SPHINX inhibition to SRPK1 resulted in an 
increase in the VEGF165b isoform which suggests that SPHINX treatment could inhibit 
tumour growth by inhibiting angiogenesis. This encourages novel studies into the 
potential use of small molecule inhibitors of SRPK1 in PCa as anti-angiogenic treatment. 
Several studies have evaluated the effects of SRPK1 inhibition on genes associated with 
apoptosis. For instance, Wang, et al., 2017 described how knocking down SRPK1 affects 
the splicing of caspase‑3 and therefore apoptosis. To expand on these findings and 
investigate the effects of SRPK1 inhibition we used the inhibitor SPHINX and examined 
the effect of SPHINX on the alternative splicing of caspase 9 and BCL2L1. In the K562 
cell line SRPK1 inhibition resulted in a splice shift in caspase 9 and BCL2L1 toward the 
more apoptotic isoforms caspase 9 a and Bcl-xs while this inhibition has led to a weaker 
but significant change in PC3 cell line in caspase 9 splicing with no detectable change in 
BCL2L1 splicing. It was interesting to note that SPHINX did not result in the exact same 
effect in different cell lines. It is possible that the influence of SRPK1 on alternative 
splicing is cell or tissue dependent.  
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7.1.3 Effect of SRPK1 inhibition on cell proliferation  
 
Wang et al., 2017 described that knocking down SRPK1 results in a reduction in cell 
viability in K562 cells. In this study, the inhibition of SRPK1 by a chemical inhibitor 
(SPHINX) and siRNA knockdown both resulted in reduced cell viability and 
proliferation in K562 and PC3 cell lines. Sanidas et al., 2010 described the possible role 
that the SRPK1a isoform may play in the assembly process of the ribosomes associated 
with K562 differentiation; in contrast, SRPK1 favoured proliferation. Ren et al., 2010 
show that by regulating AKT and JNK pathways, SRPK1 mediates TGF-2−induced 
proliferation and apoptosis. However, the opposite effect on cellular proliferation has also 
been reported namely that CRC cell proliferation was promoted by SRPK1 
overexpression (Nan Yi et al., 2018); therefore the influence of SRPK1 on cell 
proliferation may be cell line dependent.   
Several recent studies have described how silencing SRPK1 using siRNA strongly 
reduces the migration and invasion of different cells. For instance, Chang Y et al., 2015 
determined that siRNA SRPK1 knockdown strongly reduced glioma cell migration and 
invasion by regulating the expression of MMP2 and MMP9. Wu et al., 2017 reported that 
the upregulation of SRPK1 protein in NSCLC cells and tumour tissues was associated 
with potential migration and invasion, while lower expression of SRPK1 repressed 
migration and invasion of the NSCLC cells. Limited cellular migration and invasion in 
Caco2 and HT-29 cells following SRPK1 silencing using siRNA was recently described 
(Nan Yi et al., 2018). Similarly, in this study, SRPK1 inhibition with SPHINX and 
siRNA SRPK1, consistent with the literature, reduced cell migration and invasion of PC3 
cells measured via the transwell assay.      
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7.1.4 Transcriptional regulation of SRPK1 by WT1  
 
WT1 is involved in the development of several organs, including the urogenital system 
and the gonads (Kreidberg et al., 1993). As a major transcription factor, WT1 plays 
significant roles in major biological functions. For instance, WT1 regulates early gonad 
development through the activation of an important regulator of gonadogenesis known 
as steroidogenic factor 1 (SF1). Both WT1 and LHX9 (which is another transcription 
factor), bind to and activate the SF1 promoter, leading to the expression of this key 
regulator of gonadogenesis, (Wilhelm et al., 2002). In the glomerular podocytes, 
VEGF165b expression is important to keep normal glomerular filtration rates and 
permeability by regulating fenestral formation. Amin et al., 2011 showed that WT1 binds 
to the SRPK1 promoter in Denys Drash Syndrome (DDS) podocytes and alter VEGF 
splicing through transcriptional repression of SRPK1 by binding to a classic GC-rich 
sequence close to the transcription start site. This thesis investigated whether or not this 
binding also takes place in leukaemia and prostate cell lines. Through chromatin 
immunoprecipitation, this binding was confirmed to take place in K562 and PC3 cell 
lines. The physical binding of WT1 to the promoter is critical for the regulation of SRPK1 
transcription. Hayes et al., 2007 show that SRPK1 upregulation has been associated with 
pancreatic, breast and colorectal cancer. However, the regulation of SRPK1, including 
how it is upregulated in cancer is not well understood. Salesse et al., 2011 show that the 
overexpression of the oncogenic tyrosine kinase Bcr-Abl in human hematopoietic 
progenitor cells results in increased SRPK1 mRNA and protein levels, which then 
correlates with alterations in pre-mRNA processing.  
Given that WT1 is a well-established transcription factor that binds its target genes, Amin 
et al., 2011 established that WT1 binds to the SRPK1 promoter and represses its 
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transcription in glomerular podocytes. However, it should be noted that in some tissues 
SRPK1 expression is ubiquitous, whereas the expression of WT1 is not. However, WT1 
is likely only one of several transcription factors that regulate SRPK1. Furthermore, WT1 
can both activate and repress the same target genes depending on the coexpression of 
transcriptional cofactors (Toska & Roberts, 2014). For instance, WT1 transcriptionally 
regulates VEGF-A in LnCAP cells (Graham et al., 2007); however, in cells where WT1 
is not expressed, other transcription factors such as SP1, which is ubiquitously expressed, 
can instead regulate VEGF expression (Pore et al., 2005). Therefore other factors are 
likely to regulate the expression of SRPK1. 
Since WT1’s developmental roles are now much more complex than first imagined; there 
is much scope for involvement of WT1 in SRPK1 regulation beyond glomerular 
podocytes. However, it cannot be assumed that WT1 repress SRPK1 expression in any 
cell line or tissue that express WT1, as a cofactor that is expressed in podocytes cell line 
might be absent in another cell type. It is conceivable that WT1 upregulates SRPK1 in 
some contexts, as WT1 can interact with both transcriptional activator and repressors 
(Roberts 2005). As SRPK1 levels are upregulated in pancreatic, breast and colorectal 
cancer, it is important to know what else could regulate SRPK1 expression. 
This study suggests convincingly that WT1 is involved in the regulation of SRPK1 
expression in leukaemia and prostate cancer cell lines. The SRPK1 promoter activity is 
drastically reduced in prostate cancer cells transfected with a luciferase reporter construct 
with the WT1 binding site mutated in the SRPK1 promoter. To investigate that further, 
co-transfection of siRNA that knocked down WT1 with the wild type SRPK1 promoter 
resulted in a significant reduction in the promoter’s activity. Knocking down WT1 in 
both cell lines resulted in an observable reduction in SRPK1 protein levels. Thus, the 
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implication is that WT1 activates SRPK1 transcription in leukaemia and prostate cancer 
cells. Whether or not that applies to other cancer types remains to be determined. Wagner 
et al., 2019, to which this study contributed, shows that WT1 activates SRPK1 in tumour 
endothelium. When an inducible conditional vessel-specific knockout of WT1 was 
initiated, a reduction in WT1 and SRPK1 transcription was observed. It, therefore, seems 
clear that WT1 can activate SRPK1 transcription in the context of cancer. 
Splice-switching oligonucleotides (SSOs) are an emerging new technology that can 
manipulate the splicing of a given transcript, we aimed to obtain a morpholino that causes 
exon skipping. However, a manufacturer error was made by the provider GeneTools 
where instead of targeting the WT1 exonic splice junction, it was designed to target a 
sequence within the exon. Due to time constraints, it was not possible to re-design a WT1 
SSO; however, this was not critical as the WT1 siRNAs worked.  However, SSOs were 
used in this project to target the transcription factor ERG, as discussed later.  
The –KTS isoform of WT1 is best at binding DNA since it forms a more stable complex 
with DNA compared to the +KTS isoform. The insertion of the KTS amino acids is in 
the linker region between zinc figure 3 and 4 of WT1. This insertion disrupts interactions 
of the linker region with the adjacent zinc fingers and thus lowers the stability of the WT1 
(+KTS)-DNA complex (Laity et al., 2000). +KTS isoform is known to have a role in 
posttranscriptional RNA processing and pre-mRNA splicing rather than transcriptional 
regulation.         
The repressive activity of WT1 in DDS might be attributed to the inability of WT1 to 
regulate the transcription of a gene or genes involved in the regulation of VEGF 
alternative splicing as a point mutation in WT1 impairs its ability to bind DNA (Davies., 
et al., 1998 and Larsson., 1995). In this study, SRPK1 promoter’s activity was stimulated 
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more significantly when –KTS isoform of WT1 was overexpressed into the cells while 
+KTS isoform didn’t induce the same significance which suggests that –KTS is more 
involved in the activation process of SRPK1 transcription which agrees with the previous 
reasons.  However, the expression of WT1 (+KTS) was not very prominent, perhaps due 
to a technical problem with the expressing construct. Therefore additional experiments 
are needed to compare the effect of +/-KTS WT1 isoforms on SRPK1 transcription in 
cancer cells. 
7.1.5  CASPASE-9 alternative splicing following WT1 siRNA knockdown   
 
Several studies have highlighted that the WT1 promotes, in different ways, tumorigenesis 
in several types of cancer. Suppression of apoptosis is one of the proposed mechanisms 
through which WT1 exerts an oncogenic role. Through a transcriptional mechanism, 
WT1 was found to upregulate the anti-apoptotic Bcl-2 protein making rhabdoid (G401) 
cell lines more resistant to apoptosis (Mayo et al., 1999). Knocking down WT1 in several 
leukemic cell lines enhanced apoptosis. K Ito, et al., 2017 described that WT1-specific 
siRNA knockdown activated caspase-3 and -9 in the intrinsic apoptosis pathway.   
The specific loss of WT1 expression through siRNA knockdown and its implication on 
apoptosis was examined in this study. Caspase 9 splicing, which plays an important role 
in apoptosis seemed to be significantly affected by WT1 knockdown. Through increased 
caspase 3/7staining and detecting changes in caspase-9 mRNA splicing, knocking down 
WT1 appeared to make K562 and PC3 cells more apoptotic. However, there was no 
detectable change in BCL2L1 alternative splicing. 
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7.1.6 Effect of siRNA mediated WT1 knockdown on cell growth  
 
WT1’s influence on cellular proliferation and viability is complex in a way similar to its 
ability to suppress and activate the same target gene in different tissue contexts. For 
example, Parenti et al., 2014 demonstrated that silencing WT1 with siRNA resulted in 
limiting cellular proliferation in neurofibromatosis type 1(sNF96.2) cell line which could 
be attributed to the fact that WT1 plays a major role cycle progression. Another study on 
G401 presented different findings. Hong et al., 2017 show that reducing WT1 protein 
expression by WT1 siRNA markedly increased G401 cellular proliferation. In this cell 
line, this effect could be attributed to the over-arching effect of a microRNA. MiR-590 
reduces WT1 expression in G401 cell line whereas miR-590 also promotes proliferation; 
in other words, proliferation is not WT1-dependent in this cell line  
In the current study, the effect of WT1 knockdown and overexpression on cellular 
proliferation and viability of K562 and PC3 was investigated. siRNA was used to 
downregulate WT1 which resulted in a reduction in the WT1 protein levels and 
associated with marked reduction in cellular proliferation and cell viability which agrees 
with the antiproliferative effect in described (Parenti et al., 2014) unlike the pro-
proliferative effect of WT1 siRNA described in (Hong et al., 2017). 
(-/+ KTS) WT1 isoforms expressing plasmids were used to investigate the impact of WT1 
upregulation on proliferation and viability in K562 and PC3 cells in the current study.     
–KTS WT1 isoform, which forms a more stable complex with DNA, significantly 
reduced cellular proliferation and viability while + KTS WT1 didn’t have that effect. 
However, as previously discussed, it was not clear whether or not the +KTS expressing 
plasmid was working efficiently; additional experiments will address this question.   
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Overexpression of WT1 is a common feature in lung cancer. In non-small-cell lung 
cancer cells, miR-361 is downregulated while WT1 is overexpressed where it plays an 
oncogenic effect through promoting cell migration and invasion of NSCLC cells. 
Exogenous overexpression of miR-361 resulted in suppressing the migration and 
invasion of NSCLC cells. However, a similar effect was observed with WT1 knockdown. 
WT1 was identified as a direct target gene of miR‑361 which revealed the molecular 
mechanism underlying the rapid growth and metastasis of NSCLC and identified the 
association between miR-361 and WT1 (Yang, et al., 2016). 
 In the present study, a similar effect on migration and invasion was determined in PC3 
cells following WT1 knockdown by siRNA. These findings indicated that it may be 
beneficial to investigate novel therapy that targets WT1 in prostate cancer which could 
inhibit rapid growth and metastasis.     
7.1.7 BASP1 as a tumour suppressor 
 
Increasing evidence implicates BASP1 in transcriptional control and tumourigenicity in 
a variety of cell and tissue types throughout the human body (Tang et al., 2017). BASP1 
has been shown to exert tumour suppressor activity and to be a target of repression in a 
diverse range of cancer cell types including breast cancer cells, acute myelogenous 
leukaemia cells, hepatocellular carcinoma cells and thyroid cancer cells (Zhou et al., 
2018, Guo et al., 2016 and Marsh et al., 2017). Within these cancer cell types, BASP1 
has been shown to exert a number of different effects including reducing proliferation, 
migration and colony formation, as well as increasing apoptosis. New evidence 
demonstrates the complexity of the functions of BASP1 as it has, by contrast, been found 
to possess tumour promoting activity in cervical cancer cells (Tang et al., 2017). Again, 
it was found that BASP1 has multiple effects in the cancer type including increasing 
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proliferation, colony formation and tumourigenicity, as well as being associated with 
stage progression and poor prognosis. 
The transcriptional regulatory properties of WT1 is highly tissue-specific as it can act as 
a transcriptional activator or repressor sometimes for the same target genes depending on 
the tissue and the surrounding molecular environment as WT1 usually interact with 
several interaction partners as described in (Roberts, 2005). It has been described that the 
overexpression of WT1 often combined by lower expression of BASP1 and vice versa. 
During kidney development, for instance, BASP1 expression overlaps with WT1. In the 
embryonic stages of kidney development, WT1 levels are higher since it plays a critical 
role the in condensation of the metanephric mesenchyme onto the ureteric bud 
proliferation and then differentiation into the epithelia of the nephron. Later on, BASP1 
becomes more prominent in the adult kidneys, specifically in non-proliferative 
glomerular podocytes.  
BASP1 has been identified as a transcriptional co-suppressor that interacts with WT1. 
Through a transcriptional complex (WT1/BASP1), BASP1 converts WT1 from a 
transcriptional activator to a repressor of its target genes (Carpenter et al., 2004). 
The exact mechanisms through which BASP1 exerts tumour suppressor activity in breast 
cancer cells, acute myelogenous leukaemia cells, hepatocellular carcinoma cells and 
thyroid cancer is not yet entirely clear, but multiple studies have found that BASP1 
possesses transcriptional coregulatory activities. BASP1 has been shown to interact with 
several major transcription factors including WT1, MYC and ERα in a variety of cell 
types (Carpenter et al., 2004 and Marsh et al., 2017). In the BASP1-WT1 interaction, 
BASP1 binds to WT1 and converts it from a transcriptional activator to a transcriptional 
repressor of WT1 target genes. BASP1 does this by inducing the dissociation of CBP and 
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the recruitment of HDAC1 to the WT1 transcriptional complex (Toska et al., 2014). In 
the case of the BASP1-MYC interaction, BASP1 has been shown to block MYC-induced 
changes in fibroblasts, but it is not known by what mechanism this occurs. More recently, 
the BASP1-ERα interaction has been investigated, and BASP1 has been shown, in breast 
cancer cells, to interact with ERα and localise directly at the promoters of ERα target 
genes. This interaction was found to have significant effects on the transcriptional activity 
of ERα in response to treatment with the ERα ligand tamoxifen (Marsh et al., 2017). In 
some cases, it is possible that BASP1 binds independently to the promoter region of a 
target gene; however, this binding is not mandatory to achieve this repression. For 
instance, Hartl et al., 2009 has described how MYC and BASP1 transcriptional 
repression happens despite the lack of specific typical MYC binding site on the 5′ control 
region of BASP1. Transcriptional repression may occur independently through protein-
protein interactions. On the other hand, several studies confirmed that BASP1 binds to 
the promoter of target genes to achieve the co-repression. Green et al., 2009 has revealed 
via a chip assay that WT1 and BASP1 bind the promoter of the podocalyxin, Bak and c-
Myc genes in podocytes. Co-immunoprecipitation was used to pull down WT1/BASP1 
complex using anti-BASP1 polyclonal antibodies confirming the interaction (Carpenter 
et al., 2004). 
Overexpression of BASP1 reduces proliferation, apoptosis and migration in thyroid 
cancer cells (Guo et al., 2016).  Here, the effect of BASP1 overexpression on cellular 
viability and proliferation was evaluated, the results suggest that BASP1 exerted 
antitumor activities by reducing viability and proliferation of K562 and PC3 cells. This 
could be attributed to the induction of the G1 phase arrest in cell division cycle. This 
results from the overexpression of BASP1 since it is capable of suppressing the 
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expression cyclin D1, which then elevates the expression of p21 and p27, and induce G1 
phase arrest. This suggests that BASP1 may serve as an effective target for limiting the 
cellular proliferation of K562 and PC3 cells. 
7.1.8 The WT1/BASP1 repressive complex and the transcription of SRPK1  
 
In the present study, the data confirms that BASP1 turns WT1 into a repressor of SRPK1. 
WT1 represses SRPK1 in podocytes, and it is surely not a coincidence that BASP1 is also 
expressed in posocytes. A chIP for BASP1 was performed in B-K562 cells where SRPK1 
was repressed in contrast to regular K562 cells. In regular K562 cells, WT1 activates 
SRPK1 in normal K562 cells in which BASP1 is not expressed. It seems likely that as 
elsewhere, in K562 cells, WT1 and BASP1 are physically interacting with each other. 
Through a chIP assay, BASP1 appeared to be associating with SRPK1 promoter and 
regulate its transcription. The interaction of WT1 with BASP1 in B-K562 cells has 
already been confirmed by immunoprecipitation (Goodfellow et al., 2011).   
In summary, the evidence presented in this study is and in Wagner et al., 2019 is that 
WT1 activates SRPK1 expression, while represses it in podocytes (Amin et al., 2011). 
As discussed before, multiple factors could participate in this dual activity of WT1. Since 
BASP1 was described to be one of the multiple proteins that interact with WT1 and help 
to define its transcriptional influence on other genes. During the differentiation of 
podocyte precursor cell line, the overexpression of podocalyxin linked to the upregulation 
of WT1. However, when BASP1 is present on the podocalyxin promoter, the 
transcriptional activity of podocalyxin is reduced. The WT1/BASP1 repressive complex 
maintains the downregulated c-Myc and Bak promoters in a podocyte precursor cell line. 
Through incorporating a luciferase reporter with a wild-type podocalyxin promoter or a 
construct that lacks the ability to respond to WT1, Green et al., 2008 show that the 
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transcriptional activity of wild-type podocalyxin is higher in the wild type compared to 
that where WT1 cannot function. This indicates that WT1 activates the podocalyxin 
promoter. However, this WT1 mediated activation turns into repression when BASP1 is 
overexpressed as the activity of the wild type promoter goes down. 
A similar effect was noticed in this study with SRPK1 promoter. WT1-mediated 
transcriptional activation of the SRPK1 promoter turned into downregulation when 
BASP1 was overexpressed in PC3 cells. In BASP1 expressing K562 cells, SRPK1 
transcriptional activity was down-regulated compared to regular K562 cells where 
BASP1 is not expressed at detectable levels. Altogether, this suggests that there is a 
dynamic interaction between WT1 and BASP1, and the absence of BASP1 facilitates the 
transcriptional activation of SRPK1 in K562 and PC3 cell lines and by inference in cancer 
more generally. 
As described in Carpenter et al., 2004, BASP1 and WT1 are co-expressed in podocytes. 
In the early stages of kidney development, WT1 is expressed as it is essential for 
development. As the podocytes become more differentiated in adult kidney, BASP1 
expression is established, presumably consistent with the need to stop proliferation. 
 BASP1 expression in K562 cells is undetectable, therefore Goodfellow et al., 2011 
generated K562 cells with steady BASP1 expression (B-K562) to study the WT/BASP1 
interaction and to provide a better understanding on the transcriptional reprogramming 
and morphological changes mediated by BASP1 in K562 cells. As discussed they used 
co-immunoprecipitation and immunoblotting to demonstrate how BASP1 and WT1 
interact.               
Therefore, it was of interest to evaluate the endogenous protein levels of WT1, BASP1 
and SRPK1 in K562 and B-K562 cells and compare them to other cancer cell lines. 
Chapter seven: General Discussion and future work 
      
 
194 
 
Immunoblotting showed that WT1 and SRPK1 levels are similar in PC3, DU145, and 
K562 cells. BASP1, on the other hand, was barely detectable in PC3, DU145 and absent 
in K562 cells. In B-K562 cells where BASP1 was forcibly expressed, WT1, and SRPK1 
levels were reduced compared to PC3, DU145, and K562. This is consistent with the 
downregulation of SRPK1 by WT1/BASP1 also consistent with the previous DLR 
findings, however. Another incidental observation is that levels of WT1 itself are reduced 
in B-K562 cells. This observation could be explained by the fact that WT1 can 
autoregulate its transcription (Malik et al., 1994). 
7.1.9 Effect of BASP1 on VEGF-A splicing 
 
VEGF-A (often referred to as VEGF) is a key growth factor that plays important roles in 
regulating angiogenesis and other vital cellular pathways. VEGF is highly expressed in 
the podocytes of the kidney glomerulus where it facilitates the development of the 
ureteric bud. Certain VEGF isoforms, VEGF165 specifically, have been described to 
promote angiogenesis (Hanahan D et al., 2011); whereas the VEFG165b isoform is 
antiangiogenic and expressed in podocytes in a context where de novo angiogenesis is 
not required. Numerous studies have linked the downregulation or the inhibition of 
SRPK1 to the altered VEGF165 splicing as previously discussed. 
Stable SRPK1 knockdown resulted in an increase in VEGF165b at the protein level was 
observed in PC3 cells (Mavrou et al., 2014). In this study PC3 cells were chosen to 
investigate the effect of SRPK1 downregulation by WT1/BASP1 complex on the 
VEGF165/VEGF165b splicing. Downregulation of SRPK1 by BASP1 overexpression 
resulted in an increase in the VEGF165b isoform which suggests that a possible inhibition 
of angiogenesis may occur and therefore, BASP1 could be considered as an angiogenesis 
suppressor.     
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7.1.10 ERG as a transcriptional regulator  
 
As previously discussed it is likely that SRPK1 transcriptional regulation is influenced 
by several transcription factors, not just WT1. Due to ongoing research in the laboratory 
on ERG and the presence of potential binding sites in the SRPK1 promoter, this study 
investigates ETS-related gene transcription factor ERG as a potential regulator of 
SRPK1. ERG, like WT1, is a complex transcription factor with several developmental 
roles, and a clear involvement in cancer, particularly prostate cancer (Adamo and 
Ladomery, 2016). Adamo et al., 2017 demonstrated that ERG suppresses PTEN which 
is an important tumour suppressor in prostate and other cancers. Like WT1, ERG binds 
to the promoter of its target genes and helps regulate transcription. This study investigated 
wither or ERG binds to the SRPK1 promoter in an ERG expressing cell line, the 
osteosarcoma cell line MG63 (PC3, DU145 and K562 cells do not express ERG). 
Through chIP, binding was confirmed to take place in MG63 cell line.  
Similar binding of ERG to the PTEN promoter contributes to the repression of PTEN 
expression in prostate cancer cells (Adamo et al., 2017). This binding was identified by 
chIP then a dual-luciferase: renilla (DLR) transcription assay was performed where 
PTEN promoter co-transfected with increasing amounts of the ERG expressing plasmid 
into DU145 dells (ERG negative). This showed that the reduction in PTEN promoter 
activity with increasing amounts of co-transfected ERG. To expand on these findings, the 
PTEN: luciferase construct was transfected into VCaP cells (prostate cancer, ERG 
positive) where an ERG knockdown was performed using siRNA against ERG. This 
downregulation of ERG restored the activity of PTEN promoter (Adamo et al., 2017).  
ERG is also involved in EMT. For example, (Nagai et al., 2018) have shown that ERG 
and FLI1 are critical transcriptional activators for endothelial cells specific genes. They 
Chapter seven: General Discussion and future work 
      
 
196 
 
activate EC-specific genes and prevent the endothelial-to-mesenchymal transition 
through repressing mesenchymal-like genes. Moreover, a combined knockdown of ERG 
and FLI1 triggered the endothelial-to-mesenchymal transition. 
After obtaining evidence that ERG interacts with the SRPK1 promoter, K562 and PC3 
cells (ERG negative) were transfected with ERG expressing plasmids (-/+ exon 7b, an 
in-frame cassette exon of ERG thought to increase its oncogenic properties when 
included (Hagen et al, 2014). Following that, a significant reduction in SRPK1 
expression both at the transcriptional and the protein levels was observed. Cotransfection 
of increasing amounts of full-length ERG-expressing plasmids with the SRPK1 promoter: 
luciferase construct has demonstrated an increasing reduction in SRPK1 promoter 
activity.  
To expand on this, morpholinos (SSO) that induce ERG  exon 4 (a constitutive exon) and 
7b (cassette exon) skipping and siRNA against ERG was used to determine whether or 
not knocking down ERG and skipping exon 4 and 7b would result in the upregulation of 
SRPK1. siRNA reduces total ERG protein levels while exon 4 skipping by the SSOs 
resulted in making a premature stop codon which leads to nonsense-mediated decay 
which also reduces ERG protein. Reduction of ERG protein by exon 4 SSOs and siRNA 
against ERG resulted in a significant increase in SRPK1 protein and promoter activity. 
However, the other SSO against the cassette exon (E7b) resulted in exon 7b skipping 
without a clear increase in SRPK1 levels.  
In summary, it appears that at least in K562 and PC3 cells, ERG is a repressor, not an 
activator of SRPK1. This was perhaps surprising as ERG is a presumed oncogene, and 
SRPK1 upregulation is generally thought to be associated with a cancer phenotype, but 
that would be a simplistic interpretation. However, several transcription factors are likely 
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to influence overall SRPK1 expression in MG63 cells, and SRPK1 may be less important 
in any given cancer, especially as there are several other splice factor kinases, such as the 
CLKs, that could play a more prominent role, in any given cancer. Furthermore, as is the 
case with WT1, it is possible that ERG activates SRPK1 instead of repressing it, 
depending on the presence of other cofactors. These are open questions; the key finding 
here is that SRPK1 is a new transcriptional target of ERG. 
7.1.11  ERG and apoptosis  
 
Several studies have emphasised that ERG plays several key roles in regulating critical 
processes such as apoptosis. For instance, a change in caspase 3 and 7 activity was 
observed when ERG was subjected to siRNA knockdown (Birdsey et al., 2008). Caspase 
splicing, which plays an important role in apoptosis seemed to be significantly affected 
by ERG overexpression. Through active Caspases 3 and 7 staining and detecting the 
change in Caspase-9 proapoptotic (a) and antiapoptotic (b)  isoform levels, ERG 
expression appeared to make K562 and PC3 cells more apoptotic. However, there was 
no detectable change in BCL2L1 splicing.  
To further expand on these findings, the effect of ERG downregulation in MG63 (ERG 
positive cells) on apoptosis was examined. Caspase 3 and 7 activity was shown to 
increase following ERG downregulation. Reduction of ERG resulted in a significant 
splicing change in Caspase 9 favouring the pro-apoptotic isoform caspase-9a. 
As a major transcriptional regulator, ERG influences cellular proliferation and viability 
through regulating genes in major cellular pathways. (Liu et al., 2016 and Klezovitch et 
al., 2008) described how downregulation of ERG in VCaP cells showed a decrease in 
cellular viability and proliferation. This agrees with the findings in this study where ERG 
expression was targeted with ERG siRNA and exon 4 skipping SSOs resulted in a similar 
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biological effect. Overexpression or downregulation of ERG results in altered expression 
of its downstream target genes which now include SRPK1. This splice kinase plays major 
roles in maintaining cellular viability. Earlier in this project, we showed how knocking 
down SRPK1 resulted in a significant reduction in K562 and PC3 proliferation and 
viability. ERG overexpression in ERG-negative cell lines such as K562 and PC3 
apparently repressed SRPK1 and correlated with a reduction in cellular proliferation and 
viability. However, this cannot necessarily be fully attributed to SRPK1 as ERG regulates 
many other key genes.  
The evolutionarily conserved cassette exon 7b was described by (Jumbe et al., 2019) to 
play an important role in the proliferation of MG63 and VCaP cells. They show by Ki-
67 activity that the skipping of exon 7b induced by SSOs resulted in a reduction of 
cellular proliferation. The same effect was confirmed here by MTT assay following E7b 
SSOs transfection into MG63 cells. However, the contribution of exon 7b to the ability 
of ERG to regulate SRPK1 is not entirely clear and will require further investigation. 
The regulatory function of ERG extends to regulate multiple biologically important 
pathways such as inflammation, angiogenesis, haematopoiesis, migration and invasion. 
For example, HDAC6, which is involved in EC motility and migration, is an ERG target. 
ERG was shown to bind its promoter and regulate its expression. Following inhibition of 
ERG in HUVECs cells, HDAC6 expression decreased combined with a decrease in 
HUVEC cells migration (Birdsey et al., 2011). In another study, following siRNA 
knockdown of ERG in VCaP cell line, the migration and invasion were remarkably 
decreased (Liu et al., 2016). 
Here in this study, a recently described, innovative approach that switches the splicing of 
a given gene beside siRNA was used to inhibit ERG expression and then evaluate cellular 
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migration and invasion. Both exon 4 skipping and siRNA ERG knockdown in MG63 
cells resulted in a significant reduction in cellular migration and invasion. These findings 
indicated that ERG could be a useful target for a novel therapy that inhibits the rapid 
growth and metastasis in different cancers. SRPK1 was also identified as a novel ERG 
target; future research will determine the physiological importance of its regulation by 
ERG. 
7.2 Significance of the research 
The serine/arginine-rich proteins (SR proteins) are a large superfamily of nuclear RNA 
binding proteins (Zhou and Fu, 2013). The activity of SR proteins is highly regulated by 
the reversible phosphorylation of serine residues in the RS domain. Several protein 
kinases have been identified that phosphorylate SR proteins; the serine/arginine protein 
kinase family (SRPKs), cyclin-dependent like kinases (Cdc-like-kinase) or Clk/Sty (also 
known as Clk1), DNA topoisomerase I and phosphatidylinositol 3-kinase (AKT). The 
SRPKs phosphorylate SR proteins with high efficiency and specificity. However, the 
Clk/Sty family are dual specific kinases that phosphorylate serine/threonine and tyrosine 
residues. Thus, SRPKs phosphorylate SR proteins with greater efficiency and specificity 
than Clk/Sty. Despite this, Clk/Sty phosphorylates more residues than SRPKs in the RS 
domain of SRSF1. Numerous studies have revealed that members of SRPK are 
responsible for the nuclear import of phosphorylated SRSF1, while Clk/Sty members 
play key roles in interrupting phosphorylated SRSF1 (Ghosh and Adams, 2011). We have 
not considered here whether or not WT1 and ERG might also regulate the CLK splice 
factor kinases; it might be of interest to consider this possibility in future research. 
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SRPK1 has been shown to be upregulated in colon, breast and pancreatic cancers. 
However, the mechanism that causes its upregulation in these cancers is also unknown. 
To date it is known that overexpression of the oncogenic tyrosine kinase Bcr-Ab1 in 
human hematopoietic progenitor cells results in increased SRPK1 mRNA and protein 
levels, which correlate with alteration in pre-mRNA processing (Saless et al., 2004) in 
this study, SRPK1 has shown to be activated by WT1 alone and suppressed by 
WT1/BASP1 complex or ERG.  
Inhibiting SRPK1 levels could be a potential therapeutic target. In the present study, both 
the knockdown of SRPK1 mRNA levels by siRNA and the inhibition of its activity using 
a small molecular inhibitor SPHINX promoted the anti-angiogenic VEGF in the prostate 
cancer cell line. The cellular survival rate, as well as their invasive and migration abilities, 
were compromised as a result of SRPK1 inhibition. Manipulating the potential SRPK1 
transcriptional regulators has shown to shift the tumorigenicity of the cells through 
altering key cellular pathways such as apoptosis. 
However, pharmacological inhibition of SRPK1 could result in multiple side effects 
given its general role in the regulation of splice factor activity. It can be expected that 
SRPK1 will be able to regulate the alternative splicing of other genes. In addition, SRPK1 
has been shown to be a cisplatin-sensitive protein (Schenk et al., 2001). Cisplatin is a 
commonly used anti-cancer drug, and down-regulation of SRPK1 results in human 
ovarian cancer cells being less sensitive to the drug. Thus it is important to be cautious 
as more work has to be done to determine whether or not SRPK1 could be a potential 
therapeutic target.       
Clearly then there are complexities to be considered by future research. However, some 
important findings have resulted here. We have established that WT1 can upregulate 
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SRPK1 in cancer; that BASP1 is involved; and that another transcription factor and 
oncogene, ERG, contributes to SRPK1 regulation. The fact that both WT1 and ERG can 
contribute to SRPK1 regulation raises a number of important questions. Perhaps these 
oncogenes orchestrate significant changes in alternative splicing patterns in cancer, 
through the regulation of SRPK1, and potentially other splice factor kinases. A better 
understanding of these pathways could lead to novel therapeutic opportunities; for 
example, targeting WT1, could results in higher expression of antioangiogenic 
VEGF165b through reduced SRPK1. 
7.3 Future directions 
7.3.1 Global RNA Sequencing and gene promoter scan 
 
One of the goals of future work investigating SRPK1 in leukaemia and prostate cancer 
cells is to perform RNA sequencing analyses in several cell lines. RNA sequencing would 
allow the effects of SRPK1 inhibition and transcriptional manipulation through inhibition 
of WT1 and ERG to be compared to those of other cells. The crossover and differences 
between the cell types could then be analysed to investigate the differences in SRPK1 
mechanisms in different cell types. This data could reveal currently unknown roles of 
SRPK1 orchestrated by WT1, BASP1 and ERG in cancer cells. 
Gene promoter scan is a powerful tool that could identify other transcription factors that 
contribute to the regulation of SRPK1 transcription. In this study, WT1, BASP1 and ERG 
were shown through chIP to bind to the SRPK1 promoter. How these, and other 
transcription factors interact to regulate SRPK1 transcription in cancer remains to be 
investigated in more details. 
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7.3.2 SRPK1 kinase activity 
 
It was observed that SRPK1 is upregulated in both leukaemia and prostate cell lines 
which suggests that the elevated expression of SRPK1 level leads to increased splice 
factor kinase activity. This presumably results in the hyperphosphorylation of SRSF1, an 
oncogenic splice factor; but this was not measured directly here. An experiment that 
measures the kinase activity in both cell lines would be useful to prove that there is indeed 
an increase in the protein kinase activity of SRPK1 as a result of its upregulation. An 
increase in SRPK1 kinase activity resulting in activation of SRSF1 and other SR protein 
splice factors would result in significant changes in the alternative splicing of several key 
cancer-associated genes. This could also be investigated in more detail.      
7.3.3 Investigating other SRPK1 isoforms 
 
As very little is known about the different splice isoforms of SRPK1 in development and 
disease. The importance of SRPK1a remains unclear. We were unable to detect it, but 
this does not necessarily disprove its existence in vivo. A mouse model could be made to 
study their possible different roles in prostate and leukemic cancers. The possibility of 
whether or not the WT1/SRPK1/SRSF1 pathway affects the alternative splicing of 
SRPK1 itself should also be investigated. But in addition to SRPK1a, there may be 
additional SRPK1 splice isoforms; none have been described in the literature so far, but 
it is conceivable that others exist.           
7.3.4 SRPK1 intracellular localization 
 
SRPK1 localisation in the cell could also be an important parameter and it is known that 
SRPK1 autophosphorylates affecting its localisation and activity (Zhou et al., 2012). Akt 
inhibitors (MK2206 and wortmannin) to determine whether or not, through the 
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autophosphorylation of SRPK1, they change SRPK1’s intracellular localization. It will 
also be of interest to examine the effect of growth factors (EGF, IGF-1) on SRPK1 
autophosphorylation and intracellular localization, as well as the effect of cellular stress 
including hypoxia on the same parameters. The autophosphorylation and localization of 
SRPK1 will be correlated with the alternative splicing of cancer-associated genes known 
to be downstream of SRPK1, e.g. VEGF-A. 
To gain further insights into the regulation of SRPK1, the intrinsic stability of SPRK1 
mRNA could be assessed. PC3 cells could be treated with actinomycin D, a transcription 
inhibitor, and the levels of SRPK1 mRNA measured in a 72h time course. Then the effect 
of Akt inhibitors and various growth factors known to activate SRPK1 on the stability of 
its mRNA could be determined. 
7.3.5 Inducible expression of ERG/WT1 and SRPK1 regulation  
 
The findings here suggest that SRPK1 expression is activated by WT1 and the 
knockdown of WT1 resulted in a reduction in the SRPK1 transcription and expression. 
This study also suggests that ERG repress SRPK1 and knocking down ERG by SSOs and 
siRNA restored SRPK1 activity and increased its expression. However, this effect is 
temporary as it ends once the siRNA/SSOs concentration is reduced as the cell division 
continues. Therefore, it would be interesting in the future to generate a cell line with 
inducible expression of ERG and WT1. This could be achieved by using the cells with 
plasmids where the promoter could be switched on and off using a steroid or tetracycline- 
induced promoter.  
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7.3.6 SRPK1 expression and EMT Markers 
 
EMT markers are an important aspect of tumour biology as they perform an important 
tool in evaluating the metastatic ability of deferent tumours. EMT could be significantly 
affected by SRPK1. Looking at the effect of manipulating the ERG, WT1, BASP1-
SRPK1 axis on the expression of EMT markers may provide an insight into the influence 
of SRPK1 on the metastatic ability of prostate, and other cancer cells.  
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9 Appendices 
9.1 Plasmid preps 
 
 
 
 
Figure 9. 1 Plasmid preparation. 
Miniprepped plasmids separated by 1% agarose gel electrophoresis for 45 minutes at 100 V against. Both 
plasmids at the approximate size of 5000bp 
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Plasmid Midipreps 
                                  
 
 
Figure 9. 2 Plasmid Midiprep 
Midiprep plasmid running in 1% agarose gel for 45 minutes. The yield of both plasmids at the approximate 
size of 5000bp. 
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9.2 Restriction digests and plasmids validations 
 
 
   
Figure 9. 3 Wild type SRPK1 promoter. 
pMKC130; PGL3 basic vector with 511 bp (-391 relative to WT1) human SRPK1 promoter) 
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Figure 9. 4   Mutant SRPK1 promoter  
pMKC132; PGL3 basic vector with mutant 511 bp (-391 relative to WT1) human SRPK1 promoter with 
(GGGGCGGGGG replaced by GAATTCAAAA =EcoRI). To help distinguish pMKC130 from 
pMKC132, an additional EcoRI restriction enzyme site has been created within the mutagenized WT1 
binding site in plasmid pMKC132.  
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Figure 9. 5: Firefly and Renilla Luciferase Reporter Vectors. 
Plasmid pRL-TK (ampicillin resistant plasmid containing Renilla luciferase gene). 
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Figure 9. 6 PGL3 plasmid map  
PGL3 basic vector contains a modified firefly luciferase gene (luc+) and a gene conferring 
ampicillin resistance in E. coli.   
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Restriction digests of pGL3 plasmids  
 
 
 
Figure 9. 7 Enzymes digests.  
Restriction enzymes digests KE ( KpnI &EcoRI), KN ( KpnI & Nco I ) and HXB(XbaI, HindIII & BamHI) 
and using HyperLadder™ 1kb DNA marker. Then separated in 1% agarose gel for 45 minutes.   
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Plasmid  Restriction enzyme  Resulted segments  
 
 
 pMKC130 
(KpnI and EcoRI) single fragment of 5000 bp 
(no EcoRI enzyme site) 
(KpnI and Nco I) 2 fragments of 5000bp 
(contains ampicillin 
resistance and luciferase 
sequences) and 400bp 
(contains sequence of 
interest; in SRPK1 -391 
relative to WT1) 
(HindIII , XbaI 
and,BAMIII) 
3 fragment of 3000bp 
(ampicillin resistance 
sequence) 2500bp 
(luciferase sequence) and 
200bp (part of the promoter 
sequence) 
 
pMKC132 
(KpnI and EcoRI) 2 fragments of 400bp 
(contains sequence of 
interest; SRPK1 mut -391 
relative to WT1) and 5000bp 
(contains ampicillin 
resistance and luciferase 
sequences)  
(KpnI and Nco I) 2 fragments of 5000bp 
(ampR and Luc+) and 510bp 
(sequence of interest) 
(HindIII , XbaI 
and,BAMIII) 
3 fragments;3000bp 
(ampicillin resistance 
sequence) 2500bp 
(luciferase sequence) and 
200bp (part of the promoter 
sequence)  
 
Table 9. 1: Results for restriction digests for the wiled type SRPK1 promoter (pMKC130) & 
mutant SRPK1 promoter (pMKC132). 
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Restriction digests of pCDNA-BASP1 plasmids  
 
 
 
 
Figure 9. 8 Restriction digests of BASP1 plasmids  
Restriction enzymes digests using HindIII & BamHI and using HyperLadder™ 1kb DNA 
marker. Then separated in 1% agarose gel for 45 minutes.  
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Linearization of ERG plasmids 
 
 
 
 
Figure 9. 9 Restriction digests of ERG plasmids  
Restriction enzymes Double digest using XhoI and SalI and using HyperLadder™ 1kb 
DNA marker. Then separated in 1% agarose gel for 45 minutes.  
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ERG (-/+7b) plasmids validation; DDK tag western blots 
 
 
 
 
 
 
 
 
Figure 9. 10: DDK tag western blots 
PC3 and K562 Cells were transfected with ERG 218/227 plasmids where the protein has DDK as epitope 
tag. The cell lysates were collected after 48 hours. Lysates from MG63, PC3 and K562 cells were used as 
negative controls. Then western blot was performed using Monoclonal ANTI-FLAG® M2 antibody against 
DDK. Actin was used as a loading control. Three independent transfections are shown.   
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9.3 Sequencing and NCBI Nucleotide Blast of Chip pull downs  
Figure 9. 11: WT1-SRPK1 pull down sequencing   
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Figure 9. 12: WT1-SRPK1 sequencing result; NCBI Nucleotide Blast 
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 Figure 9. 13: BASP1-SRPK1 pull down sequencing   
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Figure 9. 14: BASP1-SRPK1 sequencing result; NCBI Nucleotide Blast 
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Figure 9. 15: ERG pull down-PCR sequencing; forward primers 
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Figure 9. 16: ERG-SRPK1 sequencing result; NCBI Nucleotide Blast 
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9.4 TPM values of RNA-sequences   
 
 
 
Table 9. 2: TPM values of RNA-seq of SRPK1, WT1, BASP1 and ERG in K562, PC3 and MG63.  
 
  
 
WT1 
 
 
BASP1  
 
 
ERG  
 
 
SRPK1 
 
K562 
 
26 
 
Undetectable 
 
Undetectable  
 
101  
 
PC3 
 
3 
 
89 
 
Undetectable 
 
44 
 
MG63 
 
Undetectable 
 
494 
 
10 
 
54 
Cell line  
Gene 
(TPM) 
